US5427908A
(en)
*
|
1990-05-01 |
1995-06-27 |
Affymax Technologies N.V. |
Recombinant library screening methods
|
GB9015198D0
(en)
|
1990-07-10 |
1990-08-29 |
Brien Caroline J O |
Binding substance
|
US6916605B1
(en)
|
1990-07-10 |
2005-07-12 |
Medical Research Council |
Methods for producing members of specific binding pairs
|
US7063943B1
(en)
|
1990-07-10 |
2006-06-20 |
Cambridge Antibody Technology |
Methods for producing members of specific binding pairs
|
GB9206318D0
(en)
*
|
1992-03-24 |
1992-05-06 |
Cambridge Antibody Tech |
Binding substances
|
US6172197B1
(en)
|
1991-07-10 |
2001-01-09 |
Medical Research Council |
Methods for producing members of specific binding pairs
|
EP0564531B1
(en)
*
|
1990-12-03 |
1998-03-25 |
Genentech, Inc. |
Enrichment method for variant proteins with altered binding properties
|
DK1471142T3
(da)
*
|
1991-04-10 |
2009-03-09 |
Scripps Research Inst |
Heterodimere receptor-biblioteker under anvendelse af fagemider
|
US5962255A
(en)
*
|
1992-03-24 |
1999-10-05 |
Cambridge Antibody Technology Limited |
Methods for producing recombinant vectors
|
US5871907A
(en)
*
|
1991-05-15 |
1999-02-16 |
Medical Research Council |
Methods for producing members of specific binding pairs
|
US5858657A
(en)
*
|
1992-05-15 |
1999-01-12 |
Medical Research Council |
Methods for producing members of specific binding pairs
|
US6225447B1
(en)
|
1991-05-15 |
2001-05-01 |
Cambridge Antibody Technology Ltd. |
Methods for producing members of specific binding pairs
|
US6492160B1
(en)
|
1991-05-15 |
2002-12-10 |
Cambridge Antibody Technology Limited |
Methods for producing members of specific binding pairs
|
US5733731A
(en)
*
|
1991-10-16 |
1998-03-31 |
Affymax Technologies N.V. |
Peptide library and screening method
|
US5270170A
(en)
*
|
1991-10-16 |
1993-12-14 |
Affymax Technologies N.V. |
Peptide library and screening method
|
DE69233782D1
(de)
|
1991-12-02 |
2010-05-20 |
Medical Res Council |
Herstellung von Autoantikörpern auf Phagenoberflächen ausgehend von Antikörpersegmentbibliotheken
|
US7067284B1
(en)
*
|
1992-01-27 |
2006-06-27 |
The Scripps Research Institute |
Methods for producing antibody libraries using universal or randomized immunoglobulin light chains
|
US5733743A
(en)
*
|
1992-03-24 |
1998-03-31 |
Cambridge Antibody Technology Limited |
Methods for producing members of specific binding pairs
|
WO1995015393A1
(fr)
*
|
1993-12-03 |
1995-06-08 |
Asahi Kasei Kogyo Kabushiki Kaisha |
Nouveau vecteur de detection d'expression
|
ATE243745T1
(de)
*
|
1994-01-31 |
2003-07-15 |
Univ Boston |
Bibliotheken aus polyklonalen antikörpern
|
US20060078561A1
(en)
*
|
1994-01-31 |
2006-04-13 |
The Trustees Of Boston University |
Polyclonal antibody libraries
|
US6576236B1
(en)
|
1994-07-01 |
2003-06-10 |
Dana Farber Cancer Institute |
Methods for stimulating T cell responses by manipulating a common cytokine receptor γ chain
|
US7597886B2
(en)
*
|
1994-11-07 |
2009-10-06 |
Human Genome Sciences, Inc. |
Tumor necrosis factor-gamma
|
US7820798B2
(en)
*
|
1994-11-07 |
2010-10-26 |
Human Genome Sciences, Inc. |
Tumor necrosis factor-gamma
|
US6326155B1
(en)
*
|
1995-03-20 |
2001-12-04 |
Dyax Corp. |
Engineering affinity ligands for macromolecules
|
US7429646B1
(en)
|
1995-06-05 |
2008-09-30 |
Human Genome Sciences, Inc. |
Antibodies to human tumor necrosis factor receptor-like 2
|
US5702892A
(en)
*
|
1995-05-09 |
1997-12-30 |
The United States Of America As Represented By The Department Of Health And Human Services |
Phage-display of immunoglobulin heavy chain libraries
|
US6475806B1
(en)
*
|
1995-06-07 |
2002-11-05 |
Praecis Pharmaceuticals, Inc. |
Anchor libraries and identification of peptide binding sequences
|
US7368111B2
(en)
|
1995-10-06 |
2008-05-06 |
Cambridge Antibody Technology Limited |
Human antibodies specific for TGFβ2
|
US6090382A
(en)
|
1996-02-09 |
2000-07-18 |
Basf Aktiengesellschaft |
Human antibodies that bind human TNFα
|
US6713279B1
(en)
|
1995-12-07 |
2004-03-30 |
Diversa Corporation |
Non-stochastic generation of genetic vaccines and enzymes
|
US6740506B2
(en)
|
1995-12-07 |
2004-05-25 |
Diversa Corporation |
End selection in directed evolution
|
US6358709B1
(en)
|
1995-12-07 |
2002-03-19 |
Diversa Corporation |
End selection in directed evolution
|
US20030219752A1
(en)
*
|
1995-12-07 |
2003-11-27 |
Diversa Corporation |
Novel antigen binding molecules for therapeutic, diagnostic, prophylactic, enzymatic, industrial, and agricultural applications, and methods for generating and screening thereof
|
US5830696A
(en)
|
1996-12-05 |
1998-11-03 |
Diversa Corporation |
Directed evolution of thermophilic enzymes
|
US6764835B2
(en)
*
|
1995-12-07 |
2004-07-20 |
Diversa Corporation |
Saturation mutageneis in directed evolution
|
US6537776B1
(en)
*
|
1999-06-14 |
2003-03-25 |
Diversa Corporation |
Synthetic ligation reassembly in directed evolution
|
US6939689B2
(en)
|
1995-12-07 |
2005-09-06 |
Diversa Corporation |
Exonuclease-mediated nucleic acid reassembly in directed evolution
|
US7888466B2
(en)
|
1996-01-11 |
2011-02-15 |
Human Genome Sciences, Inc. |
Human G-protein chemokine receptor HSATU68
|
DE19629143A1
(de)
*
|
1996-07-19 |
1998-01-22 |
Bayer Ag |
Vorrichtung zum Separieren von Mikroobjekten
|
US5985543A
(en)
*
|
1996-10-11 |
1999-11-16 |
The Trustees Of The University Of Pennsylvania |
Compositions and methods for detection of antibody binding to cells
|
US5876925A
(en)
*
|
1996-10-11 |
1999-03-02 |
The Trustees Of The University Of Pennsylvania |
Magnetically activated cell sorting for production of proteins
|
IL119587A
(en)
*
|
1996-11-07 |
2000-12-06 |
Univ Ramot |
Method of preparing and for obtaining bimolecular interactions
|
US5817497A
(en)
*
|
1996-11-26 |
1998-10-06 |
Incyte Pharmaceuticals |
Glutathione s-transferase
|
EP0977886A4
(en)
*
|
1997-03-07 |
2002-10-23 |
Sunol Molecular Corp |
FUSION PROTEINS, WHICH CONTAIN A BACTERIOPHAGE ENVELOPE PROTEIN AND A SINGLE CHAIN T-CELL RECEPTOR
|
US6057098A
(en)
|
1997-04-04 |
2000-05-02 |
Biosite Diagnostics, Inc. |
Polyvalent display libraries
|
WO1998047343A2
(en)
*
|
1997-04-04 |
1998-10-29 |
Biosite Diagnostics, Inc. |
Antibodies or binding protein libraries displayed on phage, cells, or other replicatable genetic packages
|
US6555310B1
(en)
*
|
1997-04-04 |
2003-04-29 |
Biosite Diagnostics, Inc. |
Polyclonal libraries
|
US20070059302A1
(en)
|
1997-04-07 |
2007-03-15 |
Genentech, Inc. |
Anti-vegf antibodies
|
DE69829891T2
(de)
|
1997-04-07 |
2005-10-06 |
Genentech, Inc., South San Francisco |
Anti-VEGF Antikörper
|
TR199902818T2
(xx)
*
|
1997-04-07 |
2000-05-22 |
Genentech, Inc. |
Be�eri kullan�m i�in antikorlar ve be�eri kullan�m i�in antikorlar olu�turmak i�in y�ntemler.
|
DK0975755T3
(da)
|
1997-04-16 |
2007-06-11 |
Millennium Pharm Inc |
CRSP-protein (cysteinrige udskilte proteiner), nukleinsyremolekyler der koder herfor samt anvendelser deraf
|
NZ516848A
(en)
|
1997-06-20 |
2004-03-26 |
Ciphergen Biosystems Inc |
Retentate chromatography apparatus with applications in biology and medicine
|
EP1032660B1
(en)
*
|
1997-11-17 |
2009-11-04 |
Micromet AG |
Method of identifying binding site domains that retain the capacity of binding to an epitop
|
WO1999031265A1
(en)
*
|
1997-12-12 |
1999-06-24 |
Way Jeffrey C |
Compounds and methods for the inhibition of protein-protein interactions
|
EP1093457B8
(en)
|
1998-03-19 |
2011-02-02 |
Human Genome Sciences, Inc. |
Cytokine receptor common gamma chain like
|
US6344330B1
(en)
*
|
1998-03-27 |
2002-02-05 |
The Regents Of The University Of California |
Pharmacophore recombination for the identification of small molecule drug lead compounds
|
US7056517B2
(en)
|
1998-04-13 |
2006-06-06 |
The Forsyth Institute |
Glucosyltransferase immunogens
|
US7163682B2
(en)
|
1998-04-13 |
2007-01-16 |
The Forsyth Institute |
Glucan binding protein and glucosyltransferase immunogens
|
EP2311490A3
(en)
|
1998-07-13 |
2011-05-04 |
Board of Regents, The University of Texas System |
Uses of antibodies to aminophospholipids for cancer treatment
|
AU5122499A
(en)
|
1998-07-27 |
2000-02-21 |
Genentech Inc. |
Improved transformation efficiency in phage display through modification of a coat protein
|
US6190908B1
(en)
|
1998-08-12 |
2001-02-20 |
The Scripps Research Institute |
Modulation of polypeptide display on modified filamentous phage
|
US6420110B1
(en)
|
1998-10-19 |
2002-07-16 |
Gpc Biotech, Inc. |
Methods and reagents for isolating biologically active peptides
|
IL127127A0
(en)
*
|
1998-11-18 |
1999-09-22 |
Peptor Ltd |
Small functional units of antibody heavy chain variable regions
|
US20090130718A1
(en)
*
|
1999-02-04 |
2009-05-21 |
Diversa Corporation |
Gene site saturation mutagenesis
|
EP2301947A3
(en)
|
1999-02-26 |
2011-11-23 |
Millennium Pharmaceuticals, Inc. |
Secreted proteins and uses thereof
|
WO2000050620A2
(en)
|
1999-02-26 |
2000-08-31 |
Human Genome Sciences, Inc. |
Human endokine alpha and methods of use
|
KR20140094647A
(ko)
|
1999-03-25 |
2014-07-30 |
아비에 도이치란트 게엠베하 운트 콤파니 카게 |
사람 il-12에 결합하는 사람 항체 및 이의 제조방법
|
DE19915057A1
(de)
|
1999-04-01 |
2000-10-19 |
Forschungszentrum Borstel |
Monoklonale Antikörper gegen das humane Mcm3 Protein, Verfahren zu ihrer Herstellung und ihre Verwendung
|
US6492497B1
(en)
|
1999-04-30 |
2002-12-10 |
Cambridge Antibody Technology Limited |
Specific binding members for TGFbeta1
|
PT1054018E
(pt)
*
|
1999-05-18 |
2009-02-16 |
Dyax Corp |
Bibliotecas de fragmentos fab e métodos para a sua utilização
|
US20020102613A1
(en)
|
1999-05-18 |
2002-08-01 |
Hoogenboom Hendricus Renerus Jacobus Mattheus |
Novel Fab fragment libraries and methods for their use
|
US7291714B1
(en)
*
|
1999-06-30 |
2007-11-06 |
Millennium Pharmaceuticals, Inc. |
Glycoprotein VI and uses thereof
|
US20040001826A1
(en)
*
|
1999-06-30 |
2004-01-01 |
Millennium Pharmaceuticals, Inc. |
Glycoprotein VI and uses thereof
|
CA2383456C
(en)
|
1999-08-23 |
2016-06-07 |
Clive Wood |
Pd-1, a receptor for b7-4, and uses therefor
|
US6673346B1
(en)
|
1999-08-31 |
2004-01-06 |
The Regents Of The University Of Michigan |
Compositions and methods for the treatment of sepsis
|
US6794132B2
(en)
|
1999-10-02 |
2004-09-21 |
Biosite, Inc. |
Human antibodies
|
US7135287B1
(en)
|
1999-10-02 |
2006-11-14 |
Biosite, Inc. |
Human antibodies
|
US20070111259A1
(en)
*
|
1999-10-02 |
2007-05-17 |
Medarex, Inc. |
Human antibodies
|
US6680209B1
(en)
*
|
1999-12-06 |
2004-01-20 |
Biosite, Incorporated |
Human antibodies as diagnostic reagents
|
AU784983B2
(en)
*
|
1999-12-15 |
2006-08-17 |
Genentech Inc. |
Shotgun scanning, a combinatorial method for mapping functional protein epitopes
|
JP2003518942A
(ja)
|
1999-12-30 |
2003-06-17 |
プレジデント・アンド・フェローズ・オブ・ハーバード・カレッジ |
肝細胞成長、形質細胞分化、又はt細胞サブセットの活性を、xbp−1活性の変調により変調することに関する方法及び組成物
|
WO2002043660A2
(en)
|
2000-11-28 |
2002-06-06 |
Mediummune, Inc |
Methods of administering/dosing anti-rsv antibodies for prophylaxis and treatment
|
TWI373343B
(en)
|
2000-02-10 |
2012-10-01 |
Abbott Gmbh & Co Kg |
Antibodies that bind human interleukin-18 and methods of making and using
|
EP2341075A1
(en)
*
|
2000-03-01 |
2011-07-06 |
MedImmune, LLC |
Antibodies binding to the f protein of a respiratory syncytial virus (rsv)
|
AU2001266557A1
(en)
|
2000-04-12 |
2001-10-23 |
Human Genome Sciences, Inc. |
Albumin fusion proteins
|
US8288322B2
(en)
|
2000-04-17 |
2012-10-16 |
Dyax Corp. |
Methods of constructing libraries comprising displayed and/or expressed members of a diverse family of peptides, polypeptides or proteins and the novel libraries
|
WO2001079481A2
(en)
*
|
2000-04-17 |
2001-10-25 |
Dyax Corp. |
Methods of constructing display libraries of genetic packages for members of a diverse family of peptides
|
US7495070B2
(en)
*
|
2000-04-24 |
2009-02-24 |
Yale University |
Protein binding miniature proteins
|
AU2001253758A1
(en)
*
|
2000-04-24 |
2001-11-07 |
Yale University |
DNA and protein binding miniature proteins
|
EP1714661A3
(en)
|
2000-05-19 |
2012-03-14 |
The Center for Blood Research, INC. |
Methods for diagnosing and treating hemostatic disorders by modulating p-selectin activity
|
US20030031675A1
(en)
|
2000-06-06 |
2003-02-13 |
Mikesell Glen E. |
B7-related nucleic acids and polypeptides useful for immunomodulation
|
EP1286682B1
(en)
|
2000-06-08 |
2010-03-03 |
Immune Disease Institute, Inc. |
Methods and compositions for inhibiting immunoglobulin-mediated-reperfusion injury
|
AU2001282856A1
(en)
|
2000-06-15 |
2001-12-24 |
Human Genome Sciences, Inc. |
Human tumor necrosis factor delta and epsilon
|
CA2407910C
(en)
|
2000-06-16 |
2013-03-12 |
Steven M. Ruben |
Antibodies that immunospecifically bind to blys
|
CA2413857C
(en)
|
2000-06-28 |
2010-04-27 |
Genetics Institute, Llc. |
Pd-l2 molecules: pd-1 ligands and uses therefor
|
US7807872B2
(en)
|
2000-07-14 |
2010-10-05 |
Cropdesign N.V. |
Down regulation of plant cyclin-dependent kinase inhibitors
|
US6902734B2
(en)
|
2000-08-07 |
2005-06-07 |
Centocor, Inc. |
Anti-IL-12 antibodies and compositions thereof
|
UA81743C2
(uk)
|
2000-08-07 |
2008-02-11 |
Центокор, Инк. |
МОНОКЛОНАЛЬНЕ АНТИТІЛО ЛЮДИНИ, ЩО СПЕЦИФІЧНО ЗВ'ЯЗУЄТЬСЯ З ФАКТОРОМ НЕКРОЗУ ПУХЛИН АЛЬФА (ФНПα), ФАРМАЦЕВТИЧНА КОМПОЗИЦІЯ, ЩО ЙОГО МІСТИТЬ, ТА СПОСІБ ЛІКУВАННЯ РЕВМАТОЇДНОГО АРТРИТУ
|
US7288390B2
(en)
|
2000-08-07 |
2007-10-30 |
Centocor, Inc. |
Anti-dual integrin antibodies, compositions, methods and uses
|
GB0022978D0
(en)
|
2000-09-19 |
2000-11-01 |
Oxford Glycosciences Uk Ltd |
Detection of peptides
|
AU4155602A
(en)
|
2000-11-01 |
2002-06-18 |
Elusys Therapeutics Inc |
Method of producing biospecific molecules by protein trans-splicing
|
EP1343912A2
(en)
|
2000-11-28 |
2003-09-17 |
Wyeth |
Expression analysis of kiaa nucleic acids and polypeptides useful in the diagnosis and treatment of prostate cancer
|
US6821731B2
(en)
|
2000-11-28 |
2004-11-23 |
Wyeth |
Expression analysis of FKBP nucleic acids and polypeptides useful in the diagnosis of prostate cancer
|
AU2002225914A1
(en)
*
|
2000-12-08 |
2002-06-18 |
Alexion Pharmaceuticals, Inc. |
Plasmid vectors
|
PT1355919E
(pt)
|
2000-12-12 |
2011-03-02 |
Medimmune Llc |
Moléculas com semivida longa, composições que as contêm e suas utilizações
|
US6979556B2
(en)
*
|
2000-12-14 |
2005-12-27 |
Genentech, Inc. |
Separate-cistron contructs for secretion of aglycosylated antibodies from prokaryotes
|
AU2002249854B2
(en)
|
2000-12-18 |
2007-09-20 |
Dyax Corp. |
Focused libraries of genetic packages
|
CA2432870A1
(en)
*
|
2000-12-22 |
2002-07-25 |
Ronghui Lin |
Substituted triazole diamine derivatives as kinase inhibitors
|
US7981420B2
(en)
|
2000-12-22 |
2011-07-19 |
Max-Planck-Gesellschaft Zur Foederung Der Wissenschaften E.V. |
Therapeutic use of antibodies directed against repulsive guidance molecule (RGM)
|
PT1399483E
(pt)
|
2001-01-05 |
2010-07-20 |
Pfizer |
Anticorpos contra o receptor do factor i de crescimento tipo insulina
|
WO2008048300A2
(en)
|
2005-11-30 |
2008-04-24 |
Massachusetts Institute Of Technology |
Pathogen detection biosensor
|
CN1564826A
(zh)
|
2001-02-09 |
2005-01-12 |
人类基因组科学公司 |
人类g蛋白趋化因子受体(ccr5)hdgnr10
|
AU2002308306B2
(en)
|
2001-02-23 |
2007-03-01 |
Dsm Ip Assets B.V. |
Genes encoding proteolytic enzymes from aspargilli
|
AU2002250236A1
(en)
*
|
2001-03-02 |
2002-09-19 |
Medimmune, Inc. |
Cd2 antagonists for treatment of autoimmune or inflammatory disease
|
WO2002070662A2
(en)
|
2001-03-02 |
2002-09-12 |
Gpc Biotech Ag |
Three hybrid assay system
|
US8231878B2
(en)
|
2001-03-20 |
2012-07-31 |
Cosmo Research & Development S.P.A. |
Receptor trem (triggering receptor expressed on myeloid cells) and uses thereof
|
US8981061B2
(en)
|
2001-03-20 |
2015-03-17 |
Novo Nordisk A/S |
Receptor TREM (triggering receptor expressed on myeloid cells) and uses thereof
|
CA2342376C
(en)
*
|
2001-03-20 |
2013-11-12 |
Marco Colonna |
A receptor trem (triggering receptor expressed on myeloid cells) and uses thereof
|
US20090081199A1
(en)
*
|
2001-03-20 |
2009-03-26 |
Bioxell S.P.A. |
Novel receptor trem (triggering receptor expressed on myeloid cells) and uses thereof
|
US7795494B2
(en)
|
2001-03-22 |
2010-09-14 |
Abbott Laboratories |
Transgenic mice expressing antibodies specific for genes of interest and uses thereof
|
JP2004533226A
(ja)
|
2001-04-02 |
2004-11-04 |
ワイス |
B7−4に対するpd−1、aレセプター、およびその使用
|
EP2228389B1
(en)
|
2001-04-13 |
2015-07-08 |
Human Genome Sciences, Inc. |
Antibodies against vascular endothelial growth factor 2
|
MXPA03009415A
(es)
|
2001-04-16 |
2004-01-29 |
Wyeth Corp |
ESTRUCTURAS NOVEDOSAS DE LECTURA ABIERTA DE STREPTOCOCCUS PNEUMONIAE QUE CODIFICAN ANTIGENOS DE POLIPePTIDOS Y USOS DE LAS MISMAS.
|
EP1390489B1
(en)
|
2001-04-27 |
2006-02-01 |
Alexion Pharmaceuticals, Inc. |
Phagemid vectors
|
CA2446723C
(en)
|
2001-05-25 |
2014-01-21 |
Human Genome Sciences, Inc. |
Antibodies that immunospecifically bind to trail receptors
|
AU2002322033A1
(en)
|
2001-06-04 |
2002-12-16 |
Ikonisys Inc. |
Method for detecting infectious agents using computer controlled automated image analysis
|
CA2817619A1
(en)
|
2001-06-08 |
2002-12-08 |
Abbott Laboratories (Bermuda) Ltd. |
Methods of administering anti-tnf.alpha. antibodies
|
EP1409551A4
(en)
*
|
2001-06-21 |
2004-10-13 |
Uab Research Foundation |
CHEMICAL CAPSIDE PROTEINS AND USES THEREOF
|
US20040002058A1
(en)
*
|
2001-06-21 |
2004-01-01 |
Uab Research Foundation |
Chimeric capsid proteins and uses thereof
|
EP2270185A3
(en)
|
2001-06-22 |
2012-04-04 |
Pioneer Hi-Bred International, Inc. |
Defensin polynucleotides and methods of use
|
EP1493028A4
(en)
*
|
2001-07-06 |
2006-06-14 |
Genentech Inc |
PHAGEN DISPLAY PRESENTED LIGANDS OF THE PDZ DOMAIN
|
US6867189B2
(en)
|
2001-07-26 |
2005-03-15 |
Genset S.A. |
Use of adipsin/complement factor D in the treatment of metabolic related disorders
|
MXPA04001566A
(es)
*
|
2001-08-27 |
2004-05-17 |
Genentech Inc |
Un sistema para expresion y ensamblado de anticuerpos.
|
JP4360906B2
(ja)
*
|
2001-09-14 |
2009-11-11 |
サイトス バイオテクノロジー アーゲー |
ウィルス様粒子によって誘導される免疫応答を高めるための、抗原提示細胞のインビボでの活性化
|
US20040142325A1
(en)
|
2001-09-14 |
2004-07-22 |
Liat Mintz |
Methods and systems for annotating biomolecular sequences
|
DE60234369D1
(de)
*
|
2001-09-19 |
2009-12-24 |
Alexion Pharma Inc |
Manipulierte matrizen und ihre verwendung bei der single-primer-amplifikation
|
US7414111B2
(en)
*
|
2001-09-19 |
2008-08-19 |
Alexion Pharmaceuticals, Inc. |
Engineered templates and their use in single primer amplification
|
EP1438400B1
(en)
|
2001-10-01 |
2009-06-17 |
Dyax Corp. |
Multi-chain eukaryotic display vectors and uses thereof
|
US20040005709A1
(en)
*
|
2001-10-24 |
2004-01-08 |
Hoogenboom Henricus Renerus Jacobus Mattheus |
Hybridization control of sequence variation
|
AR039067A1
(es)
|
2001-11-09 |
2005-02-09 |
Pfizer Prod Inc |
Anticuerpos para cd40
|
KR100450864B1
(ko)
*
|
2001-11-23 |
2004-10-01 |
한국과학기술연구원 |
Rna 표적 분자에 대해 특이성이 향상된네오마이신-클로람페니콜 헤테로 이합체 및 그의 제조방법
|
DE60234713D1
(de)
|
2001-12-18 |
2010-01-21 |
Endocube Sas |
Neue mit dem zelltod assoziierte proteine aus der thap familie und par4 verwandte signalwege, die bei der kontrolle von apoptosis involviert sind
|
US7858297B2
(en)
|
2001-12-18 |
2010-12-28 |
Centre National De La Recherche Scientifique Cnrs |
Chemokine-binding protein and methods of use
|
US7087418B2
(en)
|
2001-12-19 |
2006-08-08 |
Bristol-Myers Squibb Company |
Pichia pastoris formate dehydrogenase and uses therefor
|
EP2261250B1
(en)
|
2001-12-21 |
2015-07-01 |
Human Genome Sciences, Inc. |
GCSF-Albumin fusion proteins
|
US20040009498A1
(en)
*
|
2002-01-14 |
2004-01-15 |
Diversa Corporation |
Chimeric antigen binding molecules and methods for making and using them
|
AU2003209340A1
(en)
*
|
2002-01-18 |
2003-09-02 |
Bristol-Myers Squibb Company |
Predictor sets for tyrosine kinase pathways
|
US7094579B2
(en)
|
2002-02-13 |
2006-08-22 |
Xoma Technology Ltd. |
Eukaryotic signal sequences for prokaryotic expression
|
AU2003217716A1
(en)
*
|
2002-02-25 |
2003-09-09 |
Cabot Corporation |
Custom ligand design for biomolecular filtration and purification for bioseperation
|
EP1489968B1
(en)
*
|
2002-03-01 |
2009-02-18 |
Siemens Healthcare Diagnostics Inc. |
Assays for cancer patient monitoring based on levels of analyte components of the plasminogen activator system in body fluid samples
|
US7473534B2
(en)
|
2002-03-01 |
2009-01-06 |
Siemens Healthcare Diagnostics Inc. |
Assays for cancer patient monitoring based on levels of epidermal growth factor receptor (EGFR) extracellular domain (ECD) analyte, alone or in combination with other analytes, in body fluid samples
|
WO2003075845A2
(en)
|
2002-03-07 |
2003-09-18 |
The Forsyth Institute |
Immunogenicity of glucan binding protein
|
AU2003218456A1
(en)
*
|
2002-04-01 |
2003-10-20 |
Human Genome Sciences, Inc. |
Antibodies that specifically bind to gmad
|
GB0207533D0
(en)
|
2002-04-02 |
2002-05-08 |
Oxford Glycosciences Uk Ltd |
Protein
|
US7745192B2
(en)
|
2002-04-03 |
2010-06-29 |
Venomics Pty Limited |
Prothrombin activating protein
|
US7371383B2
(en)
|
2002-04-12 |
2008-05-13 |
Medimmune, Inc. |
Recombinant anti-interleukin-9 antibodies
|
US20030206898A1
(en)
|
2002-04-26 |
2003-11-06 |
Steven Fischkoff |
Use of anti-TNFalpha antibodies and another drug
|
AR039839A1
(es)
|
2002-05-21 |
2005-03-02 |
Dsm Ip Assets Bv |
Fosfolipasas y usos de las mismas
|
JP4753578B2
(ja)
*
|
2002-06-03 |
2011-08-24 |
ジェネンテック, インコーポレイテッド |
合成抗体ファージライブラリー
|
EP2305710A3
(en)
|
2002-06-03 |
2013-05-29 |
Genentech, Inc. |
Synthetic antibody phage libraries
|
CN100418981C
(zh)
*
|
2002-06-10 |
2008-09-17 |
瓦西尼斯公司 |
在乳腺癌和膀胱癌中差异表达的基因及编码多肽
|
AU2003240005B2
(en)
*
|
2002-06-14 |
2010-08-12 |
Takeda Pharmaceutical Company Limited |
Recombination of nucleic acid library members
|
US7425618B2
(en)
|
2002-06-14 |
2008-09-16 |
Medimmune, Inc. |
Stabilized anti-respiratory syncytial virus (RSV) antibody formulations
|
EP2283869A3
(en)
|
2002-07-15 |
2012-06-27 |
Board of Regents, The University of Texas System |
Selected antibodies and duramycin peptides binding to anionic phospholipids and aminophospholipids and their use in the treatment of viral infections and cancer
|
JP4836451B2
(ja)
|
2002-07-18 |
2011-12-14 |
メルス ベー ヴェー |
抗体混合物の組換え生産
|
USRE47770E1
(en)
|
2002-07-18 |
2019-12-17 |
Merus N.V. |
Recombinant production of mixtures of antibodies
|
US20040126372A1
(en)
|
2002-07-19 |
2004-07-01 |
Abbott Biotechnology Ltd. |
Treatment of TNFalpha related disorders
|
US7250551B2
(en)
|
2002-07-24 |
2007-07-31 |
President And Fellows Of Harvard College |
Transgenic mice expressing inducible human p25
|
CA2495121A1
(en)
|
2002-08-10 |
2004-02-19 |
Yale University |
Nogo receptor antagonists
|
US20040067532A1
(en)
*
|
2002-08-12 |
2004-04-08 |
Genetastix Corporation |
High throughput generation and affinity maturation of humanized antibody
|
DK1534335T4
(en)
|
2002-08-14 |
2015-10-05 |
Macrogenics Inc |
FCGAMMARIIB-SPECIFIC ANTIBODIES AND PROCEDURES FOR USE THEREOF
|
EA008007B1
(ru)
|
2002-08-19 |
2007-02-27 |
ДСМ Ай Пи ЭССЕТС Б.В. |
Новые липазы и их применение
|
AU2003250518A1
(en)
|
2002-08-20 |
2004-03-11 |
Yeda Research And Development Co. Ltd. |
Akap84 and its use for visualization of biological structures
|
EP2311978A1
(en)
|
2002-08-20 |
2011-04-20 |
Millennium Pharmaceuticals, Inc. |
Compositions, kits, and methods for identification, assessment, prevention, and therapy of cervical cancer
|
JP2006502167A
(ja)
|
2002-09-04 |
2006-01-19 |
バイオポリマー エンジニアリング,インコーポレイテッド |
全グルカン粒子および抗体を用いた癌治療
|
EP1539234A4
(en)
*
|
2002-09-05 |
2006-02-15 |
Medimmune Inc |
METHODS OF PREVENTING OR TREATING CELLULAR MALIGNITES BY ADMINISTERING CD2 ANTAGONISTS
|
ES2301818T3
(es)
*
|
2002-09-18 |
2008-07-01 |
The Trustees Of The University Of Pennsylvania |
Composiciones, procedimientos y kits para la deteccion de un antigeno sobre una celula y en una mezcla bilogica.
|
PT2301965E
(pt)
|
2002-10-16 |
2015-05-20 |
Purdue Pharma Lp |
Anticorpos que se ligam a ca 125/0722p associado a células e métodos para a sua utilização
|
US7427469B2
(en)
*
|
2002-11-05 |
2008-09-23 |
Institut Pasteur |
Method of treating cytomegalovirus with DC-SIGN blockers
|
BR0315975A
(pt)
*
|
2002-11-05 |
2005-09-20 |
Pasteur Institut |
Usos de uma quantidade de um modulador e de um bloqueador de dc-sign, composição farmacêutica, métodos para identificar um modulador e um bloqueador de dc-sign, bloqueador de dc-sign isolado, e, método para alvejar uma molécula objeto a uma célula que expressa um receptore de dc-sign
|
EP1629090B1
(en)
*
|
2002-11-06 |
2014-03-05 |
iBio, Inc. |
Expression of foreign sequences in plants using trans-activation system
|
US7683238B2
(en)
*
|
2002-11-12 |
2010-03-23 |
iBio, Inc. and Fraunhofer USA, Inc. |
Production of pharmaceutically active proteins in sprouted seedlings
|
US7692063B2
(en)
*
|
2002-11-12 |
2010-04-06 |
Ibio, Inc. |
Production of foreign nucleic acids and polypeptides in sprout systems
|
US8148608B2
(en)
*
|
2004-02-20 |
2012-04-03 |
Fraunhofer Usa, Inc |
Systems and methods for clonal expression in plants
|
AU2003302470A1
(en)
*
|
2002-11-26 |
2004-06-18 |
Dyax Corporation |
Methods and compositions for controlling valency of phage display
|
DE10256669B4
(de)
|
2002-12-04 |
2006-03-09 |
Universitätsklinikum Charité an der Humboldt-Universität zu Berlin Technologietransferstelle |
Gemisch mindestens zweier Fusionsproteine sowie ihre Herstellung und Verwendung
|
DE602004031589D1
(de)
|
2003-01-07 |
2011-04-14 |
Dyax Corp |
Kunitz-domäne-bibliothek
|
CA2510003A1
(en)
*
|
2003-01-16 |
2004-08-05 |
Genentech, Inc. |
Synthetic antibody phage libraries
|
WO2004065551A2
(en)
*
|
2003-01-21 |
2004-08-05 |
Bristol-Myers Squibb Company |
Polynucleotide encoding a novel acyl coenzyme a, monoacylglycerol acyltransferase-3 (mgat3), and uses thereof
|
DE10303974A1
(de)
|
2003-01-31 |
2004-08-05 |
Abbott Gmbh & Co. Kg |
Amyloid-β(1-42)-Oligomere, Verfahren zu deren Herstellung und deren Verwendung
|
ES2531125T3
(es)
*
|
2003-02-03 |
2015-03-10 |
Ibio Inc |
Sistema para la expresión de genes en plantas
|
EP1947116B1
(en)
|
2003-02-10 |
2017-06-21 |
2-BBB Medicines B.V. |
Differentially expressed nucleic acids in the blood-brain barrier under inflammatory conditions
|
CA2516455C
(en)
|
2003-02-20 |
2012-05-01 |
Seattle Genetics, Inc. |
Anti-cd70 antibody-drug conjugates and their use for the treatment of cancer and immune disorders
|
US20040180387A1
(en)
|
2003-03-13 |
2004-09-16 |
Fujirebio Diagnostics, Inc. |
Detection of urinary mesothelin-/megakaryocyte potentiating factor-related peptides for assessment of ovarian cancer
|
RS54160B1
(sr)
|
2003-03-19 |
2015-12-31 |
Biogen Idec Ma Inc. |
Protein koji se vezuje za nogo receptor
|
US7294701B2
(en)
*
|
2003-04-02 |
2007-11-13 |
Technion Research & Development Foundation Ltd. |
Antibody fragment capable of modulating multidrug resistance and compositions and kits and methods using same
|
EP2316487B1
(en)
|
2003-04-11 |
2014-06-11 |
MedImmune, LLC |
Recombinant IL-9 antibodies & uses thereof
|
US20050014932A1
(en)
|
2003-05-15 |
2005-01-20 |
Iogenetics, Llc |
Targeted biocides
|
WO2005026375A2
(en)
|
2003-05-22 |
2005-03-24 |
Fraunhofer Usa, Inc. |
Recombinant carrier molecule for expression, delivery and purification of target polypeptides
|
WO2004106375A1
(en)
|
2003-05-30 |
2004-12-09 |
Merus Biopharmaceuticals B.V. I.O. |
Fab library for the preparation of anti vegf and anti rabies virus fabs
|
US9708410B2
(en)
|
2003-05-30 |
2017-07-18 |
Janssen Biotech, Inc. |
Anti-tissue factor antibodies and compositions
|
US20100069614A1
(en)
|
2008-06-27 |
2010-03-18 |
Merus B.V. |
Antibody producing non-human mammals
|
EP2508608A1
(en)
|
2003-06-09 |
2012-10-10 |
Alnylam Pharmaceuticals Inc. |
Method of treating neurodegenerative disease
|
JP2008500005A
(ja)
*
|
2003-07-15 |
2008-01-10 |
バロス リサーチ インスティテュート |
癌及び感染症の免疫療法のための組成物及び方法
|
WO2005010163A2
(en)
*
|
2003-07-15 |
2005-02-03 |
Barros Research Institute |
Compositions and methods for immunotherapy of human immunotherapy of human immunodeficiency virus (hiv)
|
WO2005011580A2
(en)
*
|
2003-07-25 |
2005-02-10 |
Board Of Regents, The University Of Texas System |
Compositions and methods for herpes simplex prophylaxis and treatment
|
JP2007501011A
(ja)
*
|
2003-08-01 |
2007-01-25 |
ジェネンテック・インコーポレーテッド |
制限多様性配列を有する結合型ポリペプチド
|
US20050106667A1
(en)
|
2003-08-01 |
2005-05-19 |
Genentech, Inc |
Binding polypeptides with restricted diversity sequences
|
US7758859B2
(en)
|
2003-08-01 |
2010-07-20 |
Genentech, Inc. |
Anti-VEGF antibodies
|
HN2004000285A
(es)
|
2003-08-04 |
2006-04-27 |
Pfizer Prod Inc |
ANTICUERPOS DIRIGIDOS A c-MET
|
WO2005014795A2
(en)
|
2003-08-08 |
2005-02-17 |
Genenews Inc. |
Osteoarthritis biomarkers and uses thereof
|
JP4934426B2
(ja)
|
2003-08-18 |
2012-05-16 |
メディミューン,エルエルシー |
抗体のヒト化
|
AR045563A1
(es)
|
2003-09-10 |
2005-11-02 |
Warner Lambert Co |
Anticuerpos dirigidos a m-csf
|
US7799518B2
(en)
|
2003-10-07 |
2010-09-21 |
Millennium Pharmaceuticals, Inc. |
Nucleic acid molecules and proteins for the identification, assessment, prevention, and therapy of ovarian cancer
|
IL158287A0
(en)
|
2003-10-07 |
2004-05-12 |
Yeda Res & Dev |
Antibodies to nik, their preparation and use
|
US20070274988A1
(en)
*
|
2003-10-10 |
2007-11-29 |
Five Prime Therapeautics, Inc. |
Kiaa0779, Splice Variants Thereof, and Methods of Their Use
|
US7329725B1
(en)
*
|
2003-10-29 |
2008-02-12 |
Nastech Pharmaceutical Company Inc. |
Phage displayed Trp cage ligands
|
JP2005139011A
(ja)
*
|
2003-11-04 |
2005-06-02 |
Nof Corp |
火薬原料及びその製造方法
|
GB0325836D0
(en)
*
|
2003-11-05 |
2003-12-10 |
Celltech R&D Ltd |
Biological products
|
US20050100965A1
(en)
|
2003-11-12 |
2005-05-12 |
Tariq Ghayur |
IL-18 binding proteins
|
EP2974742A1
(en)
*
|
2003-11-21 |
2016-01-20 |
UCB Biopharma SPRL |
Method for the treatment of multiple sclerosis by inhibiting il-17 activity
|
ATE526037T1
(de)
*
|
2003-12-04 |
2011-10-15 |
Vaccinex Inc |
Verfahren zum abtöten von tumorzellen mittels targeting von auf apoptotischen tumorzellen exponierten internen antigenen
|
GB0329825D0
(en)
|
2003-12-23 |
2004-01-28 |
Celltech R&D Ltd |
Biological products
|
US20050266425A1
(en)
*
|
2003-12-31 |
2005-12-01 |
Vaccinex, Inc. |
Methods for producing and identifying multispecific antibodies
|
SI2177537T1
(sl)
|
2004-01-09 |
2012-01-31 |
Pfizer |
Protitielesa proti MAdCAM
|
AU2005205412B2
(en)
|
2004-01-20 |
2011-08-11 |
Merus N.V. |
Mixtures of binding proteins
|
WO2005072341A2
(en)
|
2004-01-21 |
2005-08-11 |
Fujirebio America, Inc. |
Detection of mesothelin-/megakaryocyte potentiating factor-related peptides in peritoneal fluid for assessment of the peritoneum and the peritoneal cavity
|
HUE027902T2
(en)
|
2004-02-09 |
2016-11-28 |
Human Genome Sciences Inc Corp Service Company |
Albumin fusion proteins
|
ES2337473T3
(es)
|
2004-02-19 |
2010-04-26 |
Genentech, Inc. |
Anticuerpos reparadores con cdr.
|
CA2560066A1
(en)
|
2004-03-01 |
2005-09-15 |
The Cbr Institute For Biomedical Research, Inc. |
Natural igm antibodies and inhibitors thereof
|
EP1756577B1
(en)
|
2004-03-24 |
2012-03-14 |
Tripath Imaging, Inc. |
Methods and compositions for the detection of cervical disease
|
WO2005097184A2
(en)
*
|
2004-03-26 |
2005-10-20 |
Human Genome Sciences, Inc. |
Antibodies against nogo receptor
|
US7785903B2
(en)
*
|
2004-04-09 |
2010-08-31 |
Genentech, Inc. |
Variable domain library and uses
|
TWI556829B
(zh)
|
2004-04-09 |
2016-11-11 |
艾伯維生物技術有限責任公司 |
用於治療TNFα相關失調症之多重可變劑量療法
|
ES2482142T3
(es)
|
2004-04-15 |
2014-08-01 |
University Of Florida Research Foundation, Inc. |
Proteínas neurales como biomarcadores para lesiones del sistema nervioso y otros trastornos neurales
|
ES2442386T3
(es)
|
2004-04-23 |
2014-02-11 |
Bundesrepublik Deutschland Letztvertreten Durch Das Robert Koch-Institut Vertreten Durch Seinen Pr |
Método para el tratamiento de condiciones mediadas por células T por la disminución de las células positivas de ICOS in vivo.
|
WO2005118647A2
(en)
*
|
2004-05-18 |
2005-12-15 |
Genentech, Inc. |
M13 virus major coat protein variants for c-terminal and bi-terminal display of a heterologous protein
|
AU2005250056A1
(en)
|
2004-06-03 |
2005-12-15 |
Athlomics Pty Ltd |
Agents and methods for diagnosing stress
|
GB0414054D0
(en)
|
2004-06-23 |
2004-07-28 |
Owen Mumford Ltd |
Improvements relating to automatic injection devices
|
KR101239542B1
(ko)
|
2004-06-24 |
2013-03-07 |
바이오겐 아이덱 엠에이 인코포레이티드 |
탈수초화를 수반하는 병의 치료
|
US7241598B2
(en)
*
|
2004-06-29 |
2007-07-10 |
The Chinese University Of Hong Kong |
Frame-shifting PCR for germline immunoglobulin genes retrieval and antibody engineering
|
US6986264B1
(en)
*
|
2004-07-15 |
2006-01-17 |
Carrier Corporation |
Economized dehumidification system
|
EP2322217A3
(en)
|
2004-07-16 |
2011-09-28 |
Pfizer Products Inc. |
Combination treatment for non-hematologic malignancies using an anti-IGF-1R antibody
|
US7342093B2
(en)
|
2004-07-23 |
2008-03-11 |
University Of Massachusetts |
Compounds that inhibit Hsp90 protein-protein interactions with IAP proteins
|
CA2576193A1
(en)
|
2004-08-03 |
2006-02-16 |
Biogen Idec Ma Inc. |
Taj in neuronal function
|
US20060068421A1
(en)
*
|
2004-08-05 |
2006-03-30 |
Biosite, Inc. |
Compositions and methods for phage display of polypeptides
|
ES2555355T3
(es)
|
2004-09-03 |
2015-12-30 |
Genentech, Inc. |
Antagonistas anti-beta7 humanizados y utilizaciones para los mismos
|
US7700720B2
(en)
|
2004-09-21 |
2010-04-20 |
Medimmune, Llc |
Antibodies against and methods for producing vaccines for respiratory syncytial virus
|
US7435804B2
(en)
*
|
2004-10-19 |
2008-10-14 |
Phage Biotechnology, Inc. |
Method for obtaining single chain antibodies to human interferon α2b
|
WO2006047417A2
(en)
|
2004-10-21 |
2006-05-04 |
University Of Florida Research Foundation, Inc. |
Detection of cannabinoid receptor biomarkers and uses thereof
|
EP2422811A2
(en)
|
2004-10-27 |
2012-02-29 |
MedImmune, LLC |
Modulation of antibody specificity by tailoring the affinity to cognate antigens
|
GB0426146D0
(en)
|
2004-11-29 |
2004-12-29 |
Bioxell Spa |
Therapeutic peptides and method
|
PT1772465E
(pt)
|
2005-01-05 |
2009-05-21 |
F Star Biotech Forsch & Entw |
Domínios de imunoglobulina sintética com propriedades de ligação construídos em regiões da molécula diferentes das regiões determinantes de complementaridade
|
GT200600031A
(es)
|
2005-01-28 |
2006-08-29 |
|
Formulacion anticuerpo anti a beta
|
CA2599589A1
(en)
|
2005-02-07 |
2006-08-17 |
Genenews,Inc. |
Mild osteoarthritis biomarkers and uses thereof
|
CA2597924C
(en)
|
2005-02-15 |
2018-10-02 |
Duke University |
Anti-cd19 antibodies and uses in oncology
|
GB0503546D0
(en)
*
|
2005-02-21 |
2005-03-30 |
Hellenic Pasteur Inst |
Antibody
|
US20090142338A1
(en)
*
|
2005-03-04 |
2009-06-04 |
Curedm, Inc. |
Methods and Compositions for Treating Type 1 and Type 2 Diabetes Mellitus and Related Conditions
|
EP1858545A2
(en)
|
2005-03-04 |
2007-11-28 |
Curedm Inc. |
Methods and pharmaceutical compositions for treating type 1 diabetes mellitus and other conditions
|
JP5153613B2
(ja)
|
2005-03-18 |
2013-02-27 |
メディミューン,エルエルシー |
抗体のフレームワーク・シャッフル
|
SI2567976T1
(sl)
|
2005-03-23 |
2017-11-30 |
Genmab A/S |
Protitelesa usmerjena proti cd38 za zdravljenje multiplega mieloma
|
GB0506912D0
(en)
|
2005-04-05 |
2005-05-11 |
Celltech R&D Ltd |
Biological products
|
ES2707152T3
(es)
|
2005-04-15 |
2019-04-02 |
Macrogenics Inc |
Diacuerpos covalentes y usos de los mismos
|
US9889197B2
(en)
|
2005-04-15 |
2018-02-13 |
Macrogenics, Inc. |
Covalently-associated diabody complexes that possess charged coil domains and that are capable of enhanced binding to serum albumin
|
US20060269556A1
(en)
*
|
2005-04-18 |
2006-11-30 |
Karl Nocka |
Mast cell activation using siglec 6 antibodies
|
AU2006236225C1
(en)
|
2005-04-19 |
2013-05-02 |
Seagen Inc. |
Humanized anti-CD70 binding agents and uses thereof
|
JP2008539241A
(ja)
|
2005-04-25 |
2008-11-13 |
ファイザー インコーポレイティッド |
ミオスタチンに対する抗体
|
KR101193797B1
(ko)
|
2005-04-26 |
2012-10-23 |
화이자 인코포레이티드 |
P-카드헤린 항체
|
US7595380B2
(en)
|
2005-04-27 |
2009-09-29 |
Tripath Imaging, Inc. |
Monoclonal antibodies and methods for their use in the detection of cervical disease
|
WO2006121852A2
(en)
|
2005-05-05 |
2006-11-16 |
Duke University |
Anti-cd19 antibody therapy for autoimmune disease
|
NZ591701A
(en)
|
2005-05-16 |
2012-11-30 |
Abbott Biotech Ltd |
Use of tnf inhibitor for treatment of erosive polyarthritis
|
PL1899364T3
(pl)
|
2005-05-17 |
2020-08-24 |
University Of Connecticut |
Kompozycje i sposoby immunomodulacji w organizmie
|
US7393919B2
(en)
|
2005-05-25 |
2008-07-01 |
Cure Dm, Inc. |
Peptides, derivatives and analogs thereof, and methods of using same
|
PL1888113T3
(pl)
|
2005-05-27 |
2014-11-28 |
Biogen Ma Inc |
Przeciwciała wiążące TWEAK
|
US7767789B2
(en)
*
|
2005-06-02 |
2010-08-03 |
University Hopitals of Cleveland |
Truncated proteins as cancer markers
|
ES2405079T3
(es)
|
2005-06-17 |
2013-05-30 |
Wyeth Llc |
Métodos para purificar anticuerpos de la región Fc
|
KR20080025174A
(ko)
|
2005-06-23 |
2008-03-19 |
메디뮨 인코포레이티드 |
응집 및 단편화 프로파일이 최적화된 항체 제제
|
TW201444869A
(zh)
*
|
2005-06-30 |
2014-12-01 |
Abbvie Inc |
Il-12/p40結合蛋白
|
AU2006269820B2
(en)
|
2005-07-07 |
2012-01-19 |
Athlomics Pty Ltd |
Polynucleotide marker genes and their expression, for diagnosis of endotoxemia
|
US7482124B2
(en)
|
2005-07-08 |
2009-01-27 |
Bristol-Myers Squibb Company |
Method of identifying a PPARgamma-agonist compound having a decreased likelihood of inducing dose-dependent peripheral edema
|
RS53058B
(en)
|
2005-07-08 |
2014-04-30 |
Biogen Idec Ma Inc. |
SP35 ANTIBODIES AND THEIR APPLICATIONS
|
AU2006274698B2
(en)
|
2005-08-02 |
2011-06-09 |
Xbiotech, Inc. |
Diagnosis, treatment, and prevention of vascular disorders using IL-1a autoantibodies
|
EP1920057A4
(en)
|
2005-08-03 |
2009-03-18 |
Grains Res & Dev Corp |
POLYSACCHARIDE synthases
|
WO2007117264A2
(en)
*
|
2005-08-03 |
2007-10-18 |
Fraunhofer Usa, Inc. |
Compositions and methods for production of immunoglobulins
|
US20070202512A1
(en)
*
|
2005-08-19 |
2007-08-30 |
Bristol-Myers Squibb Company |
Human single nucleotide polymorphisms associated with dose-dependent weight gain and methods of use thereof
|
US20090215992A1
(en)
*
|
2005-08-19 |
2009-08-27 |
Chengbin Wu |
Dual variable domain immunoglobulin and uses thereof
|
US20070041905A1
(en)
|
2005-08-19 |
2007-02-22 |
Hoffman Rebecca S |
Method of treating depression using a TNF-alpha antibody
|
EP1928506A4
(en)
|
2005-08-19 |
2009-10-21 |
Abbott Lab |
IMMUNOGLOBULIN HAVING TWO VARIABLE DOMAINS AND USES THEREOF
|
US7612181B2
(en)
|
2005-08-19 |
2009-11-03 |
Abbott Laboratories |
Dual variable domain immunoglobulin and uses thereof
|
EP2500353A3
(en)
|
2005-08-19 |
2012-10-10 |
Abbott Laboratories |
Dual variable domain immunoglobulin and uses thereof
|
CA2621371C
(en)
|
2005-09-07 |
2018-05-15 |
Amgen Fremont Inc. |
Human monoclonal antibodies to activin receptor-like kinase-1
|
EP1926757B1
(en)
*
|
2005-09-14 |
2012-02-22 |
UCB Pharma, S.A. |
Antibody-comb polymer conjugate
|
JP2009510002A
(ja)
|
2005-09-30 |
2009-03-12 |
アボット ゲゼルシャフト ミット ベシュレンクテル ハフツング ウント コンパニー コマンディトゲゼルシャフト |
反発誘導分子(rgm)タンパク質ファミリーのタンパク質の結合ドメイン、及びその機能的断片、及びそれらの使用
|
GB0520169D0
(en)
*
|
2005-10-04 |
2005-11-09 |
Celltech R&D Ltd |
Biological products
|
EP2319941A3
(en)
|
2005-10-21 |
2011-08-17 |
GeneNews Inc. |
Method and apparatus for correlating levels of biomarker products with disease
|
JP5602365B2
(ja)
|
2005-10-25 |
2014-10-08 |
ザ・ジョンズ・ホプキンス・ユニバーシティ |
マルファン症候群及び関連疾患を治療するための方法及び組成物。
|
JP2009513135A
(ja)
|
2005-10-28 |
2009-04-02 |
プリーシス・ファーマシューティカルズ・インコーポレイテッド |
エンコードされたライブラリーを用いて興味のある化合物を同定する方法
|
RU2438704C2
(ru)
|
2005-11-01 |
2012-01-10 |
Эбботт Байотекнолоджи Лтд. |
Способы и композиции для диагностики анкилозирующих спондилитов с использованием биомаркеров
|
CA2628451A1
(en)
|
2005-11-04 |
2007-05-18 |
Biogen Idec Ma Inc. |
Methods for promoting neurite outgrowth and survival of dopaminergic neurons
|
AU2006311661B2
(en)
|
2005-11-07 |
2011-05-26 |
The Scripps Research Institute |
Compositions and methods for controlling tissue factor signaling specificity
|
WO2007056441A2
(en)
|
2005-11-07 |
2007-05-18 |
Genentech, Inc. |
Binding polypeptides with diversified and consensus vh/vl hypervariable sequences
|
UA96139C2
(uk)
|
2005-11-08 |
2011-10-10 |
Дженентек, Інк. |
Антитіло до нейропіліну-1 (nrp1)
|
EP1949109B1
(en)
|
2005-11-14 |
2012-02-29 |
MetaMol Theranostics, LLC |
Peptide sequence that promotes tumor invasion
|
DK1963369T3
(da)
|
2005-11-28 |
2013-06-03 |
Zymogenetics Inc |
Il-21-antagonister
|
SG2014013437A
(en)
|
2005-11-30 |
2014-07-30 |
Abbott Lab |
Monoclonal antibodies and uses thereof
|
RU2442793C2
(ru)
|
2005-11-30 |
2012-02-20 |
Эбботт Лэборетриз |
АНТИТЕЛА ПРОТИВ ГЛОБУЛОМЕРА Аβ, ИХ АНТИГЕНСВЯЗЫВАЮЩИЕ ЧАСТИ, СООТВЕТСТВУЮЩИЕ ГИБРИДОМЫ, НУКЛЕИНОВЫЕ КИСЛОТЫ, ВЕКТОРЫ, КЛЕТКИ-ХОЗЯЕВА, СПОСОБЫ ПОЛУЧЕНИЯ УКАЗАННЫХ АНТИТЕЛ, КОМПОЗИЦИИ, СОДЕРЖАЩИЕ УКАЗАННЫЕ АНТИТЕЛА, ПРИМЕНЕНИЯ УКАЗАННЫХ АНТИТЕЛ И СПОСОБЫ ИСПОЛЬЗОВАНИЯ УКАЗАННЫХ АНТИТЕЛ
|
US8957187B2
(en)
*
|
2005-12-02 |
2015-02-17 |
Genentech, Inc. |
Binding polypeptides and uses thereof
|
EP2543384A3
(en)
|
2005-12-02 |
2013-04-10 |
Biogen Idec MA Inc. |
Treatment of conditions involving demyelination
|
EP1973951A2
(en)
*
|
2005-12-02 |
2008-10-01 |
Genentech, Inc. |
Binding polypeptides with restricted diversity sequences
|
ZA200804594B
(en)
|
2005-12-09 |
2010-08-25 |
Ucb Pharma Sa |
Antibody molecules having specificity for human IL-6
|
US10183986B2
(en)
|
2005-12-15 |
2019-01-22 |
Industrial Technology Research Institute |
Trimeric collagen scaffold antibodies
|
US8014957B2
(en)
|
2005-12-15 |
2011-09-06 |
Fred Hutchinson Cancer Research Center |
Genes associated with progression and response in chronic myeloid leukemia and uses thereof
|
US20070264687A1
(en)
|
2005-12-15 |
2007-11-15 |
Min-Yuan Chou |
Recombinant triplex scaffold-based polypeptides
|
US7632498B2
(en)
|
2005-12-19 |
2009-12-15 |
Tripath Imaging, Inc. |
MCM6 and MCM7 monoclonal antibodies and methods for their use in the detection of cervical disease
|
KR20080094803A
(ko)
|
2006-01-27 |
2008-10-24 |
트리패스 이미징, 인코포레이티드 |
난소암의 발병 가능성이 높은 환자를 확인하는 방법 및 그의 조성물
|
CA2913655A1
(en)
|
2006-01-27 |
2007-08-09 |
Biogen Ma Inc. |
Nogo receptor antagonists
|
EP1987361A4
(en)
*
|
2006-01-30 |
2009-03-04 |
Invitrogen Corp |
COMPOSITIONS AND METHODS FOR DETECTING AND QUANTIFYING TOXIC SUBSTANCES IN DISEASE STATES
|
US20070175313A1
(en)
*
|
2006-01-31 |
2007-08-02 |
Kevin Vandervliet |
MP3 player holder assembly
|
WO2008048344A2
(en)
*
|
2006-02-13 |
2008-04-24 |
Fraunhofer Usa, Inc. |
Bacillus anthracis antigens, vaccine compositions, and related methods
|
EP1984388B1
(en)
*
|
2006-02-13 |
2016-07-06 |
iBio, Inc. |
Hpv antigens, vaccine compositions, and related methods
|
BRPI0707733B1
(pt)
*
|
2006-02-13 |
2019-12-31 |
Fraunhofer Usa Inc |
antígeno isolado, composição de vacina, uso da referida composição e método para produção de uma proteína de antígeno
|
TWI417301B
(zh)
|
2006-02-21 |
2013-12-01 |
Wyeth Corp |
對抗人類介白素-22(il-22)之抗體及其用途
|
TW200744634A
(en)
|
2006-02-21 |
2007-12-16 |
Wyeth Corp |
Methods of using antibodies against human IL-22
|
EP2650306A1
(en)
|
2006-03-06 |
2013-10-16 |
Aeres Biomedical Limited |
Humanized Anti-CD22 antibodies and their use in treatment of oncology, transplantation and autoimmune disease
|
US8278421B2
(en)
|
2006-03-20 |
2012-10-02 |
Xoma Techolology Ltd. |
Human antibodies specific for gastrin materials and methods
|
TWI392684B
(zh)
|
2006-04-05 |
2013-04-11 |
Abbott Biotech Ltd |
抗體之純化
|
EP2708242A3
(en)
|
2006-04-10 |
2014-03-26 |
Abbott Biotechnology Ltd |
Uses and compositions for treatment of ankylosing spondylitis
|
CA2564435A1
(en)
|
2006-04-10 |
2007-10-10 |
Abbott Biotechnology Ltd. |
Methods for monitoring and treating intestinal disorders
|
WO2008063213A2
(en)
|
2006-04-10 |
2008-05-29 |
Abbott Biotechnology Ltd. |
Uses and compositions for treatment of psoriatic arthritis
|
US7702468B2
(en)
|
2006-05-03 |
2010-04-20 |
Population Diagnostics, Inc. |
Evaluating genetic disorders
|
US10522240B2
(en)
|
2006-05-03 |
2019-12-31 |
Population Bio, Inc. |
Evaluating genetic disorders
|
CA2651567A1
(en)
*
|
2006-05-09 |
2007-11-22 |
Genentech, Inc. |
Binding polypeptides with optimized scaffolds
|
WO2007137616A1
(en)
*
|
2006-05-30 |
2007-12-06 |
Millegen |
Highly diversified antibody libraries
|
GB0611116D0
(en)
|
2006-06-06 |
2006-07-19 |
Oxford Genome Sciences Uk Ltd |
Proteins
|
BRPI0713426A2
(pt)
|
2006-06-14 |
2012-10-09 |
Macrogenics Inc |
métodos de tratar, diminuir a progressão, ou melhorar um ou mais sintomas de um distúrbio, e de prevenir ou retardar o inìcio de um distúrbio
|
LT2029173T
(lt)
|
2006-06-26 |
2016-11-10 |
Macrogenics, Inc. |
Fc riib specifiniai antikūnai ir jų panaudojimo būdai
|
TWI527603B
(zh)
|
2006-06-30 |
2016-04-01 |
艾伯維生物技術有限責任公司 |
自動注射裝置
|
US7572618B2
(en)
|
2006-06-30 |
2009-08-11 |
Bristol-Myers Squibb Company |
Polynucleotides encoding novel PCSK9 variants
|
KR101476458B1
(ko)
|
2006-07-05 |
2015-01-05 |
카탈리스트 바이오사이언시즈, 인코포레이티드 |
프로테아제 스크리닝 방법 및 이에 의해 확인된 프로테아제
|
AT503889B1
(de)
|
2006-07-05 |
2011-12-15 |
Star Biotechnologische Forschungs Und Entwicklungsges M B H F |
Multivalente immunglobuline
|
EP2450710B1
(en)
|
2006-07-14 |
2020-09-02 |
The Regents of The University of California |
Cancer biomarkers and methods of use thereof
|
USRE47123E1
(en)
|
2006-07-18 |
2018-11-13 |
Sanofi |
EPHA2 receptor antagonist antibodies
|
PL2511301T3
(pl)
|
2006-08-04 |
2018-05-30 |
Medimmune Limited |
Ludzkie przeciwciała do ErbB2
|
JP5209625B2
(ja)
|
2006-08-28 |
2013-06-12 |
協和発酵キリン株式会社 |
アンタゴニストのヒトlight特異的ヒトモノクローナル抗体
|
MX349810B
(es)
|
2006-09-08 |
2017-08-14 |
Abbvie Bahamas Ltd |
Proteinas de enlace de interleucina-13.
|
SI2081595T1
(sl)
|
2006-09-26 |
2019-10-30 |
Genmab As |
Anti-cd38 plus kortikosteroidi plus ne-kortikosteroidni kemoterapevtik za zdravljenje tumorjev
|
RU2486201C2
(ru)
|
2006-10-12 |
2013-06-27 |
Дженентек, Инк. |
Антитела к лимфотоксину-альфа
|
CA2665423A1
(en)
|
2006-10-12 |
2008-04-17 |
Wyeth |
Methods and compositions with reduced opalescence
|
EP2407548A1
(en)
|
2006-10-16 |
2012-01-18 |
MedImmune, LLC |
Molecules with reduced half-lives, compositions and uses thereof
|
GB0620729D0
(en)
|
2006-10-18 |
2006-11-29 |
Ucb Sa |
Biological products
|
EP1914242A1
(en)
|
2006-10-19 |
2008-04-23 |
Sanofi-Aventis |
Novel anti-CD38 antibodies for the treatment of cancer
|
US8192951B2
(en)
|
2006-11-03 |
2012-06-05 |
Wyeth Llc |
Glycolysis-inhibiting substances in cell culture
|
EP1921142A1
(en)
*
|
2006-11-07 |
2008-05-14 |
Cytos Biotechnology AG |
Selection of human monoclonal antibodies by eukaryotic cell display
|
KR20090088896A
(ko)
|
2006-11-09 |
2009-08-20 |
아이알엠 엘엘씨 |
효현제 trkb 항체 및 그의 용도
|
EP2514439A1
(en)
|
2006-11-15 |
2012-10-24 |
Functional Genetics, Inc. |
Anti-TSG101antibodies and their uses for treatment of viral infections
|
US8785400B2
(en)
*
|
2006-11-22 |
2014-07-22 |
Curedm Group Holdings, Llc |
Methods and compositions relating to islet cell neogenesis
|
US7488807B2
(en)
|
2006-11-22 |
2009-02-10 |
3M Innovative Properties Company |
Antibody with protein A selectivity
|
US8455626B2
(en)
|
2006-11-30 |
2013-06-04 |
Abbott Laboratories |
Aβ conformer selective anti-aβ globulomer monoclonal antibodies
|
ES2523915T5
(es)
|
2006-12-01 |
2022-05-26 |
Seagen Inc |
Agentes de unión a la diana variantes y usos de los mismos
|
EP2687232A1
(en)
|
2006-12-06 |
2014-01-22 |
MedImmune, LLC |
Methods of treating systemic lupus erythematosus
|
CN103405768A
(zh)
|
2006-12-20 |
2013-11-27 |
爱克索马技术有限公司 |
用于治疗IL-1β相关疾病的方法
|
WO2008083174A2
(en)
|
2006-12-27 |
2008-07-10 |
Emory University |
Compositions and methods for the treatment of infections and tumors
|
EP2740744B1
(en)
|
2007-01-09 |
2018-03-28 |
Biogen MA Inc. |
Sp35 antibodies and uses thereof
|
US8128926B2
(en)
|
2007-01-09 |
2012-03-06 |
Biogen Idec Ma Inc. |
Sp35 antibodies and uses thereof
|
CN104524567A
(zh)
|
2007-01-16 |
2015-04-22 |
阿布维公司 |
用于治疗银屑病的方法
|
CN102317470A
(zh)
|
2007-02-07 |
2012-01-11 |
解码遗传学私营有限责任公司 |
促进***癌风险的遗传性变型
|
EP2468776A3
(en)
|
2007-02-09 |
2012-11-14 |
Genentech, Inc. |
Anti-Robo4 antibodies and uses therefor
|
US8114606B2
(en)
|
2007-02-16 |
2012-02-14 |
The Board Of Trustees Of Southern Illinois University |
ARL-1 specific antibodies
|
US8685666B2
(en)
*
|
2007-02-16 |
2014-04-01 |
The Board Of Trustees Of Southern Illinois University |
ARL-1 specific antibodies and uses thereof
|
MX2009008878A
(es)
|
2007-02-21 |
2009-08-28 |
Decode Genetics Ehf |
Variantes de susceptibilidad genetica asociada con la enfermedad cardiovascular.
|
WO2008104803A2
(en)
|
2007-02-26 |
2008-09-04 |
Oxford Genome Sciences (Uk) Limited |
Proteins
|
EP3118221B1
(en)
|
2007-02-26 |
2019-08-21 |
Oxford BioTherapeutics Ltd |
Proteins
|
US20100311767A1
(en)
|
2007-02-27 |
2010-12-09 |
Abbott Gmbh & Co. Kg |
Method for the treatment of amyloidoses
|
DK2121919T3
(da)
|
2007-03-22 |
2012-05-21 |
Heptares Therapeutics Ltd |
Mutante g-proteinkoblede receptorer og fremgangsmåder til udvælgelse heraf
|
PL2125894T3
(pl)
|
2007-03-22 |
2019-08-30 |
Biogen Ma Inc. |
Białka wiążące, w tym przeciwciała, pochodne przeciwciał i fragmenty przeciwciał, które swoiście wiążą się z CD154 i ich zastosowania
|
AU2008232902B2
(en)
|
2007-03-30 |
2013-10-03 |
Medlmmune, Llc |
Antibody formulation
|
MX2009010765A
(es)
|
2007-04-02 |
2009-10-26 |
Amgen Fremont Inc |
Anticuerpos anti-ige.
|
WO2008122310A1
(en)
*
|
2007-04-04 |
2008-10-16 |
Chimera Biotec Gmbh |
Method for the detection of an analyte in biological matrix
|
US7807168B2
(en)
*
|
2007-04-10 |
2010-10-05 |
Vaccinex, Inc. |
Selection of human TNFα specific antibodies
|
WO2008127702A2
(en)
|
2007-04-13 |
2008-10-23 |
Catalyst Biosciences, Inc. |
Modified factor vii polypetides and uses thereof
|
CA2685558A1
(en)
*
|
2007-04-28 |
2008-11-06 |
Fraunhofer Usa, Inc. |
Trypanosoma antigens, vaccine compositions, and related methods
|
CA2685213C
(en)
|
2007-05-04 |
2017-02-21 |
Technophage, Investigacao E Desenvolvimento Em Biotecnologia, Sa |
Engineered rabbit antibody variable domains and uses thereof
|
US20080279851A1
(en)
|
2007-05-07 |
2008-11-13 |
Medlmmune, Llc |
Anti-icos antibodies and their use in treatment of oncology, transplantation and autoimmune disease
|
SG10201503254TA
(en)
|
2007-05-14 |
2015-06-29 |
Medimmune Llc |
Methods of reducing eosinophil levels
|
BRPI0721707A2
(pt)
*
|
2007-05-17 |
2013-01-15 |
Genentech Inc |
estruturas de cristal de fragmentos de neuropilina e complexos de neuropilina-anticorpo
|
AU2008256219B2
(en)
|
2007-05-25 |
2014-06-05 |
Decode Genetics Ehf. |
Genetic variants on Chr 5p12 and 10q26 as markers for use in breast cancer risk assessment, diagnosis, prognosis and treatment
|
PE20090329A1
(es)
*
|
2007-05-30 |
2009-03-27 |
Abbott Lab |
Anticuerpos humanizados contra el globulomero ab(20-42) y sus usos
|
US20090232801A1
(en)
*
|
2007-05-30 |
2009-09-17 |
Abbot Laboratories |
Humanized Antibodies Which Bind To AB (1-42) Globulomer And Uses Thereof
|
EP2171451A4
(en)
|
2007-06-11 |
2011-12-07 |
Abbott Biotech Ltd |
METHOD FOR TREATING JUVENILIAN IDIOPATHIC ARTHRITIS
|
CA2691075C
(en)
|
2007-06-15 |
2017-04-11 |
Daniela Gast |
Treatment of tumors using specific anti-l1 antibody
|
JP5718637B2
(ja)
|
2007-06-21 |
2015-05-13 |
マクロジェニクス,インコーポレーテッド |
共有結合型ダイアボディおよびその使用
|
CN101802006B
(zh)
|
2007-06-26 |
2013-08-14 |
F-星生物技术研究与开发有限公司 |
展示结合剂
|
CA2692933C
(en)
|
2007-07-11 |
2016-10-18 |
Fraunhofer Usa, Inc. |
Yersinia pestis antigens, vaccine compositions, and related methods
|
RU2557319C2
(ru)
|
2007-07-16 |
2015-07-20 |
Дженентек, Инк. |
ГУМАНИЗИРОВАННЫЕ АНТИТЕЛА ПРОТИВ CD79b И ИММУНОКОНЪЮГАТЫ И СПОСОБЫ ПРИМЕНЕНИЯ
|
SG183023A1
(en)
|
2007-07-16 |
2012-08-30 |
Genentech Inc |
Anti-cd79b antibodies and immunoconjugates and methods of use
|
EP3031919B1
(en)
|
2007-07-31 |
2018-09-19 |
BASF Enzymes LLC |
Tailored multi-site combinational assembly
|
US20100273722A1
(en)
*
|
2007-08-06 |
2010-10-28 |
Yale University |
Modified miniature proteins
|
CA2696764A1
(en)
*
|
2007-08-20 |
2009-02-26 |
Fraunhofer Usa, Inc. |
Prophylactic and therapeutic influenza vaccines, antigens, compositions, and methods
|
US8816047B2
(en)
*
|
2007-08-30 |
2014-08-26 |
Cure DM Group Holdings, LLC |
Compositions and methods of using proislet peptides and analogs thereof
|
GB0717337D0
(en)
|
2007-09-06 |
2007-10-17 |
Ucb Pharma Sa |
Method of treatment
|
US8877688B2
(en)
*
|
2007-09-14 |
2014-11-04 |
Adimab, Llc |
Rationally designed, synthetic antibody libraries and uses therefor
|
CA3187687A1
(en)
*
|
2007-09-14 |
2009-03-19 |
Adimab, Llc |
Rationally designed, synthetic antibody libraries and uses therefor
|
CN101842387B
(zh)
|
2007-09-26 |
2014-05-07 |
Ucb医药有限公司 |
双特异性抗体融合物
|
MX2010004807A
(es)
*
|
2007-11-02 |
2010-08-02 |
Scripss Res Inst |
Evolucion dirigida utilizando proteinas que comprenden aminoacidos no naturales.
|
PT2219452E
(pt)
|
2007-11-05 |
2016-01-26 |
Medimmune Llc |
Métodos de tratamento de esclerodermia
|
MX2010005104A
(es)
|
2007-11-09 |
2010-08-04 |
Peregrine Pharmaceuticals Inc |
Composiciones de anticuerpo anti-factor de crecimiento endotelial vascular y metodos.
|
CA2705486C
(en)
|
2007-11-19 |
2019-04-02 |
Celera Corporation |
Lung cancer markers and uses thereof
|
US9308257B2
(en)
|
2007-11-28 |
2016-04-12 |
Medimmune, Llc |
Protein formulation
|
AR069501A1
(es)
|
2007-11-30 |
2010-01-27 |
Genentech Inc |
Anticuerpos anti- vegf (factor de crecimiento endotelial vascular)
|
US8697360B2
(en)
|
2007-11-30 |
2014-04-15 |
Decode Genetics Ehf. |
Genetic variants on CHR 11Q and 6Q as markers for prostate and colorectal cancer predisposition
|
GB0724051D0
(en)
|
2007-12-08 |
2008-01-16 |
Medical Res Council |
Mutant proteins and methods for producing them
|
ES2564523T3
(es)
|
2007-12-19 |
2016-03-23 |
Janssen Biotech, Inc. |
Diseño y generación de bibliotecas de presentación en fago por pIX de novo humanas mediante fusión con pIX o pVII, vectores, anticuerpos y métodos
|
GB0724860D0
(en)
|
2007-12-20 |
2008-01-30 |
Heptares Therapeutics Ltd |
Screening
|
US8637029B2
(en)
|
2007-12-20 |
2014-01-28 |
Xoma Technology Ltd. |
Methods for the treatment of gout
|
CN101932333A
(zh)
|
2007-12-26 |
2010-12-29 |
瓦西尼斯公司 |
抗c35抗体联合疗法和方法
|
PT2237803E
(pt)
|
2007-12-28 |
2015-10-16 |
Prothena Biosciences Ltd |
Tratamento e profilaxia da amiloidose
|
GB0800277D0
(en)
|
2008-01-08 |
2008-02-13 |
Imagination Tech Ltd |
Video motion compensation
|
AU2009203350B2
(en)
|
2008-01-11 |
2014-03-13 |
Gene Techno Science Co., Ltd. |
Humanized anti-alpha9 integrin antibodies and the uses thereof
|
CN102083460A
(zh)
|
2008-01-18 |
2011-06-01 |
米迪缪尼有限公司 |
用于位点特异性偶联的半胱氨酸工程化抗体
|
WO2009099728A1
(en)
|
2008-01-31 |
2009-08-13 |
Genentech, Inc. |
Anti-cd79b antibodies and immunoconjugates and methods of use
|
JP5608100B2
(ja)
|
2008-02-08 |
2014-10-15 |
メディミューン,エルエルシー |
低下したFcリガンド親和性を有する抗IFNAR1抗体
|
GB0802474D0
(en)
|
2008-02-11 |
2008-03-19 |
Heptares Therapeutics Ltd |
Mutant proteins and methods for selecting them
|
WO2009101639A1
(en)
|
2008-02-14 |
2009-08-20 |
Decode Genetics Ehf. |
Susceptibility variants for lung cancer
|
WO2009108652A1
(en)
|
2008-02-28 |
2009-09-03 |
3M Innovative Properties Company |
Antibodies to clostridium difficile spores and uses thereof
|
US8962803B2
(en)
|
2008-02-29 |
2015-02-24 |
AbbVie Deutschland GmbH & Co. KG |
Antibodies against the RGM A protein and uses thereof
|
WO2009114815A1
(en)
|
2008-03-13 |
2009-09-17 |
Dyax Corp |
Libraries of genetic packages comprising novel hc cdr3 designs
|
TW201513883A
(zh)
|
2008-03-18 |
2015-04-16 |
Abbvie Inc |
治療牛皮癬的方法
|
US20110020368A1
(en)
|
2008-03-25 |
2011-01-27 |
Nancy Hynes |
Treating cancer by down-regulating frizzled-4 and/or frizzled-1
|
NZ588905A
(en)
|
2008-04-01 |
2012-08-31 |
Decode Genetics Ehf |
Genetic testing method for determining susceptibility to abdominal aortic aneurysm by assay for selected polymorphisms associated with the disease
|
BRPI0906309A2
(pt)
|
2008-04-02 |
2020-05-26 |
Macrogenics, Inc |
Imunoglobulina, anticorpo, uso do anticorpo e composição farmacêutica
|
CN106349390B
(zh)
|
2008-04-02 |
2019-12-10 |
宏观基因有限公司 |
Bcr-复合体-特异性抗体和其使用方法
|
EP2276509B1
(en)
|
2008-04-11 |
2016-06-15 |
Seattle Genetics, Inc. |
Detection and tratment of pancreatic, ovarian and other cancers
|
GB0807413D0
(en)
|
2008-04-23 |
2008-05-28 |
Ucb Pharma Sa |
Biological products
|
AU2009238897B2
(en)
|
2008-04-24 |
2015-03-19 |
Gene Techno Science Co., Ltd. |
Humanized antibodies specific for amino acid sequence RGD of an extracellular matrix protein and the uses thereof
|
CA3049612C
(en)
|
2008-04-24 |
2023-01-10 |
Dyax Corp. |
Libraries of genetic packages comprising novel hc cdr1, cdr2, and cdr3 and novel lc cdr1, cdr2, and cdr3 designs
|
CN104479017A
(zh)
|
2008-04-25 |
2015-04-01 |
戴埃克斯有限公司 |
针对fcrn的抗体及其用途
|
US20090269786A1
(en)
*
|
2008-04-25 |
2009-10-29 |
The Board Of Trustees Of The University Of Illinois |
RHO1-Gamma Amino Butyric Acid C Receptor-Specific Antibodies
|
CN102076355B
(zh)
|
2008-04-29 |
2014-05-07 |
Abbvie公司 |
双重可变结构域免疫球蛋白及其用途
|
EP2113255A1
(en)
|
2008-05-02 |
2009-11-04 |
f-star Biotechnologische Forschungs- und Entwicklungsges.m.b.H. |
Cytotoxic immunoglobulin
|
US8163551B2
(en)
|
2008-05-02 |
2012-04-24 |
Seattle Genetics, Inc. |
Methods and compositions for making antibodies and antibody derivatives with reduced core fucosylation
|
BRPI0911758A8
(pt)
|
2008-05-09 |
2017-10-10 |
Abbott Lab |
Anticorpos para receptor de produtos finais de glicação avançada (rage) e utilizações dos mesmos
|
ES2533480T3
(es)
*
|
2008-05-16 |
2015-04-10 |
F. Hoffmann-La Roche Ag |
Uso de biomarcadores para evaluar el tratamiento de trastornos inflamatorios gastrointestinales con antagonistas de la integrina beta7
|
US20090291073A1
(en)
*
|
2008-05-20 |
2009-11-26 |
Ward Keith W |
Compositions Comprising PKC-theta and Methods for Treating or Controlling Ophthalmic Disorders Using Same
|
WO2009148896A2
(en)
|
2008-05-29 |
2009-12-10 |
Nuclea Biotechnologies, LLC |
Anti-phospho-akt antibodies
|
EP3002299A1
(en)
|
2008-06-03 |
2016-04-06 |
AbbVie Inc. |
Dual variable domain immunoglobulins and uses thereof
|
US9109026B2
(en)
|
2008-06-03 |
2015-08-18 |
Abbvie, Inc. |
Dual variable domain immunoglobulins and uses thereof
|
US20110081347A1
(en)
|
2008-06-04 |
2011-04-07 |
Macrogenics, Inc. |
Antibodies with Altered Binding to FcRn and Methods of Using Same
|
WO2009155484A2
(en)
|
2008-06-20 |
2009-12-23 |
Wyeth |
Compositions and methods of use of orf1358 from beta-hemolytic streptococcal strains
|
CA2729934A1
(en)
|
2008-07-07 |
2010-01-14 |
Decode Genetics Ehf |
Genetic variants for breast cancer risk assessment
|
KR20110031369A
(ko)
|
2008-07-08 |
2011-03-25 |
아보트 러보러터리즈 |
프로스타글란딘 e2 이원 가변 도메인 면역글로불린 및 이의 용도
|
RU2559525C2
(ru)
|
2008-07-08 |
2015-08-10 |
Эббви Инк |
Белки, связывающие простагландин е2, и их применение
|
DK2982695T3
(da)
|
2008-07-09 |
2019-05-13 |
Biogen Ma Inc |
Sammensætninger, der omfatter antistoffer mod lingo eller fragmenter deraf
|
AR073060A1
(es)
|
2008-08-14 |
2010-10-13 |
Arana Therapeutic Ltd |
Anticuerpos anti-il-12/il-23
|
WO2010028347A2
(en)
|
2008-09-05 |
2010-03-11 |
President & Fellows Of Harvard College |
Continuous directed evolution of proteins and nucleic acids
|
US20100081575A1
(en)
*
|
2008-09-22 |
2010-04-01 |
Robert Anthony Williamson |
Methods for creating diversity in libraries and libraries, display vectors and methods, and displayed molecules
|
AU2009293640A1
(en)
*
|
2008-09-22 |
2010-03-25 |
Calmune Corporation |
Methods and vectors for display of 2G12 -derived domain exchanged antibodies
|
EP2352841A2
(en)
|
2008-09-23 |
2011-08-10 |
President and Fellows of Harvard College |
Sirt4 and uses thereof
|
EP2344180A2
(en)
|
2008-09-23 |
2011-07-20 |
Wyeth LLC |
Methods for predicting production of activating signals by cross-linked binding proteins
|
CN102264762B
(zh)
|
2008-09-26 |
2018-03-27 |
达纳-法伯癌症研究公司 |
人抗pd‑1、pd‑l1和pd‑l2的抗体及其应用
|
US8313942B2
(en)
|
2008-09-26 |
2012-11-20 |
Wyeth Llc |
Compatible display vector systems
|
US8734803B2
(en)
|
2008-09-28 |
2014-05-27 |
Ibio Inc. |
Humanized neuraminidase antibody and methods of use thereof
|
WO2010039801A2
(en)
|
2008-10-02 |
2010-04-08 |
The J. David Gladstone Institutes |
Methods of treating hepatitis c virus infection
|
EP3335728B8
(en)
|
2008-10-10 |
2020-03-11 |
Children's Medical Center Corporation |
Biochemically stabilized hiv-1 env trimer vaccine
|
EP2349329A4
(en)
|
2008-10-14 |
2012-10-31 |
Dyax Corp |
USE OF IGF-II / IGF-II BINDING FOR THE TREATMENT AND PREVENTION OF SYSTEMIC SCLEROSIS ASSOCIATED WITH LUNG FIBROSIS
|
SG10201702922VA
(en)
|
2008-10-20 |
2017-06-29 |
Abbvie Inc |
Isolation and purification of antibodies using protein a affinity chromatography
|
CA2741523C
(en)
|
2008-10-24 |
2022-06-21 |
Jonathan S. Towner |
Human ebola virus species and compositions and methods thereof
|
EP4104821A1
(en)
|
2008-10-29 |
2022-12-21 |
Ablynx N.V. |
Formulations of single domain antigen binding molecules
|
US10118962B2
(en)
|
2008-10-29 |
2018-11-06 |
Ablynx N.V. |
Methods for purification of single domain antigen binding molecules
|
ES2631507T3
(es)
|
2008-10-29 |
2017-08-31 |
China Synthetic Rubber Corporation |
Procedimientos y agentes para el diagnóstico y tratamiento del carcinoma hepatocelular
|
EP2358392B1
(en)
|
2008-11-12 |
2019-01-09 |
MedImmune, LLC |
Antibody formulation
|
ATE523603T1
(de)
*
|
2008-11-21 |
2011-09-15 |
Chimera Biotec Gmbh |
Konjugatkomplexe zum analytnachweis
|
US20100183620A1
(en)
|
2008-11-26 |
2010-07-22 |
Kaumudi Bhawe |
Compositions and methods for regulating collagen and smooth muscle actin expression by serpine2
|
CN102282265B
(zh)
|
2008-11-28 |
2020-07-24 |
埃默里大学 |
用于治疗传染病和肿瘤的方法
|
RU2011127198A
(ru)
*
|
2008-12-04 |
2013-01-10 |
Эбботт Лэборетриз |
Иммуноглобулины с двойными вариабельными доменами и их применение
|
TWI686405B
(zh)
|
2008-12-09 |
2020-03-01 |
建南德克公司 |
抗pd-l1抗體及其於增進t細胞功能之用途
|
RU2593720C2
(ru)
|
2008-12-19 |
2016-08-10 |
Макродженикс, Инк. |
Ковалентные диантитела и их применение
|
AU2009334498A1
(en)
|
2008-12-31 |
2011-07-21 |
Biogen Idec Ma Inc. |
Anti-lymphotoxin antibodies
|
WO2010080985A1
(en)
|
2009-01-08 |
2010-07-15 |
Dana-Farber Cancer Institute, Inc. |
Compositions and methods for induced brown fat differentiation
|
GB0900425D0
(en)
|
2009-01-12 |
2009-02-11 |
Ucb Pharma Sa |
Biological products
|
WO2010082134A1
(en)
|
2009-01-14 |
2010-07-22 |
Iq Therapeutics Bv |
Combination antibodies for the treatment and prevention of disease caused by bacillus anthracis and related bacteria and their toxins
|
EP2389195B1
(en)
|
2009-01-20 |
2015-05-20 |
Homayoun H. Zadeh |
Antibody mediated osseous regeneration
|
WO2010084408A2
(en)
|
2009-01-21 |
2010-07-29 |
Oxford Biotherapeutics Ltd. |
Pta089 protein
|
RU2011135768A
(ru)
|
2009-01-29 |
2013-03-10 |
Эбботт Лэборетриз |
Белки, связывающие il-1
|
US20110165063A1
(en)
*
|
2009-01-29 |
2011-07-07 |
Abbott Laboratories |
Il-1 binding proteins
|
WO2010087702A1
(en)
|
2009-01-30 |
2010-08-05 |
Stichting Katholieke Universiteit |
TET2 gene as a marker for diagnosing a myelodysuplastic syndrome (MDS) or an acute myeloid leukemia (AML) and determining the prognosis in a subject
|
US8852608B2
(en)
|
2009-02-02 |
2014-10-07 |
Medimmune, Llc |
Antibodies against and methods for producing vaccines for respiratory syncytial virus
|
WO2010093993A2
(en)
|
2009-02-12 |
2010-08-19 |
Human Genome Sciences, Inc. |
Use of b lymphocyte stimulator protein antagonists to promote transplantation tolerance
|
PL2398498T3
(pl)
|
2009-02-17 |
2019-03-29 |
Ucb Biopharma Sprl |
Cząsteczki przeciwciał swoiste wobec ludzkiego OX40
|
US8030026B2
(en)
|
2009-02-24 |
2011-10-04 |
Abbott Laboratories |
Antibodies to troponin I and methods of use thereof
|
EP2403880A1
(en)
|
2009-03-05 |
2012-01-11 |
Tripath Imaging, Inc. |
Matrix metalloproteinase-7 (mmp-7) monoclonal antibodies and methods for their use in the detection of ovarian cancer
|
EP2810652A3
(en)
|
2009-03-05 |
2015-03-11 |
AbbVie Inc. |
IL-17 binding proteins
|
AU2010221188A1
(en)
|
2009-03-06 |
2011-10-20 |
Tripath Imaging, Inc. |
Glycodelin monoclonal antibodies and methods for their use in the detection of ovarian cancer
|
WO2010100247A1
(en)
|
2009-03-06 |
2010-09-10 |
Novartis Forschungsstiftung, Zweigniederlassung, Friedrich Miescher Institute For Biomedical Research |
Novel therapy for anxiety
|
KR101667227B1
(ko)
|
2009-03-10 |
2016-10-18 |
가부시키가이샤 진 테크노 사이언스 |
인간화된 k33n 단일 클론 항체의 제조, 발현 및 해석
|
GB0904214D0
(en)
|
2009-03-11 |
2009-04-22 |
Ucb Pharma Sa |
Biological products
|
RU2587621C2
(ru)
|
2009-04-01 |
2016-06-20 |
Дженентек, Инк. |
АНТИТЕЛА К FcRH5, ИХ ИММУНОКОНЪЮГАТЫ И СПОСОБЫ ИХ ПРИМЕНЕНИЯ
|
EP2414543B1
(en)
|
2009-04-03 |
2016-10-12 |
Decode Genetics EHF |
Genetic markers for risk management of atrial fibrillation and stroke
|
EP2241323A1
(en)
|
2009-04-14 |
2010-10-20 |
Novartis Forschungsstiftung, Zweigniederlassung Friedrich Miescher Institute For Biomedical Research |
Tenascin-W and brain cancers
|
KR101736076B1
(ko)
|
2009-04-20 |
2017-05-16 |
옥스포드 바이오테라퓨틱스 리미티드 |
카드헤린-17에 특이적인 항체
|
ES2495367T3
(es)
|
2009-04-29 |
2014-09-17 |
The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. |
Anticuerpos monoclonales de ERG
|
US20110033389A1
(en)
*
|
2009-04-29 |
2011-02-10 |
Zhifeng Chen |
Modified antibodies for passive immunotherapy
|
MX2011011541A
(es)
|
2009-04-29 |
2012-02-28 |
Abbott Biotech Ltd |
Dispositivo de inyeccion automatico.
|
AU2010249470B2
(en)
*
|
2009-05-20 |
2015-06-25 |
Novimmune S.A. |
Synthetic Polypeptide Libraries And Methods For Generating Naturally Diversified Polypeptide Variants
|
EP2261242A1
(en)
|
2009-06-10 |
2010-12-15 |
Universite Catholique De Louvain |
Aspartate-N-acetyltransferase enzyme, diagnostic method and therapeutic method
|
GB0910725D0
(en)
|
2009-06-22 |
2009-08-05 |
Heptares Therapeutics Ltd |
Mutant proteins and methods for producing them
|
US20120213705A1
(en)
|
2009-06-22 |
2012-08-23 |
Medimmune, Llc |
ENGINEERED Fc REGIONS FOR SITE-SPECIFIC CONJUGATION
|
EP2272979A1
(en)
|
2009-06-30 |
2011-01-12 |
Centre National de la Recherche Scientifique (CNRS) |
Method for testing a subject thought to be predisposed to having cancer
|
SG177583A1
(en)
|
2009-07-09 |
2012-02-28 |
Hoffmann La Roche |
In vivo tumor vasculature imaging
|
NZ598009A
(en)
|
2009-07-10 |
2013-11-29 |
Decode Genetics Ehf |
Genetic markers associated with risk of diabetes mellitus
|
US9259476B2
(en)
|
2009-07-31 |
2016-02-16 |
Wayne State University |
Monophosphorylated lipid A derivatives
|
CN102596220A
(zh)
|
2009-07-31 |
2012-07-18 |
韦恩州立大学 |
单磷酸化的脂质a衍生物
|
DK2464664T3
(da)
|
2009-08-13 |
2016-01-18 |
Crucell Holland Bv |
Antistoffer mod humant respiratorisk syncytialvirus (rsv) og fremgangsmåder til anvendelse deraf
|
EP2292266A1
(en)
|
2009-08-27 |
2011-03-09 |
Novartis Forschungsstiftung, Zweigniederlassung |
Treating cancer by modulating copine III
|
PE20121647A1
(es)
*
|
2009-08-29 |
2012-12-31 |
Abbvie Inc |
Proteinas terapeuticas de union a dll4
|
US20110059111A1
(en)
|
2009-09-01 |
2011-03-10 |
Los Angeles Biomedical Research Institute At Harbor-Ucla Medical Center |
Mammalian receptors as targets for antibody and active vaccination therapy against mold infections
|
NZ598929A
(en)
|
2009-09-01 |
2014-05-30 |
Abbvie Inc |
Dual variable domain immunoglobulins and uses thereof
|
WO2011030107A1
(en)
|
2009-09-10 |
2011-03-17 |
Ucb Pharma S.A. |
Multivalent antibodies
|
JP2013504602A
(ja)
*
|
2009-09-14 |
2013-02-07 |
ダイアックス コーポレーション |
新しく設計したhccdr3を含む遺伝子パッケージライブラリー
|
JP2013505232A
(ja)
|
2009-09-16 |
2013-02-14 |
スティヒティング ヘット ネーデルラント カンカー インスティテュート |
癌治療のための薬剤標的としてのFra−1標的遺伝子
|
WO2011035205A2
(en)
|
2009-09-18 |
2011-03-24 |
Calmune Corporation |
Antibodies against candida, collections thereof and methods of use
|
EP2305717A1
(en)
|
2009-09-21 |
2011-04-06 |
Koninklijke Nederlandse Akademie van Wetenschappen |
Inhibiting TNIK for treating colon cancer
|
EP2480573A1
(en)
|
2009-09-22 |
2012-08-01 |
Novartis Forschungsstiftung, Zweigniederlassung Friedrich Miescher Institute For Biomedical Research |
Treating cancer by modulating mex-3
|
US9175070B2
(en)
|
2009-09-25 |
2015-11-03 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Neutralizing antibodies to HIV-1 and their use
|
US9598692B2
(en)
|
2009-09-25 |
2017-03-21 |
University Of Oslo |
Multivalent phage display systems and methods
|
WO2011038301A2
(en)
|
2009-09-25 |
2011-03-31 |
Xoma Technology Ltd. |
Screening methods
|
GB201005063D0
(en)
|
2010-03-25 |
2010-05-12 |
Ucb Pharma Sa |
Biological products
|
US8926976B2
(en)
|
2009-09-25 |
2015-01-06 |
Xoma Technology Ltd. |
Modulators
|
WO2011041391A1
(en)
|
2009-09-29 |
2011-04-07 |
Fraunhofer Usa, Inc. |
Influenza hemagglutinin antibodies, compositions, and related methods
|
EP2483407A2
(en)
|
2009-09-30 |
2012-08-08 |
President and Fellows of Harvard College |
Methods for modulation of autophagy through the modulation of autophagy-enhancing gene products
|
AR078470A1
(es)
|
2009-10-02 |
2011-11-09 |
Sanofi Aventis |
Anticuerpos que se unen especificamente al receptor epha2
|
WO2011047083A1
(en)
|
2009-10-13 |
2011-04-21 |
Oxford Biotherapeutics Ltd. |
Antibodies against epha10
|
WO2011045352A2
(en)
|
2009-10-15 |
2011-04-21 |
Novartis Forschungsstiftung |
Spleen tyrosine kinase and brain cancers
|
CN102666875A
(zh)
|
2009-10-15 |
2012-09-12 |
雅培制药有限公司 |
双重可变结构域免疫球蛋白及其用途
|
CN104744560A
(zh)
|
2009-10-20 |
2015-07-01 |
Abbvie公司 |
使用蛋白a亲和色谱法分离和纯化抗-il-13抗体
|
GB0922435D0
(en)
|
2009-12-22 |
2010-02-03 |
Ucb Pharma Sa |
Method
|
US9234037B2
(en)
|
2009-10-27 |
2016-01-12 |
Ucb Biopharma Sprl |
Method to generate antibodies to ion channels
|
WO2011051350A1
(en)
|
2009-10-27 |
2011-05-05 |
Ucb Pharma S.A. |
Function modifying nav 1.7 antibodies
|
GB0922434D0
(en)
|
2009-12-22 |
2010-02-03 |
Ucb Pharma Sa |
antibodies and fragments thereof
|
US20110098862A1
(en)
|
2009-10-27 |
2011-04-28 |
ExxonMobil Research Engineering Company Law Department |
Multi-stage processes and control thereof
|
UY32979A
(es)
|
2009-10-28 |
2011-02-28 |
Abbott Lab |
Inmunoglobulinas con dominio variable dual y usos de las mismas
|
US20120213801A1
(en)
|
2009-10-30 |
2012-08-23 |
Ekaterina Gresko |
Phosphorylated Twist1 and cancer
|
WO2011053707A1
(en)
|
2009-10-31 |
2011-05-05 |
Abbott Laboratories |
Antibodies to receptor for advanced glycation end products (rage) and uses thereof
|
WO2011054007A1
(en)
|
2009-11-02 |
2011-05-05 |
Oxford Biotherapeutics Ltd. |
Ror1 as therapeutic and diagnostic target
|
US9244063B2
(en)
|
2009-11-11 |
2016-01-26 |
Gentian As |
Immunoassay for assessing related analytes of different origin
|
EP3168232B1
(en)
|
2009-11-13 |
2021-09-29 |
Dana-Farber Cancer Institute, Inc. |
Compositions, kits, and methods for the diagnosis, prognosis, monitoring, treatment and modulation of post-transplant lymphoproliferative disorders and hypoxia associated angiogenesis disorders using galectin-1
|
GB0920127D0
(en)
|
2009-11-17 |
2009-12-30 |
Ucb Pharma Sa |
Antibodies
|
AU2010322205B2
(en)
|
2009-11-17 |
2015-01-22 |
Janssen Biotech, Inc. |
Improved bacterial membrane protein secretion
|
GB0920324D0
(en)
|
2009-11-19 |
2010-01-06 |
Ucb Pharma Sa |
Antibodies
|
MX2012006560A
(es)
|
2009-12-08 |
2012-10-05 |
Abbott Gmbh & Co Kg |
Anticuerpos monoclonales contra la proteina rgm a para utilizarse en el tratamiento de degeneracion de capa de fibra de nervio retinal.
|
HUE057244T2
(hu)
|
2010-01-06 |
2022-04-28 |
Takeda Pharmaceuticals Co |
Plazma kallikreint kötõ fehérjék
|
GB201000467D0
(en)
|
2010-01-12 |
2010-02-24 |
Ucb Pharma Sa |
Antibodies
|
US9745589B2
(en)
|
2010-01-14 |
2017-08-29 |
Cornell University |
Methods for modulating skeletal remodeling and patterning by modulating SHN2 activity, SHN3 activity, or SHN2 and SHN3 activity in combination
|
JP2013520162A
(ja)
|
2010-01-22 |
2013-06-06 |
デイナ ファーバー キャンサー インスティチュート,インコーポレイテッド |
代謝障害の同定、査定、予防および治療のための組成物、キットおよび方法
|
EP2531613A2
(en)
|
2010-02-02 |
2012-12-12 |
Abbott Biotechnology Ltd. |
Methods and compositions for predicting responsiveness to treatment with tnf-alpha inhibitor
|
EP2354245A1
(en)
|
2010-02-04 |
2011-08-10 |
Stichting Top Institute Food and Nutrition |
MBL2 as a marker of hepatic PPAR- activity
|
TWI518325B
(zh)
|
2010-02-04 |
2016-01-21 |
自治醫科大學 |
對alk抑制劑具有先抗性或後抗性癌症的識別、判斷和治療
|
EP2354244A1
(en)
|
2010-02-04 |
2011-08-10 |
Stichting Top Institute Food and Nutrition |
MBL2 as a marker of liver-specific insulin resistance
|
RU2605928C2
(ru)
|
2010-03-02 |
2016-12-27 |
Эббви Инк. |
Терапевтические dll4-связывающие белки
|
AU2011223547B2
(en)
*
|
2010-03-04 |
2016-05-05 |
Vet Therapeutics, Inc. |
Monoclonal antibodies directed to CD52
|
US9616120B2
(en)
*
|
2010-03-04 |
2017-04-11 |
Vet Therapeutics, Inc. |
Monoclonal antibodies directed to CD20
|
WO2011107586A1
(en)
|
2010-03-05 |
2011-09-09 |
Novartis Forschungsstiftung, Zweigniederlassung, Friedrich Miescher Institute For Biomedical Research, |
Smoc1, tenascin-c and brain cancers
|
WO2011119484A1
(en)
|
2010-03-23 |
2011-09-29 |
Iogenetics, Llc |
Bioinformatic processes for determination of peptide binding
|
US10472426B2
(en)
|
2010-03-25 |
2019-11-12 |
Ucb Biopharma Sprl |
Disulfide stabilized DVD-Ig molecules
|
GB201005064D0
(en)
|
2010-03-25 |
2010-05-12 |
Ucb Pharma Sa |
Biological products
|
MX360403B
(es)
|
2010-04-15 |
2018-10-31 |
Abbvie Inc |
Proteinas de union a amiloide beta.
|
SI2558577T1
(sl)
|
2010-04-16 |
2019-05-31 |
Nuevolution A/S |
Bifunkcionalni kompleksi in metode za pripravo in uporabo takšnih kompleksov
|
WO2011131611A1
(en)
|
2010-04-19 |
2011-10-27 |
Novartis Forschungsstiftung, Zweigniederlassung Friedrich Miescher Institute For Biomedical Research |
Modulating xrn1
|
EP2380909A1
(en)
|
2010-04-26 |
2011-10-26 |
Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. |
PTK-7 protein involved in breast cancer
|
US20120003639A1
(en)
|
2010-04-27 |
2012-01-05 |
Prelude, Inc. |
Cancer biomarkers and methods of use thereof
|
US9011852B2
(en)
|
2010-04-30 |
2015-04-21 |
Alexion Pharmaceuticals, Inc. |
Anti-C5a antibodies
|
EP3569256B1
(en)
|
2010-04-30 |
2022-06-15 |
Janssen Biotech, Inc. |
Stabilized fibronectin domain compositions, methods and uses
|
PE20130205A1
(es)
|
2010-05-14 |
2013-03-24 |
Abbvie Inc |
Proteinas de union a il-1
|
US20110293629A1
(en)
|
2010-05-14 |
2011-12-01 |
Bastid Jeremy |
Methods of Treating and/or Preventing Cell Proliferation Disorders with IL-17 Antagonists
|
CN105056232A
(zh)
|
2010-06-03 |
2015-11-18 |
阿布维生物技术有限公司 |
用于治疗化脓性汗腺炎(hs)的用途和组合物
|
US9499813B2
(en)
|
2010-06-10 |
2016-11-22 |
President And Fellows Of Harvard College |
Systems and methods for amplification and phage display
|
EP2580239A1
(en)
|
2010-06-10 |
2013-04-17 |
Novartis Forschungsstiftung, Zweigniederlassung Friedrich Miescher Institute For Biomedical Research |
Treating cancer by modulating mammalian sterile 20-like kinase 3
|
AU2011268310A1
(en)
|
2010-06-16 |
2013-01-10 |
Abbvie Inc. |
Comparison of protein samples
|
PT3034608T
(pt)
|
2010-06-22 |
2019-05-28 |
Regeneron Pharma |
Ratinhos expressando uma cadeia leve híbrida de imunoglobulina com uma região variável humana
|
WO2012006500A2
(en)
|
2010-07-08 |
2012-01-12 |
Abbott Laboratories |
Monoclonal antibodies against hepatitis c virus core protein
|
NZ605449A
(en)
|
2010-07-09 |
2015-03-27 |
Genentech Inc |
Anti-neuropilin antibodies and methods of use
|
UY33492A
(es)
|
2010-07-09 |
2012-01-31 |
Abbott Lab |
Inmunoglobulinas con dominio variable dual y usos de las mismas
|
NZ603488A
(en)
|
2010-07-09 |
2015-02-27 |
Crucell Holland Bv |
Anti-human respiratory syncytial virus (rsv) antibodies and methods of use
|
CN108314733A
(zh)
|
2010-07-16 |
2018-07-24 |
埃博灵克斯股份有限公司 |
修饰的单结构域抗原结合分子及其应用
|
DK2593594T3
(en)
|
2010-07-16 |
2017-12-11 |
Adimab Llc |
ANTIBODY LIBRARIES
|
CN103392182B
(zh)
|
2010-08-02 |
2017-07-04 |
众有生物有限公司 |
用于发现遗传疾病中致病突变的***和方法
|
BR112013002578A2
(pt)
|
2010-08-03 |
2019-05-14 |
Abbvie Inc. |
imunoglobinas de domínio variável duplo e usos das mesmas
|
WO2012019061A2
(en)
|
2010-08-05 |
2012-02-09 |
Stem Centrx, Inc. |
Novel effectors and methods of use
|
EP2420250A1
(en)
|
2010-08-13 |
2012-02-22 |
Universitätsklinikum Münster |
Anti-Syndecan-4 antibodies
|
JP6147665B2
(ja)
|
2010-08-14 |
2017-06-14 |
アッヴィ・インコーポレイテッド |
アミロイドベータ結合タンパク質
|
BR112013003557A2
(pt)
|
2010-08-17 |
2018-03-27 |
Stichting Katholieke Univ |
novo método para diagnosticar febre q usando um teste imunológico celular.
|
AU2011291462A1
(en)
|
2010-08-19 |
2013-03-14 |
Zoetis Belgium S.A. |
Anti-NGF antibodies and their use
|
GB201014033D0
(en)
|
2010-08-20 |
2010-10-06 |
Ucb Pharma Sa |
Biological products
|
AU2011293253B2
(en)
|
2010-08-26 |
2014-12-11 |
Abbvie Inc. |
Dual variable domain immunoglobulins and uses thereof
|
SG10201506782XA
(en)
|
2010-08-27 |
2015-10-29 |
Stem Centrx Inc |
Notum protein modulators and methods of use
|
KR20140014064A
(ko)
|
2010-09-03 |
2014-02-05 |
스템 센트알엑스 인코포레이티드 |
신규한 조절 인자 및 사용 방법
|
WO2012032143A1
(en)
|
2010-09-10 |
2012-03-15 |
Novartis Forschungsstiftung, Zweigniederlassung, Friedrich Miescher Institute For Biomedical Research |
Phosphorylated twist1 and metastasis
|
WO2012040041A1
(en)
|
2010-09-20 |
2012-03-29 |
Abbott Laboratories |
Purification of antibodies using simulated moving bed chromatography
|
EP2619584B1
(en)
|
2010-09-21 |
2016-10-12 |
Stichting Katholieke Universiteit |
Novel method for diagnosing lyme disease using a cellular immunological test
|
US9005907B2
(en)
|
2010-10-01 |
2015-04-14 |
St. Jude Children's Research Hospital |
Methods and compositions for typing molecular subgroups of medulloblastoma
|
WO2012052391A1
(en)
|
2010-10-19 |
2012-04-26 |
Glaxo Group Limited |
Polypeptide with jmjd3 catalytic activity
|
JP6243737B2
(ja)
|
2010-10-27 |
2017-12-06 |
ザ リサーチ ファウンデーション フォー ザ ステイト ユニバーシティ オブ ニューヨーク |
E−カドヘリンの可溶性細胞外ドメインを標的とする組成物および癌治療のための関連方法
|
EP2640738A1
(en)
|
2010-11-15 |
2013-09-25 |
Novartis Forschungsstiftung, Zweigniederlassung Friedrich Miescher Institute For Biomedical Research |
Anti-fungal agents
|
WO2012068463A2
(en)
|
2010-11-18 |
2012-05-24 |
Beth Israel Deaconess Medicall Center, Inc. |
Methods of treating obesity by inhibiting nicotinamide n-methyl transferase (nnmt)
|
NZ611428A
(en)
|
2010-12-08 |
2015-07-31 |
Stemcentrx Inc |
Novel modulators and methods of use
|
EP2465928A1
(en)
|
2010-12-16 |
2012-06-20 |
Academisch Medisch Centrum bij de Universiteit van Amsterdam |
Treatment of Th17-mediated diseases
|
SG10201604699VA
(en)
|
2010-12-21 |
2016-07-28 |
Abbvie Inc |
Il-1 -alpha and -beta bispecific dual variable domain immunoglobulins and their use
|
TW201307388A
(zh)
|
2010-12-21 |
2013-02-16 |
Abbott Lab |
Il-1結合蛋白
|
US9505826B2
(en)
|
2010-12-22 |
2016-11-29 |
Teva Pharmaceuticals Australia Pty Ltd |
Modified antibody with improved half-life
|
EP2655614B1
(en)
|
2010-12-22 |
2017-03-15 |
President and Fellows of Harvard College |
Continuous directed evolution
|
JP2014504503A
(ja)
|
2010-12-28 |
2014-02-24 |
ゾーマ テクノロジー リミテッド |
Pdzドメインを用いた細胞表面提示
|
EP2658869B1
(en)
|
2010-12-30 |
2019-06-12 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Antigen binding formats for use in therapeutic treatments or diagnostic assays
|
GB201100282D0
(en)
|
2011-01-07 |
2011-02-23 |
Ucb Pharma Sa |
Biological methods
|
US10208349B2
(en)
|
2011-01-07 |
2019-02-19 |
Ucb Biopharma Sprl |
Lipocalin 2 as a biomarker for IL-17 inhibitor therapy efficacy
|
ES2632583T3
(es)
|
2011-01-14 |
2017-09-14 |
Ucb Biopharma Sprl |
Anticuerpo que se une a IL-17A e IL-17F
|
EP2667918B1
(en)
|
2011-01-24 |
2017-03-01 |
AbbVie Biotechnology Ltd |
Automatic injection devices having overmolded gripping surfaces
|
DK2668210T3
(da)
|
2011-01-26 |
2020-08-24 |
Celldex Therapeutics Inc |
Anti-kit antistoffer og anvendelser deraf
|
WO2012109238A2
(en)
|
2011-02-07 |
2012-08-16 |
President And Fellows Of Harvard College |
Methods for increasing immune responses using agents that directly bind to and activate ire-1
|
SA112330278B1
(ar)
|
2011-02-18 |
2015-10-09 |
ستيم سينتركس، انك. |
مواد ضابطة جديدة وطرق للاستخدام
|
EA201391245A1
(ru)
|
2011-03-02 |
2014-05-30 |
Берг Ллк |
Интеррогативные клеточные анализы и их применение
|
WO2012122219A2
(en)
|
2011-03-07 |
2012-09-13 |
University Of Louisville Research Foundation |
Predictive marker of dnmt1 inhibitor therapeutic efficacy and methods of using the marker
|
US20120238730A1
(en)
|
2011-03-15 |
2012-09-20 |
Abbott Laboratories |
Integrated approach to the isolation and purification of antibodies
|
EP2689250A1
(en)
|
2011-03-23 |
2014-01-29 |
AbbVie Inc. |
Methods and systems for the analysis of protein samples
|
MX361242B
(es)
|
2011-03-30 |
2018-11-30 |
Ablynx Nv |
Anticuerpos de dominio sencillo contra tnf-alfa y usos de los mismos.
|
US9777332B2
(en)
|
2011-03-31 |
2017-10-03 |
St. Jude Children's Research Hospital |
Methods and compositions for identifying minimal residual disease in acute lymphoblastic leukemia
|
AU2012239961A1
(en)
|
2011-04-08 |
2013-10-24 |
Biogen Ma Inc. |
Biomarkers predictive of therapeutic responsiveness to IFNbeta and uses thereof
|
US9150644B2
(en)
|
2011-04-12 |
2015-10-06 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Human monoclonal antibodies that bind insulin-like growth factor (IGF) I and II
|
RU2625034C2
(ru)
|
2011-04-20 |
2017-07-11 |
МЕДИММЬЮН, ЭлЭлСи |
Антитела и другие молекулы, которые связывают в7-н1 и pd-1
|
EA201391753A1
(ru)
|
2011-05-21 |
2014-08-29 |
Макродженикс, Инк. |
Домены, связывающиеся с деиммунизованной сывороткой, и их применение для увеличения времени полужизни в сыворотке
|
EP2966089B1
(en)
|
2011-06-02 |
2020-03-25 |
Dyax Corp. |
Fc receptor binding proteins
|
PT2714735T
(pt)
|
2011-06-03 |
2021-10-26 |
Xoma Technology Ltd |
Anticorpos específicos para tgf-beta
|
WO2012168259A1
(en)
|
2011-06-06 |
2012-12-13 |
Novartis Forschungsstiftung, Zweigniederlassung |
Protein tyrosine phosphatase, non-receptor type 11 (ptpn11) and triple-negative breast cancer
|
US9561274B2
(en)
|
2011-06-07 |
2017-02-07 |
University Of Hawaii |
Treatment and prevention of cancer with HMGB1 antagonists
|
US9244074B2
(en)
|
2011-06-07 |
2016-01-26 |
University Of Hawaii |
Biomarker of asbestos exposure and mesothelioma
|
EP3385280A1
(en)
|
2011-06-10 |
2018-10-10 |
MedImmune Limited |
Anti-pseudomonas psl binding molecules and uses thereof
|
PE20140756A1
(es)
|
2011-06-28 |
2014-07-04 |
Oxford Biotherapeutics Ltd |
Anticuerpos que se unen a bst1
|
LT2726094T
(lt)
|
2011-06-28 |
2017-02-10 |
Oxford Biotherapeutics Ltd |
Gydymo ir diagnozavimo objektas
|
AU2012283039A1
(en)
|
2011-07-13 |
2014-01-30 |
Abbvie Inc. |
Methods and compositions for treating asthma using anti-IL-13 antibodies
|
GB201112056D0
(en)
|
2011-07-14 |
2011-08-31 |
Univ Leuven Kath |
Antibodies
|
CA2845536A1
(en)
|
2011-08-15 |
2013-02-21 |
Amplimmune, Inc. |
Anti-b7-h4 antibodies and their uses
|
EP3564261A1
(en)
|
2011-08-23 |
2019-11-06 |
Foundation Medicine, Inc. |
Kif5b-ret fusion molecules and uses thereof
|
US20130058947A1
(en)
|
2011-09-02 |
2013-03-07 |
Stem Centrx, Inc |
Novel Modulators and Methods of Use
|
WO2013034579A1
(en)
|
2011-09-05 |
2013-03-14 |
Rheinische Friedrich-Wilhelms-Universität Bonn |
Biosynthetic gene cluster for the production of peptide/protein analogues
|
WO2013034660A1
(en)
|
2011-09-09 |
2013-03-14 |
Medimmune Limited |
Anti-siglec-15 antibodies and uses thereof
|
US10093705B2
(en)
|
2011-09-13 |
2018-10-09 |
Dana-Farber Cancer Institute, Inc. |
Compositions and methods for brown fat induction and activity using FNDC5
|
EP2771349B1
(en)
|
2011-09-16 |
2020-02-26 |
Iogenetics, LLC. |
Bioinformatic processes for determination of peptide binding
|
US10221454B2
(en)
|
2011-10-10 |
2019-03-05 |
The Hospital For Sick Children |
Methods and compositions for screening and treating developmental disorders
|
SG11201401791WA
(en)
|
2011-10-24 |
2014-08-28 |
Abbvie Inc |
Immunobinders directed against sclerostin
|
BR112014009799A2
(pt)
|
2011-10-24 |
2017-06-13 |
Abbvie Inc |
imunoligantes dirigidos conra tnf
|
JP2014533247A
(ja)
|
2011-11-01 |
2014-12-11 |
バイオノミクス インコーポレイテッド |
抗体および癌を治療する方法
|
EP2773664A1
(en)
|
2011-11-01 |
2014-09-10 |
Bionomics, Inc. |
Anti-gpr49 antibodies
|
AU2012332593B2
(en)
|
2011-11-01 |
2016-11-17 |
Bionomics, Inc. |
Anti-GPR49 antibodies
|
ES2697674T3
(es)
|
2011-11-01 |
2019-01-25 |
Bionomics Inc |
Procedimientos para bloquear el crecimiento de células madre cancerosas
|
ES2847867T3
(es)
|
2011-11-03 |
2021-08-04 |
Tripath Imaging Inc |
Métodos y composiciones para preparar muestras para inmunotinción
|
US11180807B2
(en)
|
2011-11-04 |
2021-11-23 |
Population Bio, Inc. |
Methods for detecting a genetic variation in attractin-like 1 (ATRNL1) gene in subject with Parkinson's disease
|
RS60920B1
(sr)
|
2011-11-07 |
2020-11-30 |
Medimmune Ltd |
Kombinovane terapije primenom anti-pseudomonas psl i pcrv vezujućih molekula
|
WO2013068431A1
(en)
|
2011-11-08 |
2013-05-16 |
Novartis Forschungsstiftung, Zweigniederlassung, Friedrich Miescher Institute For Biomedical Research |
New treatment for neurodegenerative diseases
|
AU2012335247A1
(en)
|
2011-11-08 |
2014-05-29 |
Pfizer Inc. |
Methods of treating inflammatory disorders using anti-M-CSF antibodies
|
US20140294732A1
(en)
|
2011-11-08 |
2014-10-02 |
Novartis Forschungsstiftung, Zweigniederlassung, Friedrich Miescher Institute |
Early diagnostic of neurodegenerative diseases
|
DK2776466T3
(da)
|
2011-11-11 |
2017-11-20 |
Ucb Biopharma Sprl |
Albuminbindende antistoffer og bindingsfragmenter deraf
|
EP2786156A2
(en)
|
2011-11-30 |
2014-10-08 |
AbbVie Deutschland GmbH & Co KG |
Methods and compositions for determining responsiveness to treatment with a tnf-alpha inhibitor
|
WO2013090633A2
(en)
|
2011-12-14 |
2013-06-20 |
AbbVie Deutschland GmbH & Co. KG |
Composition and method for the diagnosis and treatment of iron-related disorders
|
US10118958B2
(en)
|
2011-12-14 |
2018-11-06 |
AbbVie Deutschland GmbH & Co. KG |
Composition and method for the diagnosis and treatment of iron-related disorders
|
CN104144946A
(zh)
|
2011-12-19 |
2014-11-12 |
爱克索马美国有限责任公司 |
治疗痤疮的方法
|
RU2664181C2
(ru)
|
2011-12-20 |
2018-08-15 |
Регенерон Фармасьютикалз, Инк. |
Мыши с гуманизированной легкой цепью
|
CA3111357A1
(en)
|
2011-12-23 |
2013-06-27 |
Pfizer Inc. |
Engineered antibody constant regions for site-specific conjugation and methods and uses therefor
|
TW201333035A
(zh)
|
2011-12-30 |
2013-08-16 |
Abbvie Inc |
針對il-13及/或il-17之雙特異性結合蛋白
|
WO2013102825A1
(en)
|
2012-01-02 |
2013-07-11 |
Novartis Ag |
Cdcp1 and breast cancer
|
GB201201332D0
(en)
|
2012-01-26 |
2012-03-14 |
Imp Innovations Ltd |
Method
|
PL2807192T3
(pl)
|
2012-01-27 |
2019-02-28 |
Abbvie Deutschland |
Kompozycja oraz sposób diagnostyki i leczenia chorób związanych ze zwyrodnieniem neurytów
|
CA2863887C
(en)
|
2012-02-09 |
2023-01-03 |
Population Diagnostics, Inc. |
Methods of screening low frequency gdna variation biomarkers for pervasive developmental disorder (pdd) or pervasive developmental disorder - not otherwise specified (pdd_nos)
|
CN104254778A
(zh)
|
2012-02-10 |
2014-12-31 |
西雅图遗传学公司 |
Cd30+癌症的检测和治疗
|
CN104203977A
(zh)
|
2012-02-15 |
2014-12-10 |
诺和诺德A/S(股份有限公司) |
结合肽聚糖识别蛋白1的抗体
|
EP2814844B1
(en)
|
2012-02-15 |
2017-08-02 |
Novo Nordisk A/S |
Antibodies that bind and block triggering receptor expressed on myeloid cells-1 (trem-1)
|
US9550830B2
(en)
|
2012-02-15 |
2017-01-24 |
Novo Nordisk A/S |
Antibodies that bind and block triggering receptor expressed on myeloid cells-1 (TREM-1)
|
GB201203051D0
(en)
|
2012-02-22 |
2012-04-04 |
Ucb Pharma Sa |
Biological products
|
GB201203071D0
(en)
|
2012-02-22 |
2012-04-04 |
Ucb Pharma Sa |
Biological products
|
EP2817338B1
(en)
|
2012-02-24 |
2017-07-26 |
AbbVie Stemcentrx LLC |
Dll3 modulators and methods of use
|
EP2822970A1
(en)
|
2012-03-08 |
2015-01-14 |
Halozyme, Inc. |
Conditionally active anti-epidermal growth factor receptor antibodies and methods of use thereof
|
WO2013138522A2
(en)
|
2012-03-16 |
2013-09-19 |
Genelux Corporation |
Methods for assessing effectiveness and monitoring oncolytic virus treatment
|
CA2866185C
(en)
|
2012-03-23 |
2021-04-06 |
The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services |
Pathogenic phlebovirus isolates and compositions and methods of use
|
EP2831112A1
(en)
|
2012-03-29 |
2015-02-04 |
Friedrich Miescher Institute for Biomedical Research |
Inhibition of interleukin- 8 and/or its receptor cxcrl in the treatment her2/her3 -overexpressing breast cancer
|
AU2012376214B2
(en)
|
2012-04-02 |
2019-02-14 |
Berg Llc |
Interrogatory cell-based assays and uses thereof
|
WO2013151649A1
(en)
|
2012-04-04 |
2013-10-10 |
Sialix Inc |
Glycan-interacting compounds
|
WO2013158275A1
(en)
|
2012-04-20 |
2013-10-24 |
Abbvie Inc. |
Cell culture methods to reduce acidic species
|
PT2838917T
(pt)
|
2012-04-20 |
2019-09-12 |
Merus Nv |
Métodos e meios para a produção de moléculas similares a ig heterodiméricas
|
US9150645B2
(en)
|
2012-04-20 |
2015-10-06 |
Abbvie, Inc. |
Cell culture methods to reduce acidic species
|
US9181572B2
(en)
|
2012-04-20 |
2015-11-10 |
Abbvie, Inc. |
Methods to modulate lysine variant distribution
|
NZ702178A
(en)
|
2012-05-14 |
2017-01-27 |
Biogen Ma Inc |
Lingo-2 antagonists for treatment of conditions involving motor neurons
|
MX362497B
(es)
|
2012-05-15 |
2019-01-21 |
Eisai Inc |
Un anticuerpo que se une específicamente al receptor alfa del folato y usos del mismo.
|
TW201348247A
(zh)
|
2012-05-21 |
2013-12-01 |
Abbvie Inc |
利用蛋白質a親和性層析之非人類抗體之新穎純化
|
WO2013176754A1
(en)
|
2012-05-24 |
2013-11-28 |
Abbvie Inc. |
Novel purification of antibodies using hydrophobic interaction chromatography
|
EP2859018B1
(en)
|
2012-06-06 |
2021-09-22 |
Zoetis Services LLC |
Caninized anti-ngf antibodies and methods thereof
|
EP2867674B1
(en)
|
2012-06-28 |
2018-10-10 |
UCB Biopharma SPRL |
A method for identifying compounds of therapeutic interest
|
WO2014001482A1
(en)
|
2012-06-29 |
2014-01-03 |
Novartis Forschungsstiftung, Zweigniererlassung, Friedrich Miescher Institute For Biomedical Research |
Treating diseases by modulating a specific isoform of mkl1
|
WO2014006114A1
(en)
|
2012-07-05 |
2014-01-09 |
Novartis Forschungsstiftung, Zweigniederlassung Friedrich Miescher Institute For Biomedical Research |
New treatment for neurodegenerative diseases
|
EP2869818A1
(en)
|
2012-07-06 |
2015-05-13 |
Novartis AG |
Combination of a phosphoinositide 3-kinase inhibitor and an inhibitor of the il-8/cxcr interaction
|
AR091755A1
(es)
|
2012-07-12 |
2015-02-25 |
Abbvie Inc |
Proteinas de union a il-1
|
GB201213652D0
(en)
|
2012-08-01 |
2012-09-12 |
Oxford Biotherapeutics Ltd |
Therapeutic and diagnostic target
|
EP2879710B1
(en)
|
2012-08-03 |
2019-11-13 |
Dana-Farber Cancer Institute, Inc. |
Medical uses of agents that modulate immune cell activation and corresponding screening methods
|
WO2014039860A2
(en)
|
2012-09-07 |
2014-03-13 |
University Of Louisville Research Foundation, Inc. |
Compositions and methods for modulating dnmt1 inhibitor activity
|
DK2895621T3
(da)
|
2012-09-14 |
2020-11-30 |
Population Bio Inc |
Fremgangsmåder og sammensætning til diagnosticering, prognose og behandling af neurologiske tilstande
|
US10233495B2
(en)
|
2012-09-27 |
2019-03-19 |
The Hospital For Sick Children |
Methods and compositions for screening and treating developmental disorders
|
US9365641B2
(en)
|
2012-10-01 |
2016-06-14 |
The Trustees Of The University Of Pennsylvania |
Compositions and methods for targeting stromal cells for the treatment of cancer
|
EP3750560A3
(en)
|
2012-10-09 |
2021-03-24 |
Biogen MA Inc. |
Combination therapies and uses for treatment of demyelinating disorders
|
EP2906241B1
(en)
|
2012-10-12 |
2020-01-08 |
The Brigham and Women's Hospital, Inc. |
Enhancement of the immune response
|
MY194330A
(en)
|
2012-11-01 |
2022-11-28 |
Abbvie Inc |
Anti-dll4/vegf dual variable domain immunoglobulin and uses thereof
|
WO2014071295A1
(en)
*
|
2012-11-02 |
2014-05-08 |
Enzymatics Inc. |
Methods and kits for nucleic acid sample preparation for sequencing
|
EP2914621B1
(en)
|
2012-11-05 |
2023-06-07 |
Foundation Medicine, Inc. |
Novel ntrk1 fusion molecules and uses thereof
|
EP2917238A1
(en)
|
2012-11-08 |
2015-09-16 |
Eleven Biotherapeutics, Inc. |
Il-6 antagonists and uses thereof
|
WO2014074942A1
(en)
|
2012-11-08 |
2014-05-15 |
Illumina, Inc. |
Risk variants of alzheimer's disease
|
RS60084B1
(sr)
|
2012-12-10 |
2020-05-29 |
Biogen Ma Inc |
Antitela anti-antigen 2 dendritske ćelije krvi i njihove upotrebe
|
WO2014100542A1
(en)
|
2012-12-21 |
2014-06-26 |
Abbvie, Inc. |
High-throughput antibody humanization
|
JP6359031B2
(ja)
|
2012-12-21 |
2018-07-18 |
メディミューン,エルエルシー |
抗h7cr抗体
|
GB201223276D0
(en)
|
2012-12-21 |
2013-02-06 |
Ucb Pharma Sa |
Antibodies and methods of producing same
|
AU2013202668B2
(en)
|
2012-12-24 |
2014-12-18 |
Adelaide Research & Innovation Pty Ltd |
Inhibition of cancer growth and metastasis
|
US10717965B2
(en)
|
2013-01-10 |
2020-07-21 |
Gloriana Therapeutics, Inc. |
Mammalian cell culture-produced neublastin antibodies
|
WO2014113729A2
(en)
|
2013-01-18 |
2014-07-24 |
Foundation Mecicine, Inc. |
Methods of treating cholangiocarcinoma
|
GB201302447D0
(en)
|
2013-02-12 |
2013-03-27 |
Oxford Biotherapeutics Ltd |
Therapeutic and diagnostic target
|
KR20160037130A
(ko)
|
2013-02-22 |
2016-04-05 |
스템센트알엑스 인코포레이티드 |
신규한 항체 접합체 및 이의 용도
|
WO2014142646A1
(en)
|
2013-03-13 |
2014-09-18 |
Stichting Katholieke Universiteit |
Q-fever diagnostic
|
PE20151893A1
(es)
|
2013-03-14 |
2015-12-30 |
Parkash Gill |
Tratamiento del cancer usando anticuerpos que se unen a grp78 en la superficie celular
|
EP2968526A4
(en)
|
2013-03-14 |
2016-11-09 |
Abbott Lab |
ANTIGEN-ANTIBODY COMBINATION ASSAY OF HEPATITIS C VIRUS AND METHODS AND COMPOSITIONS FOR USE THEREWITH
|
WO2014142882A1
(en)
|
2013-03-14 |
2014-09-18 |
Abbvie Inc. |
Protein purification using displacement chromatography
|
EP2836515A1
(en)
|
2013-03-14 |
2015-02-18 |
AbbVie Inc. |
Low acidic species compositions and methods for producing and using the same
|
CN113549148A
(zh)
|
2013-03-14 |
2021-10-26 |
雅培制药有限公司 |
Hcv核心脂质结合结构域单克隆抗体
|
EP2970375A1
(en)
|
2013-03-14 |
2016-01-20 |
AbbVie Inc. |
Low acidic species compositions and methods for producing the same using displacement chromatography
|
CN105209616A
(zh)
|
2013-03-14 |
2015-12-30 |
雅培制药有限公司 |
用于改进的抗体检测的hcv ns3重组抗原及其突变体
|
US9469686B2
(en)
|
2013-03-15 |
2016-10-18 |
Abbott Laboratories |
Anti-GP73 monoclonal antibodies and methods of obtaining the same
|
JP2016515120A
(ja)
|
2013-03-15 |
2016-05-26 |
バイオジェン・エムエイ・インコーポレイテッドBiogen MA Inc. |
抗アルファvベータ5抗体を用いた急性腎損傷の治療及び予防
|
KR20220041957A
(ko)
|
2013-03-15 |
2022-04-01 |
아비에 도이치란트 게엠베하 운트 콤파니 카게 |
항-egfr 항체 약물 접합체 제형
|
WO2014144292A2
(en)
|
2013-03-15 |
2014-09-18 |
Sanofi Pasteur Biologics , Llc |
Antibodies against clostridium difficile toxins and methods of using the same
|
SG10201800313UA
(en)
|
2013-03-15 |
2018-02-27 |
Abbvie Inc |
Antibody drug conjugate (adc) purification
|
CN105324396A
(zh)
|
2013-03-15 |
2016-02-10 |
艾伯维公司 |
针对IL-1β和/或IL-17的双重特异性结合蛋白
|
CA2944989A1
(en)
|
2013-04-08 |
2014-10-16 |
Cytodyn Inc. |
Felinized antibodies and methods of treating retroviral infections in felines
|
CN105308460A
(zh)
|
2013-05-02 |
2016-02-03 |
天主教大学基金会 |
个性化药物
|
EP3816625A1
(en)
|
2013-05-06 |
2021-05-05 |
Scholar Rock, Inc. |
Compositions and methods for growth factor modulation
|
CA2911600A1
(en)
|
2013-05-17 |
2014-11-20 |
Centre National De La Recherche Scientifique (Cnrs) |
Anti-cxcl1, cxcl7 and cxcl8 antibodies and their applications
|
AU2014268298B2
(en)
|
2013-05-24 |
2019-01-17 |
Medlmmune, Llc |
Anti-B7-H5 antibodies and their uses
|
AU2014275166B2
(en)
|
2013-06-06 |
2020-09-10 |
Dana-Farber Cancer Institute, Inc. |
Compositions and methods for identification, assessment prevention, and treatment of cancer using PD-L1 isoforms
|
SG11201509982UA
(fi)
|
2013-06-06 |
2016-04-28 |
Igenica Biotherapeutics Inc |
|
EP3003372B1
(en)
|
2013-06-07 |
2019-10-09 |
Duke University |
Inhibitors of complement factor h
|
US20160175401A1
(en)
|
2013-07-31 |
2016-06-23 |
Dana-Farber Cancer Institute Inc. |
Compoitions and methods for modulating thermogenesis using pth-related and egf-related compounds
|
US20160178610A1
(en)
|
2013-08-07 |
2016-06-23 |
Friedrich Miescher Institute For Biomedical Research |
New screening method for the treatment Friedreich's ataxia
|
US9163284B2
(en)
|
2013-08-09 |
2015-10-20 |
President And Fellows Of Harvard College |
Methods for identifying a target site of a Cas9 nuclease
|
PL3036320T3
(pl)
|
2013-08-19 |
2021-11-02 |
Biogen Ma Inc. |
Kontrola glikozylacji białka poprzez parametry procesu suplementacji pożywki hodowlanej i hodowli komórkowej
|
DK3041507T3
(da)
|
2013-08-26 |
2021-07-26 |
Biontech Res And Development Inc |
Nukleinsyrer, der koder for humane antistoffer mod sialyl-lewis a
|
WO2015031541A1
(en)
|
2013-08-28 |
2015-03-05 |
Stem Centrx, Inc. |
Novel sez6 modulators and methods of use
|
CN105848671B
(zh)
|
2013-08-28 |
2019-12-13 |
艾伯维施特姆森特克斯有限责任公司 |
位点特异性抗体缀合方法和组合物
|
US9340800B2
(en)
|
2013-09-06 |
2016-05-17 |
President And Fellows Of Harvard College |
Extended DNA-sensing GRNAS
|
JP6282745B2
(ja)
|
2013-09-12 |
2018-02-21 |
ハロザイム インコーポレイテッド |
修飾抗上皮成長因子受容体抗体およびその使用法
|
ES2724300T3
(es)
|
2013-09-25 |
2019-09-10 |
Univ Cornell |
Compuestos para inducir inmunidad antitumoral y métodos de lo mismo
|
EP3903599A1
(en)
|
2013-09-25 |
2021-11-03 |
Bioverativ Therapeutics Inc. |
On-column viral inactivation methods
|
WO2015048312A1
(en)
|
2013-09-26 |
2015-04-02 |
Costim Pharmaceuticals Inc. |
Methods for treating hematologic cancers
|
WO2015057939A1
(en)
|
2013-10-18 |
2015-04-23 |
Biogen Idec Ma Inc. |
Anti-s1p4 antibodies and uses thereof
|
EP3063317B1
(en)
|
2013-10-28 |
2020-06-03 |
DOTS Technology Corp. |
Allergen detection
|
EP3777980B1
(en)
|
2013-10-29 |
2023-12-06 |
President and Fellows of Harvard College |
Nuclear factor erythroid 2-like 2 (nrf2) for use in treatment of age-related macular degeneration
|
EP2871189A1
(en)
|
2013-11-07 |
2015-05-13 |
Institut Pasteur |
High-affinity monoclonal anti-strep-tag antibody
|
WO2015070068A1
(en)
|
2013-11-07 |
2015-05-14 |
Abbvie Inc. |
Isolation and purification of antibodies
|
EP3511422B1
(en)
|
2013-11-12 |
2022-12-28 |
Population Bio, Inc. |
Methods and compositions for diagnosing, prognosing, and treating endometriosis
|
WO2015071759A1
(en)
|
2013-11-15 |
2015-05-21 |
Institut Pasteur |
A molecular marker of plasmodium falciparum artemisinin resistance
|
US9067998B1
(en)
|
2014-07-15 |
2015-06-30 |
Kymab Limited |
Targeting PD-1 variants for treatment of cancer
|
US9914769B2
(en)
|
2014-07-15 |
2018-03-13 |
Kymab Limited |
Precision medicine for cholesterol treatment
|
US8986694B1
(en)
|
2014-07-15 |
2015-03-24 |
Kymab Limited |
Targeting human nav1.7 variants for treatment of pain
|
US8992927B1
(en)
|
2014-07-15 |
2015-03-31 |
Kymab Limited |
Targeting human NAV1.7 variants for treatment of pain
|
US9045545B1
(en)
|
2014-07-15 |
2015-06-02 |
Kymab Limited |
Precision medicine by targeting PD-L1 variants for treatment of cancer
|
RU2714902C2
(ru)
|
2013-12-19 |
2020-02-20 |
Новартис Аг |
Химерные рецепторы антигена против мезотелина человека и их применение
|
WO2015095868A1
(en)
|
2013-12-20 |
2015-06-25 |
Wake Forest University Health Sciences |
Methods and compositions for increasing protective antibody levels induced by pneumococcal polysaccharide vaccines
|
US20160289633A1
(en)
|
2013-12-20 |
2016-10-06 |
Biogen Ma Inc. |
Use of Perfusion Seed Cultures to Improve Biopharmaceutical Fed-Batch Production Capacity and Product Quality
|
EP2960252A1
(en)
|
2014-06-26 |
2015-12-30 |
Institut Pasteur |
Phospholipase for treatment of immunosuppression
|
DK3087098T3
(da)
|
2013-12-24 |
2020-06-08 |
Janssen Pharmaceutica Nv |
Anti-Vista-antistoffer og -fragmenter
|
US10238700B2
(en)
|
2014-01-02 |
2019-03-26 |
Genelux Corporation |
Oncolytic virus adjunct therapy with agents that increase virus infectivity
|
WO2015134121A2
(en)
|
2014-01-20 |
2015-09-11 |
President And Fellows Of Harvard College |
Negative selection and stringency modulation in continuous evolution systems
|
JOP20200094A1
(ar)
|
2014-01-24 |
2017-06-16 |
Dana Farber Cancer Inst Inc |
جزيئات جسم مضاد لـ pd-1 واستخداماتها
|
JOP20200096A1
(ar)
|
2014-01-31 |
2017-06-16 |
Children’S Medical Center Corp |
جزيئات جسم مضاد لـ tim-3 واستخداماتها
|
KR102356951B1
(ko)
|
2014-02-11 |
2022-01-27 |
비스테라, 인크. |
뎅기열 바이러스에 대한 항체 분자 및 그의 용도
|
JP2017514143A
(ja)
|
2014-02-21 |
2017-06-01 |
アッヴィ・ステムセントルクス・エル・エル・シー |
メラノーマに使用するための抗dll3抗体および薬物コンジュゲート
|
GB201403775D0
(en)
|
2014-03-04 |
2014-04-16 |
Kymab Ltd |
Antibodies, uses & methods
|
US9738702B2
(en)
|
2014-03-14 |
2017-08-22 |
Janssen Biotech, Inc. |
Antibodies with improved half-life in ferrets
|
TWI777174B
(zh)
|
2014-03-14 |
2022-09-11 |
瑞士商諾華公司 |
針對lag-3之抗體分子及其用途
|
DK3122869T3
(da)
|
2014-03-24 |
2019-09-09 |
Biogen Ma Inc |
Fremgangsmåder til afhjælpning af glutamindeprivation under pattedyrecellekultur
|
CA2944649C
(en)
|
2014-04-04 |
2022-06-21 |
Bionomics, Inc. |
Humanized antibodies that bind lgr5
|
JP2017515841A
(ja)
|
2014-05-13 |
2017-06-15 |
バヴァリアン・ノルディック・アクティーゼルスカブ |
腫瘍抗原を発現するポックスウイルス及びtim−3に対するモノクローナル抗体を用いた癌治療のための併用療法
|
US20170267780A1
(en)
|
2014-05-16 |
2017-09-21 |
Medimmune, Llc |
Molecules with altered neonate fc receptor binding having enhanced therapeutic and diagnostic properties
|
RS61678B1
(sr)
|
2014-05-28 |
2021-05-31 |
Agenus Inc |
Anti-gitr antitela i postupci za njihovu primenu
|
GB201409558D0
(en)
|
2014-05-29 |
2014-07-16 |
Ucb Biopharma Sprl |
Method
|
KR101753553B1
(ko)
|
2014-06-03 |
2017-07-03 |
엑스바이오테크, 인크. |
스타필로코커스 아우레우스 감염의 치료 및 예방을 위한 조성물 및 방법
|
KR102614642B1
(ko)
|
2014-06-04 |
2023-12-19 |
바이오엔테크 리서치 앤드 디벨롭먼트 인코포레이티드 |
강글리오사이드 gd2에 대한 사람 단클론 항체
|
US20170137824A1
(en)
|
2014-06-13 |
2017-05-18 |
Indranil BANERJEE |
New treatment against influenza virus
|
US10308935B2
(en)
|
2014-06-23 |
2019-06-04 |
Friedrich Miescher Institute For Biomedical Research |
Methods for triggering de novo formation of heterochromatin and or epigenetic silencing with small RNAS
|
GB201411320D0
(en)
|
2014-06-25 |
2014-08-06 |
Ucb Biopharma Sprl |
Antibody construct
|
EP3164129A1
(en)
|
2014-07-01 |
2017-05-10 |
Friedrich Miescher Institute for Biomedical Research |
Combination of a brafv600e inhibitor and mertk inhibitor to treat melanoma
|
US9139648B1
(en)
|
2014-07-15 |
2015-09-22 |
Kymab Limited |
Precision medicine by targeting human NAV1.9 variants for treatment of pain
|
GB201412658D0
(en)
|
2014-07-16 |
2014-08-27 |
Ucb Biopharma Sprl |
Molecules
|
GB201412659D0
(en)
|
2014-07-16 |
2014-08-27 |
Ucb Biopharma Sprl |
Molecules
|
CN106536559B
(zh)
|
2014-07-17 |
2021-04-27 |
诺和诺德股份有限公司 |
定点诱变trem-1抗体以降低黏度
|
CN107109419B
(zh)
|
2014-07-21 |
2020-12-22 |
诺华股份有限公司 |
使用cd33嵌合抗原受体治疗癌症
|
EP3172228B1
(en)
|
2014-07-25 |
2019-02-27 |
Theravectys |
Lentiviral vectors for regulated expression of a chimeric antigen receptor molecule
|
WO2016022363A2
(en)
|
2014-07-30 |
2016-02-11 |
President And Fellows Of Harvard College |
Cas9 proteins including ligand-dependent inteins
|
WO2016025880A1
(en)
|
2014-08-14 |
2016-02-18 |
Novartis Ag |
Treatment of cancer using gfr alpha-4 chimeric antigen receptor
|
SG11201700770PA
(en)
|
2014-08-19 |
2017-03-30 |
Novartis Ag |
Anti-cd123 chimeric antigen receptor (car) for use in cancer treatment
|
EP3186281B1
(en)
|
2014-08-28 |
2019-04-10 |
Halozyme, Inc. |
Combination therapy with a hyaluronan-degrading enzyme and an immune checkpoint inhibitor
|
WO2016036403A1
(en)
|
2014-09-05 |
2016-03-10 |
Population Diagnostics Inc. |
Methods and compositions for inhibiting and treating neurological conditions
|
WO2016040892A1
(en)
|
2014-09-13 |
2016-03-17 |
Novartis Ag |
Combination therapies
|
IL250902B
(en)
|
2014-09-16 |
2022-08-01 |
Symphogen As |
Anti-met antibodies and preparations
|
US20170298360A1
(en)
|
2014-09-24 |
2017-10-19 |
Friedrich Miescher Institute For Biomedical Research |
Lats and breast cancer
|
WO2016050702A1
(en)
|
2014-09-30 |
2016-04-07 |
Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts |
Binding molecules, especially antibodies, binding to l1cam (cd171)
|
MX2017004196A
(es)
|
2014-10-01 |
2017-07-19 |
Medimmune Ltd |
Anticuerpos contra ticagrelor y metodos de uso.
|
EP3200775B1
(en)
|
2014-10-03 |
2019-11-20 |
Novartis AG |
Combination therapies
|
CN114920840A
(zh)
|
2014-10-14 |
2022-08-19 |
诺华股份有限公司 |
针对pd-l1的抗体分子及其用途
|
MA41685A
(fr)
|
2014-10-17 |
2017-08-22 |
Biogen Ma Inc |
Supplémentation en cuivre pour la régulation de la glycosylation dans un procédé de culture cellulaire de mammifère
|
US10920208B2
(en)
|
2014-10-22 |
2021-02-16 |
President And Fellows Of Harvard College |
Evolution of proteases
|
MA40864A
(fr)
|
2014-10-31 |
2017-09-05 |
Biogen Ma Inc |
Hypotaurine, gaba, bêta-alanine et choline pour la régulation de l'accumulation de sous-produits résiduaires dans des procédés de culture de cellules mammifères
|
JP6951246B2
(ja)
|
2014-11-05 |
2021-10-20 |
アネクソン,インコーポレーテッド |
ヒト化抗補体因子C1q抗体及びその使用
|
WO2016073894A1
(en)
|
2014-11-07 |
2016-05-12 |
Eleven Biotherapeutics, Inc. |
Therapeutic agents with increased ocular retention
|
PT3215530T
(pt)
|
2014-11-07 |
2019-11-21 |
Sesen Bio Inc |
Anticorpos de il-6 melhorados
|
US9879087B2
(en)
|
2014-11-12 |
2018-01-30 |
Siamab Therapeutics, Inc. |
Glycan-interacting compounds and methods of use
|
CA2967595A1
(en)
|
2014-11-12 |
2016-05-19 |
Siamab Therapeutics, Inc. |
Glycan-interacting compounds and methods of use
|
WO2016081835A2
(en)
|
2014-11-21 |
2016-05-26 |
University Of Maryland, Baltimore |
Targeted structure-specific particulate delivery systems
|
EP3227687A4
(en)
|
2014-12-05 |
2018-10-24 |
Prelude, Inc. |
Dcis recurrence and invasive breast cancer
|
US11220545B2
(en)
|
2014-12-08 |
2022-01-11 |
Dana-Farber Cancer Institute, Inc. |
Methods for upregulating immune responses using combinations of anti-RGMb and anti-PD-1 agents
|
US10093733B2
(en)
|
2014-12-11 |
2018-10-09 |
Abbvie Inc. |
LRP-8 binding dual variable domain immunoglobulin proteins
|
PT3333191T
(pt)
|
2014-12-11 |
2020-12-15 |
Pf Medicament |
Anticorpos anti-c10orf54 e suas utilizações
|
US20170340733A1
(en)
|
2014-12-19 |
2017-11-30 |
Novartis Ag |
Combination therapies
|
EP3789039A1
(en)
|
2014-12-22 |
2021-03-10 |
The Rockefeller University |
Anti-mertk agonistic antibodies and uses thereof
|
AU2016205197B2
(en)
|
2015-01-08 |
2021-10-21 |
Biogen Ma Inc. |
LINGO-1 antagonists and uses for treatment of demyelinating disorders
|
EP4177267A1
(en)
|
2015-02-02 |
2023-05-10 |
Children's Health Care d/b/a Children's Minnesota |
Anti-surrogate light chain antibodies
|
BR112017015880A2
(pt)
|
2015-03-03 |
2018-07-31 |
Kymab Ltd |
anticorpos, usos e métodos
|
WO2016141111A1
(en)
|
2015-03-03 |
2016-09-09 |
Xoma (Us) Llc |
Treatment of post-prandial hyperinsulinemia and hypoglycemia after bariatric surgery
|
ES2805206T3
(es)
|
2015-03-10 |
2021-02-11 |
Univ Massachusetts |
Enfoque dirigido a GDF6 y a señalización de BMP para la terapia contra el melanoma
|
JP2018518152A
(ja)
|
2015-03-27 |
2018-07-12 |
ユニバーシティ オブ サザン カリフォルニア |
充実性腫瘍を処置するためのlhrに指向されたcar t細胞治療
|
EP3770171A1
(en)
|
2015-04-03 |
2021-01-27 |
XOMA Technology Ltd. |
Treatment of cancer using inhibitors of tgf-beta and pd-1
|
WO2016168631A1
(en)
|
2015-04-17 |
2016-10-20 |
President And Fellows Of Harvard College |
Vector-based mutagenesis system
|
WO2016168755A1
(en)
|
2015-04-17 |
2016-10-20 |
Distributed Bio, Inc. |
Method for mass humanization of non-human antibodies
|
WO2016170022A1
(en)
|
2015-04-21 |
2016-10-27 |
Institut Gustave Roussy |
Therapeutic methods, products and compositions inhibiting znf555
|
GB201506870D0
(en)
|
2015-04-22 |
2015-06-03 |
Ucb Biopharma Sprl |
Method
|
GB201506869D0
(en)
|
2015-04-22 |
2015-06-03 |
Ucb Biopharma Sprl |
Method
|
WO2016172769A1
(en)
|
2015-04-29 |
2016-11-03 |
University Of South Australia |
Compositions and methods for administering antibodies
|
US11685773B2
(en)
|
2015-04-30 |
2023-06-27 |
Abcheck S.R.O. |
Method for mass humanization of rabbit antibodies
|
KR20180002782A
(ko)
|
2015-05-06 |
2018-01-08 |
얀센 바이오테크 인코포레이티드 |
전립선 특이적 막 항원(psma) 이중특이성 결합제 및 그의 용도
|
EP3292152A1
(en)
|
2015-05-07 |
2018-03-14 |
Agenus Inc. |
Anti-ox40 antibodies and methods of use thereof
|
US10316097B2
(en)
|
2015-05-27 |
2019-06-11 |
Ucb Biopharma Sprl |
Method for the treatment of epilepsy, epileptogenesis, seizures or convulsions by an anti-colony-stimulating factor 1 receptor (CSF-1R) antibody
|
HUE048284T2
(hu)
|
2015-05-29 |
2020-07-28 |
Abbvie Inc |
Anti-CD40 antitestek és alkalmazásuk
|
JP6900323B2
(ja)
|
2015-05-29 |
2021-07-07 |
アジェナス インコーポレイテッド |
抗ctla−4抗体およびその使用方法
|
WO2016197064A1
(en)
|
2015-06-04 |
2016-12-08 |
Epstein Alan L |
Lym-1 and lym-2 targeted car cell immunotherapy
|
TW201710286A
(zh)
|
2015-06-15 |
2017-03-16 |
艾伯維有限公司 |
抗vegf、pdgf及/或其受體之結合蛋白
|
GB201510758D0
(en)
|
2015-06-18 |
2015-08-05 |
Ucb Biopharma Sprl |
Novel TNFa structure for use in therapy
|
US11009509B2
(en)
|
2015-06-24 |
2021-05-18 |
Janssen Pharmaceutica Nv |
Anti-VISTA antibodies and fragments
|
GB201601073D0
(en)
|
2016-01-20 |
2016-03-02 |
Ucb Biopharma Sprl |
Antibodies
|
GB201601077D0
(en)
|
2016-01-20 |
2016-03-02 |
Ucb Biopharma Sprl |
Antibody molecule
|
GB201601075D0
(en)
|
2016-01-20 |
2016-03-02 |
Ucb Biopharma Sprl |
Antibodies molecules
|
US10392674B2
(en)
|
2015-07-22 |
2019-08-27 |
President And Fellows Of Harvard College |
Evolution of site-specific recombinases
|
US11524983B2
(en)
|
2015-07-23 |
2022-12-13 |
President And Fellows Of Harvard College |
Evolution of Bt toxins
|
EP3964528A1
(en)
|
2015-07-29 |
2022-03-09 |
Novartis AG |
Combination therapies comprising antibody molecules to lag-3
|
EP3878465A1
(en)
|
2015-07-29 |
2021-09-15 |
Novartis AG |
Combination therapies comprising antibody molecules to tim-3
|
WO2017019895A1
(en)
|
2015-07-30 |
2017-02-02 |
President And Fellows Of Harvard College |
Evolution of talens
|
WO2017024285A2
(en)
|
2015-08-06 |
2017-02-09 |
Xoma (Us) Llc |
Antibody fragments against the insulin receptor and uses thereof to treat hypoglycemia
|
CN108026180B
(zh)
|
2015-08-28 |
2022-06-07 |
豪夫迈·罗氏有限公司 |
抗羟腐胺赖氨酸抗体及其用途
|
EP3344656A1
(en)
|
2015-09-01 |
2018-07-11 |
Agenus Inc. |
Anti-pd-1 antibodies and methods of use thereof
|
IL305148A
(en)
|
2015-09-15 |
2023-10-01 |
Scholar Rock Inc |
Anti-pro/hidden myostatin antibodies and their uses
|
BR112018005737A2
(pt)
|
2015-09-23 |
2018-10-09 |
Genentech Inc |
anticorpos, polinucleotídeo, vetor, célula hospedeira, método para produzir o anticorpo, para reduzir ou inibir a angiogênese, para tratar um distúrbio associado à angiogênese, para inibir a permeabilidade vascular, composição, conjugado de anticorpo, proteína de fusão, para identificar uma alteração de resíduos, utilização do anticorpo, utilização do conjugado e utilização da proteína
|
EP3569244A1
(en)
|
2015-09-23 |
2019-11-20 |
CytoImmune Therapeutics, LLC |
Flt3 directed car cells for immunotherapy
|
US11207393B2
(en)
|
2015-10-16 |
2021-12-28 |
President And Fellows Of Harvard College |
Regulatory T cell PD-1 modulation for regulating T cell effector immune responses
|
IL258821B
(en)
|
2015-10-23 |
2022-07-01 |
Harvard College |
Nucleobase editors and their uses
|
MX2018005031A
(es)
|
2015-10-27 |
2018-06-13 |
Ucb Biopharma Sprl |
Metodos de tratamiento con anticuerpos anti interleucina 17a/17f (il-17a/f).
|
EP3368566A1
(en)
|
2015-10-28 |
2018-09-05 |
Friedrich Miescher Institute for Biomedical Research |
Tenascin-w and biliary tract cancers
|
WO2017075329A2
(en)
|
2015-10-29 |
2017-05-04 |
Dana-Farber Cancer Institute, Inc. |
Methods for identification, assessment, prevention, and treatment of metabolic disorders using pm20d1 and n-lipidated amino acids
|
KR20180101341A
(ko)
|
2015-11-10 |
2018-09-12 |
비스테라, 인크. |
리포폴리사카라이드에 특이적으로 결합하는 항체 분자-약물 접합체 및 그의 용도
|
MX2018005061A
(es)
|
2015-11-12 |
2019-02-28 |
Siamab Therapeutics Inc |
Compuestos de interacción con glicanos y métodos de uso.
|
EP3380522B1
(en)
|
2015-11-25 |
2023-11-08 |
Visterra, Inc. |
Antibody molecules to april and uses thereof
|
EP3909983A1
(en)
|
2015-12-02 |
2021-11-17 |
STCube & Co. Inc. |
Antibodies and molecules that immunospecifically bind to btn1a1 and the therapeutic uses thereof
|
KR20180100122A
(ko)
|
2015-12-02 |
2018-09-07 |
주식회사 에스티사이언스 |
당화된 btla(b- 및 t-림프구 약화인자)에 특이적인 항체
|
GB201521389D0
(en)
|
2015-12-03 |
2016-01-20 |
Ucb Biopharma Sprl |
Method
|
GB201521383D0
(en)
|
2015-12-03 |
2016-01-20 |
Ucb Biopharma Sprl And Ucb Celltech |
Method
|
GB201521393D0
(en)
|
2015-12-03 |
2016-01-20 |
Ucb Biopharma Sprl |
Antibodies
|
GB201521391D0
(en)
|
2015-12-03 |
2016-01-20 |
Ucb Biopharma Sprl |
Antibodies
|
GB201521382D0
(en)
|
2015-12-03 |
2016-01-20 |
Ucb Biopharma Sprl |
Antibodies
|
WO2017097889A1
(en)
|
2015-12-10 |
2017-06-15 |
Katholieke Universiteit Leuven |
Anti adamts13 antibodies and their use for treatment or prevention of haemorrhagic disorders due to ventricular assist device
|
AU2016369537B2
(en)
|
2015-12-17 |
2024-03-14 |
Novartis Ag |
Antibody molecules to PD-1 and uses thereof
|
AU2016369623A1
(en)
|
2015-12-17 |
2018-06-28 |
Novartis Ag |
Combination of c-Met inhibitor with antibody molecule to PD-1 and uses thereof
|
JP2019504064A
(ja)
|
2016-01-08 |
2019-02-14 |
スカラー ロック インコーポレイテッドScholar Rock,Inc. |
抗プロ/潜在型ミオスタチン抗体およびその使用方法
|
GB201602413D0
(en)
|
2016-02-10 |
2016-03-23 |
Nascient Ltd |
Method
|
TW202216201A
(zh)
|
2016-02-12 |
2022-05-01 |
比利時商楊森製藥公司 |
抗vista抗體及片段、其用途及鑑定其之方法
|
JP2019509282A
(ja)
|
2016-02-29 |
2019-04-04 |
ファウンデーション・メディシン・インコーポレイテッド |
癌の治療方法
|
US11072652B2
(en)
|
2016-03-10 |
2021-07-27 |
Viela Bio, Inc. |
ILT7 binding molecules and methods of using the same
|
KR20180122397A
(ko)
|
2016-03-11 |
2018-11-12 |
스칼러 락, 인크. |
TGFβ1-결합 이뮤노글로불린 및 그의 용도
|
WO2017160599A1
(en)
|
2016-03-14 |
2017-09-21 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Use of cd300b antagonists to treat sepsis and septic shock
|
WO2017161206A1
(en)
|
2016-03-16 |
2017-09-21 |
Halozyme, Inc. |
Conjugates containing conditionally active antibodies or antigen-binding fragments thereof, and methods of use
|
US11186641B2
(en)
|
2016-03-17 |
2021-11-30 |
Oslo Universitetssykehus Hf |
Fusion proteins targeting tumour associated macrophages for treating cancer
|
CA3016563A1
(en)
|
2016-03-21 |
2017-09-28 |
Elstar Therapeutics, Inc. |
Multispecific and multifunctional molecules and uses thereof
|
AU2017239038A1
(en)
|
2016-03-22 |
2018-10-04 |
Bionomics Inc |
Administration of an anti-LGR5 monoclonal antibody
|
EP3433377A4
(en)
|
2016-03-23 |
2019-08-28 |
The General Hospital Corporation |
ASSAYS AND METHOD FOR DETECTING UDP-GLUCOSE
|
TWI763660B
(zh)
|
2016-03-25 |
2022-05-11 |
美商威特拉公司 |
登革病毒的抗體分子之配方設計
|
CA3019164A1
(en)
|
2016-03-29 |
2017-10-05 |
Janssen Biotech, Inc. |
Method of treating psoriasis with increased interval dosing of anti-il12/23 antibody
|
WO2017175058A1
(en)
|
2016-04-07 |
2017-10-12 |
Janssen Pharmaceutica Nv |
Anti-vista antibodies and fragments, uses thereof, and methods of identifying same
|
US11168145B2
(en)
|
2016-04-08 |
2021-11-09 |
Zielbio, Inc. |
Plectin-1 binding antibodies and uses thereof
|
US20170298119A1
(en)
|
2016-04-15 |
2017-10-19 |
Visterra, Inc. |
Antibody molecules to zika virus and uses thereof
|
US11649291B2
(en)
|
2016-05-24 |
2023-05-16 |
Insmed Incorporated |
Antibodies and methods of making same
|
SG11201810023QA
(en)
|
2016-05-27 |
2018-12-28 |
Agenus Inc |
Anti-tim-3 antibodies and methods of use thereof
|
MA45491A
(fr)
|
2016-06-27 |
2019-05-01 |
Juno Therapeutics Inc |
Épitopes à restriction cmh-e, molécules de liaison et procédés et utilisations associés
|
CN110291402B
(zh)
|
2016-06-27 |
2023-09-01 |
朱诺治疗学股份有限公司 |
鉴定肽表位的方法、结合此类表位的分子和相关用途
|
US11427632B2
(en)
|
2016-07-06 |
2022-08-30 |
Celgene Corporation |
Antibodies with low immunogenicity and uses thereof
|
CN109689685A
(zh)
|
2016-07-08 |
2019-04-26 |
斯塔滕生物技术有限公司 |
抗apoc3抗体及其使用方法
|
AU2017297404A1
(en)
|
2016-07-13 |
2019-01-24 |
Biogen Ma Inc. |
Dosage regimens of LINGO-1 antagonists and uses for treatment of demyelinating disorders
|
EP3484455A2
(en)
|
2016-07-15 |
2019-05-22 |
Novartis AG |
Treatment and prevention of cytokine release syndrome using a chimeric antigen receptor in combination with a kinase inhibitor
|
MA45715A
(fr)
|
2016-07-25 |
2019-05-29 |
Biogen Ma Inc |
Anticorps anti-hspa5 (grp78) et leurs utilisations
|
CN109803680B
(zh)
|
2016-08-01 |
2024-05-17 |
佐马美国有限公司 |
甲状旁腺激素受体1(pth1r)抗体和其用途
|
JP7464389B2
(ja)
|
2016-08-02 |
2024-04-09 |
ビステラ, インコーポレイテッド |
操作されたポリペプチドおよびその使用
|
US11649285B2
(en)
|
2016-08-03 |
2023-05-16 |
Bio-Techne Corporation |
Identification of VSIG3/VISTA as a novel immune checkpoint and use thereof for immunotherapy
|
SG11201900907YA
(en)
|
2016-08-03 |
2019-02-27 |
Harvard College |
Adenosine nucleobase editors and uses thereof
|
US11661590B2
(en)
|
2016-08-09 |
2023-05-30 |
President And Fellows Of Harvard College |
Programmable CAS9-recombinase fusion proteins and uses thereof
|
US11542509B2
(en)
|
2016-08-24 |
2023-01-03 |
President And Fellows Of Harvard College |
Incorporation of unnatural amino acids into proteins using base editing
|
JP6997773B2
(ja)
|
2016-09-15 |
2022-01-18 |
アーチャーディーエックス, エルエルシー |
無細胞dnaの分析用の核酸サンプル調製の方法
|
EP3933039A1
(en)
|
2016-09-15 |
2022-01-05 |
ArcherDX, LLC |
Methods of nucleic acid sample preparation
|
AU2017331277B2
(en)
|
2016-09-23 |
2024-05-30 |
Marengo Therapeutics, Inc. |
Multispecific antibody molecules comprising lambda and kappa light chains
|
EP3518969A2
(en)
|
2016-09-28 |
2019-08-07 |
Xoma (Us) Llc |
Antibodies that bind interleukin-2 and uses thereof
|
GB201616596D0
(en)
|
2016-09-29 |
2016-11-16 |
Nascient Limited |
Epitope and antibodies
|
EP3519049A4
(en)
|
2016-09-30 |
2020-05-27 |
Janssen Biotech, Inc. |
SAFE AND EFFICIENT METHOD FOR TREATING PSORIASIS WITH ANTI-IL23-SPECIFIC ANTIBODY
|
EP3519824A1
(en)
|
2016-10-03 |
2019-08-07 |
Abbott Laboratories |
Improved methods of assessing uch-l1 status in patient samples
|
CN117866991A
(zh)
|
2016-10-07 |
2024-04-12 |
诺华股份有限公司 |
用于治疗癌症的嵌合抗原受体
|
CA3037380A1
(en)
|
2016-10-11 |
2018-04-19 |
Agenus Inc. |
Anti-lag-3 antibodies and methods of use thereof
|
GB2573062A
(en)
|
2016-10-14 |
2019-10-23 |
Harvard College |
AAV delivery of nucleobase editors
|
WO2018071576A1
(en)
|
2016-10-14 |
2018-04-19 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Treatment of tumors by inhibition of cd300f
|
KR20190107656A
(ko)
|
2016-11-02 |
2019-09-20 |
이뮤노젠 아이엔씨 |
항체-약물 콘주게이트 및 parp 억제제로 병용 치료
|
EP3534947A1
(en)
|
2016-11-03 |
2019-09-11 |
Kymab Limited |
Antibodies, combinations comprising antibodies, biomarkers, uses & methods
|
KR102539159B1
(ko)
|
2016-11-07 |
2023-06-02 |
주식회사 뉴라클사이언스 |
서열 유사성을 가진 항-패밀리 19, 멤버 a5 항체 및 그것의 사용 방법
|
DE102016121899A1
(de)
*
|
2016-11-15 |
2018-05-17 |
Immatics Biotechnologies Gmbh |
Verfahren zur Herstellung von elektrokompetenten Hefezellen und Verfahren zur Verwendung dieser Zellen
|
MX2019005661A
(es)
|
2016-11-16 |
2019-10-07 |
Janssen Biotech Inc |
Método para tratar la psoriasis con el anticuerpo específico anti-il23.
|
US11401330B2
(en)
|
2016-11-17 |
2022-08-02 |
Seagen Inc. |
Glycan-interacting compounds and methods of use
|
KR102504605B1
(ko)
|
2016-12-07 |
2023-03-02 |
아게누스 인코포레이티드 |
항-ctla-4 항체 및 이의 사용 방법
|
CA3046082A1
(en)
|
2016-12-07 |
2018-06-14 |
Agenus Inc. |
Antibodies and methods of use thereof
|
WO2018111976A1
(en)
|
2016-12-14 |
2018-06-21 |
Janssen Biotech, Inc. |
Pd-l1 binding fibronectin type iii domains
|
EP3554561B1
(en)
|
2016-12-14 |
2023-06-28 |
Janssen Biotech, Inc. |
Cd137 binding fibronectin type iii domains
|
US10626165B2
(en)
|
2016-12-14 |
2020-04-21 |
Janssen Biotech, Inc. |
CD8a-binding fibronectin type III domains
|
GB201621635D0
(en)
|
2016-12-19 |
2017-02-01 |
Ucb Biopharma Sprl |
Crystal structure
|
MY201744A
(en)
|
2016-12-23 |
2024-03-15 |
Visterra Inc |
Binding polypeptides and methods of making the same
|
WO2018119359A1
(en)
|
2016-12-23 |
2018-06-28 |
President And Fellows Of Harvard College |
Editing of ccr5 receptor gene to protect against hiv infection
|
WO2018129395A1
(en)
|
2017-01-06 |
2018-07-12 |
Scholar Rock, Inc. |
Methods for treating metabolic diseases by inhibiting myostatin activation
|
AU2018205270B2
(en)
|
2017-01-06 |
2022-08-11 |
Scholar Rock, Inc. |
Methods for treating metabolic diseases by inhibiting myostatin activation
|
EP3551658A1
(en)
|
2017-01-06 |
2019-10-16 |
Scholar Rock, Inc. |
Isoform-specific, context-permissive tgf 1 inhibitors and use thereof
|
CN110290811A
(zh)
|
2017-01-13 |
2019-09-27 |
中央研究院 |
用以治疗脑部疾病的可重复装载的水胶***
|
TWI659750B
(zh)
|
2017-01-13 |
2019-05-21 |
中央研究院 |
用以治療心肌梗塞之可重複裝載之改良水膠系統
|
WO2018136626A1
(en)
|
2017-01-18 |
2018-07-26 |
Visterra, Inc. |
Antibody molecule-drug conjugates and uses thereof
|
EP3573658A4
(en)
|
2017-01-30 |
2021-07-21 |
Janssen Biotech, Inc. |
ANTI-TNF ANTIBODIES, COMPOSITIONS, AND METHODS FOR TREATMENT OF ACTIVE PSORIATIC ARTHRITIS
|
US10240205B2
(en)
|
2017-02-03 |
2019-03-26 |
Population Bio, Inc. |
Methods for assessing risk of developing a viral disease using a genetic test
|
US11623945B2
(en)
|
2017-02-06 |
2023-04-11 |
The United States Of America, As Represented By The Secretary Of Agriculture |
Immunostimulating compositions and uses therefore
|
WO2018147915A1
(en)
|
2017-02-07 |
2018-08-16 |
Janssen Biotech, Inc. |
Anti-tnf antibodies, compositions, and methods for the treatment of active ankylosing spondylitis
|
US20200291089A1
(en)
|
2017-02-16 |
2020-09-17 |
Elstar Therapeutics, Inc. |
Multifunctional molecules comprising a trimeric ligand and uses thereof
|
CN118063619A
(zh)
|
2017-03-02 |
2024-05-24 |
诺华股份有限公司 |
工程化的异源二聚体蛋白质
|
CN110913903B
(zh)
|
2017-03-03 |
2024-03-01 |
思进股份有限公司 |
聚糖相互作用化合物和使用方法
|
EP3592853A1
(en)
|
2017-03-09 |
2020-01-15 |
President and Fellows of Harvard College |
Suppression of pain by gene editing
|
WO2018165629A1
(en)
|
2017-03-10 |
2018-09-13 |
President And Fellows Of Harvard College |
Cytosine to guanine base editor
|
US11016092B2
(en)
|
2017-03-23 |
2021-05-25 |
Abbott Laboratories |
Methods for aiding in the diagnosis and determination of the extent of traumatic brain injury in a human subject using the early biomarker ubiquitin carboxy-terminal hydrolase L1
|
CA3057192A1
(en)
|
2017-03-23 |
2018-09-27 |
President And Fellows Of Harvard College |
Nucleobase editors comprising nucleic acid programmable dna binding proteins
|
US20200132673A1
(en)
|
2017-03-24 |
2020-04-30 |
The Regents Of The University Of California |
Proteoglycan irregularities in abnormal fibroblasts and therapies based therefrom
|
CN110914300A
(zh)
|
2017-04-03 |
2020-03-24 |
安康乐济股份有限公司 |
使用ps靶向抗体与免疫肿瘤学药剂治疗癌症的方法
|
US20230192839A1
(en)
|
2017-04-12 |
2023-06-22 |
Pfizer Inc. |
Antibodies having conditional affinity and methods of use thereof
|
BR112019017241A2
(pt)
|
2017-04-13 |
2020-04-14 |
Agenus Inc |
anticorpos anti-cd137 e métodos de uso dos mesmos
|
BR112019021612A2
(pt)
|
2017-04-15 |
2020-05-12 |
Abbott Laboratories |
Métodos para auxiliar o diagnóstico hiperagudo e determinação de traumatismo crânioencefálico em um indivíduo humano com o uso de biomarcadores precoces
|
JP2020517256A
(ja)
|
2017-04-19 |
2020-06-18 |
エルスター セラピューティクス, インコーポレイテッド |
多重特異性分子およびその使用
|
MA50958A
(fr)
|
2017-04-21 |
2020-10-14 |
Staten Biotechnology B V |
Anticorps anti-apoc3 et leurs méthodes d'utilisation
|
EP4328241A3
(en)
|
2017-04-28 |
2024-06-05 |
Marengo Therapeutics, Inc. |
Multispecific molecules comprising a non-immunoglobulin heterodimerization domain and uses thereof
|
EP3635407A1
(en)
|
2017-04-28 |
2020-04-15 |
Abbott Laboratories |
Methods for aiding in the hyperacute diagnosis and determination of traumatic brain injury using early biomarkers on at least two samples from the same human subject
|
CA3062061A1
(en)
|
2017-05-01 |
2018-11-08 |
Agenus Inc. |
Anti-tigit antibodies and methods of use thereof
|
US10865238B1
(en)
|
2017-05-05 |
2020-12-15 |
Duke University |
Complement factor H antibodies
|
US11560566B2
(en)
|
2017-05-12 |
2023-01-24 |
President And Fellows Of Harvard College |
Aptazyme-embedded guide RNAs for use with CRISPR-Cas9 in genome editing and transcriptional activation
|
JOP20190256A1
(ar)
|
2017-05-12 |
2019-10-28 |
Icahn School Med Mount Sinai |
فيروسات داء نيوكاسل واستخداماتها
|
EP3630830A1
(en)
|
2017-05-23 |
2020-04-08 |
Helmholtz Zentrum München - Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH) |
Novel cd73 antibody, preparation and uses thereof
|
CN110651190A
(zh)
|
2017-05-25 |
2020-01-03 |
雅培实验室 |
用早期生物标记物帮助确定是否对已遭受或可能已遭受头部损伤的人受试者执行成像的方法
|
US11129564B2
(en)
|
2017-05-30 |
2021-09-28 |
Abbott Laboratories |
Methods for aiding in diagnosing and evaluating a mild traumatic brain injury in a human subject using cardiac troponin I
|
WO2018222901A1
(en)
|
2017-05-31 |
2018-12-06 |
Elstar Therapeutics, Inc. |
Multispecific molecules that bind to myeloproliferative leukemia (mpl) protein and uses thereof
|
CN111051346A
(zh)
|
2017-05-31 |
2020-04-21 |
斯特库伯株式会社 |
使用免疫特异性结合btn1a1的抗体和分子治疗癌症的方法
|
KR20200015602A
(ko)
|
2017-05-31 |
2020-02-12 |
주식회사 에스티큐브앤컴퍼니 |
Btn1a1에 면역특이적으로 결합하는 항체 및 분자 및 이의 치료적 용도
|
EP3635007A1
(en)
|
2017-06-06 |
2020-04-15 |
STCube & Co., Inc. |
Methods of treating cancer using antibodies and molecules that bind to btn1a1 or btn1a1-ligands
|
KR20200015717A
(ko)
|
2017-06-09 |
2020-02-12 |
프로비던스 헬스 앤드 서비시즈 - 오레곤 |
암 치료를 위한 인간 종양 반응성 t 세포의 확인을 위한 cd39 및 cd103의 활용
|
GB201709379D0
(en)
|
2017-06-13 |
2017-07-26 |
Univ Leuven Kath |
Humanised ADAMTS13 binding antibodies
|
WO2018236904A1
(en)
|
2017-06-19 |
2018-12-27 |
Surface Oncology, Inc. |
COMBINATION OF ANTI-CD47 ANTIBODIES AND CELL DEATH INDUCING AGENTS, AND USES THEREOF
|
EP3642240A1
(en)
|
2017-06-22 |
2020-04-29 |
Novartis AG |
Antibody molecules to cd73 and uses thereof
|
WO2019005817A2
(en)
|
2017-06-26 |
2019-01-03 |
Bio-Techne Corporation |
HYBRIDOMIC CLONES, MONOCLONAL ANTIBODIES DIRECTED AGAINST VSIG-4, AND METHODS OF MAKING AND USING SAME
|
EP3645037A1
(en)
|
2017-06-27 |
2020-05-06 |
Novartis AG |
Dosage regimens for anti-tim-3 antibodies and uses thereof
|
US11169159B2
(en)
|
2017-07-03 |
2021-11-09 |
Abbott Laboratories |
Methods for measuring ubiquitin carboxy-terminal hydrolase L1 levels in blood
|
WO2019010164A1
(en)
|
2017-07-06 |
2019-01-10 |
President And Fellows Of Harvard College |
EVOLUTION OF ARNT SYNTHÉTASES
|
AU2018301393A1
(en)
|
2017-07-11 |
2020-02-06 |
Compass Therapeutics Llc |
Agonist antibodies that bind human CD137 and uses thereof
|
AU2018300189A1
(en)
|
2017-07-14 |
2020-01-30 |
Pfizer, Inc. |
Antibodies to MAdCAM
|
EP3431496A1
(en)
|
2017-07-19 |
2019-01-23 |
Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. |
Anti- isoasp7 amyloid beta antibodies and uses thereof
|
JP2020527572A
(ja)
|
2017-07-20 |
2020-09-10 |
ノバルティス アーゲー |
抗lag−3抗体の投薬量レジメンおよびその使用
|
US20200231682A1
(en)
|
2017-07-28 |
2020-07-23 |
Scholar Rock, Inc. |
Ltbp complex-specific inhibitors of tgf-beta 1 and uses thereof
|
JP2020534795A
(ja)
|
2017-07-28 |
2020-12-03 |
プレジデント アンド フェローズ オブ ハーバード カレッジ |
ファージによって支援される連続的進化(pace)を用いて塩基編集因子を進化させるための方法および組成物
|
WO2019035938A1
(en)
|
2017-08-16 |
2019-02-21 |
Elstar Therapeutics, Inc. |
MULTISPECIFIC MOLECULES BINDING TO BCMA AND USES THEREOF
|
EP3684811A2
(en)
|
2017-08-17 |
2020-07-29 |
Massachusetts Institute of Technology |
Multiple specificity binders of cxc chemokines and uses thereof
|
JP7437301B2
(ja)
|
2017-08-25 |
2024-02-22 |
ファイヴ プライム セラピューティクス インク |
B7-h4抗体及びその使用方法
|
US11319532B2
(en)
|
2017-08-30 |
2022-05-03 |
President And Fellows Of Harvard College |
High efficiency base editors comprising Gam
|
US11624130B2
(en)
|
2017-09-18 |
2023-04-11 |
President And Fellows Of Harvard College |
Continuous evolution for stabilized proteins
|
TW201922780A
(zh)
|
2017-09-25 |
2019-06-16 |
美商健生生物科技公司 |
以抗il12/il23抗體治療狼瘡之安全且有效之方法
|
BR112020005419A2
(pt)
|
2017-10-02 |
2020-09-29 |
Visterra, Inc. |
moléculas de anticorpo para cd138 e seus usos
|
EP3461841B1
(en)
|
2017-10-02 |
2019-09-11 |
Certest Biotec, S.L. |
Anti-dps antibodies and test devices for the detection of bacteria of the genus campylobacter
|
WO2019070161A2
(en)
|
2017-10-04 |
2019-04-11 |
Opko Pharmaceuticals, Llc |
ARTICLES AND METHODS FOR PERSONALIZED THERAPY OF CANCER
|
US11707522B2
(en)
|
2017-10-13 |
2023-07-25 |
Boehringer Ingelheim International Gmbh |
Human antibodies to Tn antigen
|
US11795443B2
(en)
|
2017-10-16 |
2023-10-24 |
The Broad Institute, Inc. |
Uses of adenosine base editors
|
CA3078155A1
(en)
|
2017-10-19 |
2019-04-25 |
Debiopharm International S.A. |
Combination product for the treatment of cancer
|
WO2019077165A1
(en)
|
2017-10-20 |
2019-04-25 |
Institut Curie |
DAP10 / 12-BASED CHIMERIC ANTIGENIC RECEPTORS (CAR) ADAPTED FOR RUSH
|
WO2019089594A1
(en)
|
2017-10-31 |
2019-05-09 |
Immunogen, Inc. |
Combination treatment with antibody-drug conjugates and cytarabine
|
WO2019087115A1
(en)
|
2017-10-31 |
2019-05-09 |
Staten Biotechnology B.V. |
Anti-apoc3 antibodies and methods of use thereof
|
WO2019089753A2
(en)
|
2017-10-31 |
2019-05-09 |
Compass Therapeutics Llc |
Cd137 antibodies and pd-1 antagonists and uses thereof
|
EP3706795A4
(en)
|
2017-11-09 |
2021-10-13 |
Pinteon Therapeutics Inc. |
METHODS AND COMPOSITIONS FOR GENERATING AND USING HUMANIZED CONFORMATION SPECIFIC PHOSPHORYLATED TAU ANTIBODIES
|
AU2018368731A1
(en)
|
2017-11-16 |
2020-05-14 |
Novartis Ag |
Combination therapies
|
US11851497B2
(en)
|
2017-11-20 |
2023-12-26 |
Compass Therapeutics Llc |
CD137 antibodies and tumor antigen-targeting antibodies and uses thereof
|
CA3083345A1
(en)
|
2017-11-27 |
2019-05-31 |
Purdue Pharma L.P. |
Humanized antibodies targeting human tissue factor
|
WO2019113464A1
(en)
|
2017-12-08 |
2019-06-13 |
Elstar Therapeutics, Inc. |
Multispecific molecules and uses thereof
|
CN111094983A
(zh)
|
2017-12-09 |
2020-05-01 |
雅培实验室 |
使用胶质细胞原纤维酸性蛋白(gfap)和/或泛素羧基末端水解酶l1(uch-l1)帮助诊断和评价已遭受骨科损伤并已遭受或可能已遭受头部损伤诸如轻度创伤性脑损伤(tbi)的患者的方法
|
US11016105B2
(en)
|
2017-12-09 |
2021-05-25 |
Abbott Laboratories |
Methods for aiding in diagnosing and evaluating a traumatic brain injury in a human subject using a combination of GFAP and UCH-L1
|
WO2019150309A1
(en)
|
2018-02-02 |
2019-08-08 |
Hammack Scott |
Modulators of gpr68 and uses thereof for treating and preventing diseases
|
JP2021512120A
(ja)
|
2018-02-02 |
2021-05-13 |
バイオ−テクネ コーポレーション |
Vistaとvsig3との相互作用を調節する化合物ならびにその製造および使用方法
|
GB201802486D0
(en)
|
2018-02-15 |
2018-04-04 |
Ucb Biopharma Sprl |
Methods
|
CN111971308A
(zh)
|
2018-03-02 |
2020-11-20 |
戊瑞治疗有限公司 |
B7-h4抗体及其使用方法
|
EP3762015A4
(en)
|
2018-03-05 |
2022-04-27 |
Janssen Biotech, Inc. |
METHODS OF TREATING CROHN'S DISEASE WITH SPECIFIC ANTI-IL23 ANTIBODY
|
BR112020017701A2
(pt)
|
2018-03-12 |
2020-12-29 |
Zoetis Services Llc |
Anticorpos anti-ngf e métodos dos mesmos
|
KR102411489B1
(ko)
|
2018-03-14 |
2022-06-23 |
서피스 온콜로지, 인크. |
Cd39에 결합하는 항체 및 이의 용도
|
EP3765517A1
(en)
|
2018-03-14 |
2021-01-20 |
Elstar Therapeutics, Inc. |
Multifunctional molecules that bind to calreticulin and uses thereof
|
WO2019178364A2
(en)
|
2018-03-14 |
2019-09-19 |
Elstar Therapeutics, Inc. |
Multifunctional molecules and uses thereof
|
CA3093740A1
(en)
|
2018-03-22 |
2019-09-26 |
Surface Oncology, Inc. |
Anti-il-27 antibodies and uses thereof
|
WO2019180272A1
(en)
|
2018-03-23 |
2019-09-26 |
Fundación Instituto De Investigación Sanitaria De Santiago De Compostela |
Anti-leptin affinity reagents for use in the treatment of obesity and other leptin-resistance associated diseases
|
HUE062414T2
(hu)
|
2018-03-26 |
2023-10-28 |
Glycanostics S R O |
Eszközök és eljárások fehérje glikoprofilozására
|
KR20200139219A
(ko)
|
2018-04-02 |
2020-12-11 |
브리스톨-마이어스 스큅 컴퍼니 |
항-trem-1 항체 및 이의 용도
|
WO2019200357A1
(en)
|
2018-04-12 |
2019-10-17 |
Surface Oncology, Inc. |
Biomarker for cd47 targeting therapeutics and uses therefor
|
US20210147547A1
(en)
|
2018-04-13 |
2021-05-20 |
Novartis Ag |
Dosage Regimens For Anti-Pd-L1 Antibodies And Uses Thereof
|
EP3784274A1
(en)
|
2018-04-27 |
2021-03-03 |
Fondazione Ebri Rita Levi-Montalcini |
Antibody directed against a tau-derived neurotoxic peptide and uses thereof
|
AU2019265888A1
(en)
|
2018-05-10 |
2020-11-26 |
Neuracle Science Co., Ltd. |
Anti-family with sequence similarity 19, member A5 antibodies and method of use thereof
|
WO2019222130A1
(en)
|
2018-05-15 |
2019-11-21 |
Immunogen, Inc. |
Combination treatment with antibody-drug conjugates and flt3 inhibitors
|
EP3797120A1
(en)
|
2018-05-21 |
2021-03-31 |
Compass Therapeutics LLC |
Compositions and methods for enhancing the killing of target cells by nk cells
|
WO2019226658A1
(en)
|
2018-05-21 |
2019-11-28 |
Compass Therapeutics Llc |
Multispecific antigen-binding compositions and methods of use
|
AR126019A1
(es)
|
2018-05-30 |
2023-09-06 |
Novartis Ag |
Anticuerpos frente a entpd2, terapias de combinación y métodos de uso de los anticuerpos y las terapias de combinación
|
WO2019241649A1
(en)
|
2018-06-14 |
2019-12-19 |
President And Fellows Of Harvard College |
Evolution of cytidine deaminases
|
MX2020013808A
(es)
|
2018-06-18 |
2021-05-27 |
UCB Biopharma SRL |
Antagonista de gremlina-1 para la prevencion y el tratamiento del cancer.
|
CA3104295A1
(en)
|
2018-06-19 |
2019-12-26 |
Atarga, Llc |
Antibody molecules to complement component 5 and uses thereof
|
TW202016144A
(zh)
|
2018-06-21 |
2020-05-01 |
日商第一三共股份有限公司 |
包括cd3抗原結合片段之組成物及其用途
|
EP3814376A4
(en)
|
2018-06-26 |
2022-07-06 |
Mor Research Applications Ltd. |
ANTI-TRANSTHYRETIN ANTIBODIES AND THEIR USES
|
US11845797B2
(en)
|
2018-07-03 |
2023-12-19 |
Marengo Therapeutics, Inc. |
Anti-TCR antibody molecules and uses thereof
|
WO2020008083A1
(es)
|
2018-07-05 |
2020-01-09 |
Consejo Superior De Investigaciones Científicas |
Diana terapéutica en receptores de quimiocinas para la selección de compuestos útiles para el tratamiento de procesos patológicos que implican la señalización de quimiocinas
|
WO2020014473A1
(en)
|
2018-07-11 |
2020-01-16 |
Scholar Rock, Inc. |
TGFβ1 INHIBITORS AND USE THEREOF
|
HUE056501T2
(hu)
|
2018-07-11 |
2022-02-28 |
Scholar Rock Inc |
Izoforma-szelektív TGF-béta1 inhibitorok és alkalmazásuk
|
JP2021531254A
(ja)
|
2018-07-11 |
2021-11-18 |
スカラー ロック インコーポレイテッドScholar Rock, Inc. |
高親和性のアイソフォーム選択的TGFβ1阻害剤、およびその使用
|
JP2021530697A
(ja)
|
2018-07-18 |
2021-11-11 |
ヤンセン バイオテツク,インコーポレーテツド |
抗il23特異的抗体で治療した後の持続応答予測因子
|
EP3824287A1
(en)
|
2018-07-20 |
2021-05-26 |
Pierre Fabre Médicament |
Receptor for vista
|
WO2020021465A1
(en)
|
2018-07-25 |
2020-01-30 |
Advanced Accelerator Applications (Italy) S.R.L. |
Method of treatment of neuroendocrine tumors
|
HRP20221504T1
(hr)
|
2018-08-08 |
2023-03-31 |
Pml Screening, Llc |
Postupci procjene rizika od razvoja progresivne multifokalne leukoencefalopatije uzrokovane john cunningham virusom pomoću genetskog testiranja
|
WO2020033926A2
(en)
|
2018-08-09 |
2020-02-13 |
Compass Therapeutics Llc |
Antibodies that bind cd277 and uses thereof
|
WO2020033923A1
(en)
|
2018-08-09 |
2020-02-13 |
Compass Therapeutics Llc |
Antigen binding agents that bind cd277 and uses thereof
|
WO2020033925A2
(en)
|
2018-08-09 |
2020-02-13 |
Compass Therapeutics Llc |
Antibodies that bind cd277 and uses thereof
|
EP3844289A4
(en)
*
|
2018-08-29 |
2022-07-20 |
Shanghaitech University |
COMPOSITION AND USE OF CAS PROTEIN INHIBITORS
|
WO2020056338A1
(en)
|
2018-09-14 |
2020-03-19 |
Prelude Corporation |
Method of selection for treatment of subjects at risk of invasive breast cancer
|
PL3883606T3
(pl)
|
2018-09-24 |
2023-11-27 |
Janssen Biotech, Inc. |
Bezpieczny i skuteczny sposób leczenia wrzodziejącego zapalenia jelita grubego przeciwciałami anty-il12/il23
|
CN113164777A
(zh)
|
2018-09-27 |
2021-07-23 |
马伦戈治疗公司 |
Csf1r/ccr2多特异性抗体
|
EP3856773A1
(en)
|
2018-09-28 |
2021-08-04 |
Kyowa Kirin Co., Ltd. |
Il-36 antibodies and uses thereof
|
JP2022504287A
(ja)
|
2018-10-03 |
2022-01-13 |
スターテン・バイオテクノロジー・ベー・フェー |
ヒト及びカニクイザルapoc3に特異的な抗体、並びにその使用の方法
|
JP2022512595A
(ja)
|
2018-10-05 |
2022-02-07 |
バヴァリアン・ノルディック・アクティーゼルスカブ |
組み換えmva、及び免疫チェックポイントアンタゴニストまたは免疫チェックポイントアゴニストの静脈内投与によって、がんを治療する併用療法
|
UY38407A
(es)
|
2018-10-15 |
2020-05-29 |
Novartis Ag |
Anticuerpos estabilizadores de trem2
|
WO2020086736A1
(en)
|
2018-10-23 |
2020-04-30 |
Scholar Rock, Inc. |
Rgmc-selective inhibitors and use thereof
|
GB201817309D0
(en)
|
2018-10-24 |
2018-12-05 |
Ucb Biopharma Sprl |
Antibodies
|
GB201817311D0
(en)
|
2018-10-24 |
2018-12-05 |
Ucb Biopharma Sprl |
Antibodies
|
WO2020086408A1
(en)
|
2018-10-26 |
2020-04-30 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
A high-yield perfusion-based transient gene expression bioprocess
|
CN113166269A
(zh)
|
2018-11-13 |
2021-07-23 |
指南针制药有限责任公司 |
对抗检查点分子的多特异性结合构建体及其用途
|
CN113395979A
(zh)
|
2018-11-20 |
2021-09-14 |
詹森生物科技公司 |
用抗il-23特异性抗体治疗银屑病的安全且有效的方法
|
EP3883599A1
(en)
|
2018-11-20 |
2021-09-29 |
Bavarian Nordic A/S |
Therapy for treating cancer with an intratumoral and/or intravenous administration of a recombinant mva encoding 4-1bbl (cd137l) and/or cd40l
|
WO2020128864A1
(en)
|
2018-12-18 |
2020-06-25 |
Janssen Biotech, Inc. |
Safe and effective method of treating lupus with anti-il12/il23 antibody
|
EP3898687A1
(en)
|
2018-12-20 |
2021-10-27 |
Kyowa Kirin Co., Ltd. |
Fn14 antibodies and uses thereof
|
KR20210106491A
(ko)
|
2018-12-20 |
2021-08-30 |
노파르티스 아게 |
약제학적 조합물
|
WO2020148651A1
(en)
|
2019-01-15 |
2020-07-23 |
Janssen Biotech, Inc. |
Anti-tnf antibody compositions and methods for the treatment of juvenile idiopathic arthritis
|
JP2022518441A
(ja)
|
2019-01-16 |
2022-03-15 |
コンパス セラピューティクス リミテッド ライアビリティ カンパニー |
ヒトcd137に結合する抗体の製剤およびその使用
|
GB201900732D0
(en)
|
2019-01-18 |
2019-03-06 |
Ucb Biopharma Sprl |
Antibodies
|
CN113330031A
(zh)
|
2019-01-23 |
2021-08-31 |
詹森生物科技公司 |
用于在治疗银屑病关节炎的方法中使用的抗tnf抗体组合物
|
WO2020160291A2
(en)
|
2019-01-30 |
2020-08-06 |
Scholar Rock, Inc. |
LTBP COMPLEX-SPECIFIC INHIBITORS OF TGFβ AND USES THEREOF
|
US11738050B2
(en)
|
2019-02-01 |
2023-08-29 |
Regents Of The University Of Minnesota |
Compounds binding to fibroblast activation protein alpha
|
EP3693063A1
(en)
|
2019-02-06 |
2020-08-12 |
Diaccurate |
Methods and compositions for treating cancer
|
EP3696191A1
(en)
|
2019-02-14 |
2020-08-19 |
Fundación Instituto de Investigación contra la Leucemia Josep Carreras (IJC) |
Car t-cells for the treatment of cd1a-positive cancer
|
US10871640B2
(en)
|
2019-02-15 |
2020-12-22 |
Perkinelmer Cellular Technologies Germany Gmbh |
Methods and systems for automated imaging of three-dimensional objects
|
CN114127112A
(zh)
|
2019-02-21 |
2022-03-01 |
马伦戈治疗公司 |
与t细胞结合的多功能分子及其治疗自身免疫性病症的用途
|
JP2022521937A
(ja)
|
2019-02-21 |
2022-04-13 |
マレンゴ・セラピューティクス,インコーポレーテッド |
NKp30に結合する抗体分子およびその使用
|
CN114126714A
(zh)
|
2019-02-21 |
2022-03-01 |
马伦戈治疗公司 |
抗tcr抗体分子及其用途
|
SG11202109061YA
(en)
|
2019-02-21 |
2021-09-29 |
Marengo Therapeutics Inc |
Multifunctional molecules that bind to t cell related cancer cells and uses thereof
|
CA3131016A1
(en)
|
2019-02-21 |
2020-08-27 |
Andreas Loew |
Multifunctional molecules that bind to calreticulin and uses thereof
|
CA3130303A1
(en)
|
2019-02-26 |
2020-09-03 |
Rgenix, Inc. |
High-affinity anti-mertk antibodies and uses thereof
|
JP2022525145A
(ja)
|
2019-03-14 |
2022-05-11 |
ヤンセン バイオテツク,インコーポレーテツド |
抗il12/il23抗体組成物を生成するための製造方法
|
US20220144934A1
(en)
|
2019-03-14 |
2022-05-12 |
Janssen Biotech, Inc. |
Methods for Producing Anti-TNF Antibody Compositions
|
CN113840837A
(zh)
|
2019-03-14 |
2021-12-24 |
詹森生物科技公司 |
用于产生抗tnf抗体组合物的方法
|
JP2022525179A
(ja)
|
2019-03-14 |
2022-05-11 |
ヤンセン バイオテツク,インコーポレーテツド |
抗tnf抗体組成物を産生するための産生方法
|
BR112021018441A2
(pt)
|
2019-03-18 |
2023-02-28 |
Janssen Biotech Inc |
Método para tratamento de psoríase em indivíduos pediátricos com anticorpo anti-il12/il23
|
WO2020191153A2
(en)
|
2019-03-19 |
2020-09-24 |
The Broad Institute, Inc. |
Methods and compositions for editing nucleotide sequences
|
CN113874392A
(zh)
|
2019-03-28 |
2021-12-31 |
丹尼斯科美国公司 |
工程化抗体
|
BR112021019337A2
(pt)
|
2019-03-29 |
2021-12-07 |
Atarga Llc |
Anticorpo anti-fgf23
|
EP3962529A4
(en)
|
2019-04-30 |
2023-11-01 |
Dana-Farber Cancer Institute, Inc. |
METHOD FOR CANCER TREATMENT USING ANTI-CX3CR1 AND IMMUNE CHECKPOINT BLOCKING REAGENTS COMBINATIONS
|
AU2020279987A1
(en)
|
2019-05-23 |
2021-11-18 |
Janssen Biotech, Inc. |
Method of treating inflammatory bowel disease with a combination therapy of antibodies to IL-23 and TNF alpha
|
AU2020288404A1
(en)
|
2019-06-03 |
2022-02-03 |
Janssen Biotech, Inc. |
Anti-TNF antibodies, compositions, and methods for the treatment of active Ankylosing Spondylitis
|
KR20220029593A
(ko)
|
2019-06-03 |
2022-03-08 |
얀센 바이오테크 인코포레이티드 |
건선성 관절염의 치료를 위한 항-tnf 항체 조성물, 및 방법
|
KR20220044939A
(ko)
|
2019-06-17 |
2022-04-12 |
비스테라, 인크. |
Cd138에 대한 인간화 항체 분자 및 이의 용도
|
CN114450298A
(zh)
|
2019-07-26 |
2022-05-06 |
威特拉公司 |
白介素-2制剂及其用途
|
LT4007777T
(lt)
|
2019-08-02 |
2024-02-12 |
Fundació de Recerca Clínic Barcelona-Institut d'Investigacions Biomèdiques August Pi i Sunyer (FRCB-IDIBAPS) |
Car t ląstelės prieš bcma, skirtos dauginės mielomos gydymui
|
WO2021023860A1
(en)
|
2019-08-07 |
2021-02-11 |
Db Biotech, As |
Improved horseradish peroxidase polypeptides
|
JP2022545368A
(ja)
|
2019-08-12 |
2022-10-27 |
アプティーボ リサーチ アンド デベロップメント エルエルシー |
4-1bbおよび0x40結合タンパク質ならびに関連する組成物および方法、4-1bbに対する抗体、0x40に対する抗体
|
WO2021028752A1
(en)
|
2019-08-15 |
2021-02-18 |
Janssen Biotech, Inc. |
Anti-tfn antibodies for treating type i diabetes
|
AU2020335928A1
(en)
|
2019-08-30 |
2022-02-17 |
Agenus Inc. |
Anti-CD96 antibodies and methods of use thereof
|
WO2021044009A1
(en)
|
2019-09-04 |
2021-03-11 |
Deutsches Zentrum Für Neurodegenerative Erkrankungen E.V. (Dzne) |
Herv inhibitors for use in treating tauopathies
|
US20220306736A1
(en)
|
2019-09-04 |
2022-09-29 |
Y-Biologics Inc. |
Anti-vsig4 antibody or antigen binding fragment and uses thereof
|
KR20220062500A
(ko)
|
2019-09-16 |
2022-05-17 |
서피스 온콜로지, 인크. |
항-cd39 항체 조성물 및 방법
|
TW202124446A
(zh)
|
2019-09-18 |
2021-07-01 |
瑞士商諾華公司 |
與entpd2抗體之組合療法
|
EP4031578A1
(en)
|
2019-09-18 |
2022-07-27 |
Novartis AG |
Entpd2 antibodies, combination therapies, and methods of using the antibodies and combination therapies
|
AU2020353672A1
(en)
|
2019-09-25 |
2022-03-31 |
Surface Oncology, LLC |
Anti-IL-27 antibodies and uses thereof
|
US20220411511A1
(en)
|
2019-09-26 |
2022-12-29 |
Stcube & Co. |
Antibodies specific to glycosylated ctla-4 and methods of use thereof
|
US20220356248A1
(en)
|
2019-10-09 |
2022-11-10 |
Stcube & Co |
Antibodies specific to glycosylated lag3 and methods of use thereof
|
JP2022551204A
(ja)
|
2019-10-14 |
2022-12-07 |
アロ・バイオセラピューティクス・カンパニー |
Cd71結合フィブロネクチンiii型ドメイン
|
WO2021076574A2
(en)
|
2019-10-14 |
2021-04-22 |
Aro Biotherapeutics Company |
Fn3 domain-sirna conjugates and uses thereof
|
IL292347A
(en)
|
2019-10-21 |
2022-06-01 |
Novartis Ag |
Combination treatments with ventoclax and tim-3 inhibitors
|
EP4048285A1
(en)
|
2019-10-21 |
2022-08-31 |
Novartis AG |
Tim-3 inhibitors and uses thereof
|
WO2021080682A1
(en)
|
2019-10-24 |
2021-04-29 |
Massachusetts Institute Of Technology |
Monoclonal antibodies that bind human cd161 and uses thereof
|
KR20220106775A
(ko)
|
2019-11-20 |
2022-07-29 |
버베리안 노딕 에이/에스 |
암 치료를 위한 종양내 및/또는 정맥내 투여를 위한 재조합 mva 바이러스
|
GB201917480D0
(en)
|
2019-11-29 |
2020-01-15 |
Univ Oxford Innovation Ltd |
Antibodies
|
GB201919062D0
(en)
|
2019-12-20 |
2020-02-05 |
Ucb Biopharma Sprl |
Antibody
|
GB201919061D0
(en)
|
2019-12-20 |
2020-02-05 |
Ucb Biopharma Sprl |
Multi-specific antibody
|
GB201919058D0
(en)
|
2019-12-20 |
2020-02-05 |
Ucb Biopharma Sprl |
Multi-specific antibodies
|
KR20220116257A
(ko)
|
2019-12-20 |
2022-08-22 |
노파르티스 아게 |
골수섬유증 및 골수이형성 증후군을 치료하기 위한, 데시타빈 또는 항 pd-1 항체 스파르탈리주맙을 포함하거나 또는 포함하지 않는, 항 tim-3 항체 mbg453 및 항 tgf-베타 항체 nis793의 조합물
|
TW202138388A
(zh)
|
2019-12-30 |
2021-10-16 |
美商西根公司 |
以非海藻糖苷化抗-cd70抗體治療癌症之方法
|
EP4084821A4
(en)
|
2020-01-03 |
2024-04-24 |
Marengo Therapeutics Inc |
CD33-BINDING MULTIFUNCTIONAL MOLECULES AND THEIR USES
|
BR112022011749A2
(pt)
|
2020-01-06 |
2022-08-30 |
Vaccinex Inc |
Anticorpos anti-ccr8 e seus usos
|
AU2021205440A1
(en)
|
2020-01-11 |
2022-09-01 |
Scholar Rock,Inc. |
TGF-beta inhibitors and use thereof
|
CA3167427A1
(en)
|
2020-01-11 |
2021-07-15 |
Scholar Rock, Inc. |
Tgfb inhibitors and use thereof
|
TW202140553A
(zh)
|
2020-01-13 |
2021-11-01 |
美商威特拉公司 |
C5ar1抗體分子及其用途
|
BR112022012310A2
(pt)
|
2020-01-17 |
2022-09-06 |
Novartis Ag |
Combinação compreendendo um inibidor de tim-3 e um agente hipometilante para uso no tratamento de síndrome mielodisplásica ou leucemia mielomonocítica crônica
|
KR20220137698A
(ko)
|
2020-02-05 |
2022-10-12 |
라리마 테라퓨틱스, 인코포레이티드 |
Tat 펩티드 결합 단백질 및 이의 용도
|
WO2021160269A1
(en)
|
2020-02-13 |
2021-08-19 |
UCB Biopharma SRL |
Anti cd44-ctla4 bispecific antibodies
|
EP4103609A1
(en)
|
2020-02-13 |
2022-12-21 |
UCB Biopharma SRL |
Bispecific antibodies against cd9 and cd7
|
US20230151109A1
(en)
|
2020-02-13 |
2023-05-18 |
UCB Biopharma SRL |
Bispecific antibodies against cd9
|
US20230192900A1
(en)
|
2020-02-13 |
2023-06-22 |
UCB Biopharma SRL |
Bispecific antibodies binding hvem and cd9
|
EP4103608A1
(en)
|
2020-02-13 |
2022-12-21 |
UCB Biopharma SRL |
Bispecific antibodies against cd9 and cd137
|
JP2023513834A
(ja)
|
2020-02-18 |
2023-04-03 |
アレクトル エルエルシー |
Pilra抗体及びその使用方法
|
MX2022011050A
(es)
|
2020-03-06 |
2022-12-15 |
Ona Therapeutics S L |
Anticuerpos anti-cd36 y su uso para tratar cancer.
|
CA3173981A1
(en)
|
2020-03-10 |
2021-09-16 |
Massachusetts Institute Of Technology |
Compositions and methods for immunotherapy of npm1c-positive cancer
|
EP4117789A1
(en)
|
2020-03-11 |
2023-01-18 |
Fundació Institut de Recerca Contra la Leucèmia Josep Carreras |
Cd22 targeting-moiety for the treatment of b-cell acute lymphoblastic leukemia (b-all)
|
WO2021202473A2
(en)
|
2020-03-30 |
2021-10-07 |
Danisco Us Inc |
Engineered antibodies
|
EP4126064A1
(en)
|
2020-04-03 |
2023-02-08 |
Visterra, Inc. |
Antibody molecule-drug conjugates and uses thereof
|
EP4136459A1
(en)
|
2020-04-13 |
2023-02-22 |
Abbott Laboratories |
Methods, complexes and kits for detecting or determining an amount of a ss-coronavirus antibody in a sample
|
KR20230028242A
(ko)
|
2020-04-24 |
2023-02-28 |
마렝고 테라퓨틱스, 인크. |
T 세포 관련 암 세포에 결합하는 다중기능성 분자 및 그것의 용도
|
US20230167193A1
(en)
|
2020-05-01 |
2023-06-01 |
Novartis Ag |
Immunoglobulin variants
|
US20230242647A1
(en)
|
2020-05-01 |
2023-08-03 |
Novartis Ag |
Engineered immunoglobulins
|
KR20230019843A
(ko)
|
2020-05-08 |
2023-02-09 |
더 브로드 인스티튜트, 인코퍼레이티드 |
표적 이중 가닥 뉴클레오티드 서열의 두 가닥의 동시 편집을 위한 방법 및 조성물
|
US20210355196A1
(en)
|
2020-05-17 |
2021-11-18 |
Astrazeneca Uk Limited |
Sars-cov-2 antibodies and methods of selecting and using the same
|
WO2021239666A1
(en)
|
2020-05-26 |
2021-12-02 |
Diaccurate |
Therapeutic methods
|
WO2021247908A1
(en)
|
2020-06-03 |
2021-12-09 |
Bionecure Therapeutics, Inc. |
Trophoblast cell-surface antigen-2 (trop-2) antibodies
|
TW202216195A
(zh)
|
2020-06-24 |
2022-05-01 |
美商威特拉公司 |
April抗體分子及其用途
|
WO2022010797A2
(en)
|
2020-07-07 |
2022-01-13 |
Bionecure Therapeutics, Inc. |
Novel maytansinoids as adc payloads and their use for the treatment of cancer
|
KR20230038783A
(ko)
|
2020-07-20 |
2023-03-21 |
아스트라제네카 유케이 리미티드 |
Sars-cov-2 단백질, 항-sars-cov-2 항체, 및 이를 사용하는 방법
|
WO2022026592A2
(en)
|
2020-07-28 |
2022-02-03 |
Celltas Bio, Inc. |
Antibody molecules to coronavirus and uses thereof
|
WO2022031804A1
(en)
|
2020-08-04 |
2022-02-10 |
Abbott Laboratories |
Improved methods and kits for detecting sars-cov-2 protein in a sample
|
EP4200018A1
(en)
|
2020-08-18 |
2023-06-28 |
Cephalon LLC |
Anti-par-2 antibodies and methods of use thereof
|
JP2023542080A
(ja)
|
2020-08-26 |
2023-10-05 |
マレンゴ・セラピューティクス,インコーポレーテッド |
カルレティキュリンに結合する多機能性分子およびその使用
|
GB2616128A
(en)
|
2020-08-26 |
2023-08-30 |
Marengo Therapeutics Inc |
Antibody molecules that bind to NKp30 and uses thereof
|
CN116761818A
(zh)
|
2020-08-26 |
2023-09-15 |
马伦戈治疗公司 |
检测trbc1或trbc2的方法
|
WO2022043557A1
(en)
|
2020-08-31 |
2022-03-03 |
Advanced Accelerator Applications International Sa |
Method of treating psma-expressing cancers
|
WO2022043558A1
(en)
|
2020-08-31 |
2022-03-03 |
Advanced Accelerator Applications International Sa |
Method of treating psma-expressing cancers
|
EP4228764A1
(en)
|
2020-10-14 |
2023-08-23 |
Five Prime Therapeutics, Inc. |
Anti-c-c chemokine receptor 8 (ccr8) antibodies and methods of use thereof
|
WO2022081436A1
(en)
|
2020-10-15 |
2022-04-21 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Antibody specific for sars-cov-2 receptor binding domain and therapeutic methods
|
EP4229086A1
(en)
|
2020-10-15 |
2023-08-23 |
UCB Biopharma SRL |
Binding molecules that multimerise cd45
|
WO2022087274A1
(en)
|
2020-10-21 |
2022-04-28 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Antibodies that neutralize type-i interferon (ifn) activity
|
EP4251647A1
(en)
|
2020-11-24 |
2023-10-04 |
Bio-Techne Corporation |
Anti-severe acute respiratory syndrome coronavirus antibodies
|
CA3198161A1
(en)
|
2020-12-01 |
2022-06-09 |
Beth MCQUISTON |
Use of one or more biomarkers to determine traumatic brain injury (tbi) in a subject having received a head computerized tomography scan that is negative for a tbi
|
IL303328A
(en)
|
2020-12-01 |
2023-07-01 |
Aptevo Res & Development Llc |
CD3-binding bispecific and heterodimeric antibodies to PSMA
|
WO2023102384A1
(en)
|
2021-11-30 |
2023-06-08 |
Abbott Laboratories |
Use of one or more biomarkers to determine traumatic brain injury (tbi) in a subject having received a head computerized tomography scan that is negative for a tbi
|
TW202237171A
(zh)
|
2020-12-04 |
2022-10-01 |
美商威特拉公司 |
使用介白素-2藥劑之方法
|
US20220281914A1
(en)
|
2020-12-18 |
2022-09-08 |
Kiniksa Pharmaceuticals, Ltd. |
Protein compositions and methods for producing and using the same
|
EP4271998A1
(en)
|
2020-12-30 |
2023-11-08 |
Abbott Laboratories |
Methods for determining sars-cov-2 antigen and anti-sars-cov-2 antibody in a sample
|
WO2022153195A1
(en)
|
2021-01-13 |
2022-07-21 |
Memorial Sloan Kettering Cancer Center |
Anti-dll3 antibody-drug conjugate
|
TW202237135A
(zh)
|
2021-01-13 |
2022-10-01 |
紀念斯隆凱特琳癌症中心 |
抗體-吡咯并苯并二氮呯衍生物結合物
|
TW202245825A
(zh)
|
2021-01-20 |
2022-12-01 |
美商威特拉公司 |
介白素-2藥劑及其用途
|
JP2024505049A
(ja)
|
2021-01-29 |
2024-02-02 |
ノバルティス アーゲー |
抗cd73及び抗entpd2抗体のための投与方式並びにその使用
|
US20240133898A1
(en)
|
2021-02-24 |
2024-04-25 |
Alladapt Immunotherapeutics, Inc. |
Compositions and methods for identification of cross-reactive allergenic proteins and treatment of allergies
|
US20240041978A1
(en)
|
2021-03-03 |
2024-02-08 |
The U.S.A., As Represented By The Secretary, Department Of Health And Human Services |
La protein as a novel regulator of osteoclastogenesis
|
KR20230156727A
(ko)
|
2021-03-03 |
2023-11-14 |
피에르 파브르 메디카먼트 |
항-vsig4 항체 또는 이의 항원 결합 단편 및 용도
|
AU2022233792A1
(en)
|
2021-03-12 |
2023-10-26 |
Janssen Biotech, Inc. |
Safe and effective method of treating psoriatic arthritis with anti-il23 specific antibody
|
KR20230156764A
(ko)
|
2021-03-12 |
2023-11-14 |
얀센 바이오테크 인코포레이티드 |
항-il23 특이적 항체에 의해 tnf 요법에 부적절한 반응을 보이는 건선성 관절염 환자를 치료하는 방법
|
JP2024511373A
(ja)
|
2021-03-18 |
2024-03-13 |
ノバルティス アーゲー |
がんのためのバイオマーカーおよびその使用
|
WO2022204581A2
(en)
|
2021-03-26 |
2022-09-29 |
Scholar Rock, Inc. |
Tgf-beta inhibitors and use thereof
|
EP4067381A1
(en)
|
2021-04-01 |
2022-10-05 |
Julius-Maximilians-Universität Würzburg |
Novel tnfr2 binding molecules
|
TW202304979A
(zh)
|
2021-04-07 |
2023-02-01 |
瑞士商諾華公司 |
抗TGFβ抗體及其他治療劑用於治療增殖性疾病之用途
|
EP4320147A2
(en)
|
2021-04-08 |
2024-02-14 |
Marengo Therapeutics, Inc. |
Multifunctional molecules binding to tcr and uses thereof
|
IL308198A
(en)
|
2021-05-07 |
2024-01-01 |
Surface Oncology Llc |
Anti-IL-27 antibodies and uses thereof
|
JP2024519858A
(ja)
|
2021-05-18 |
2024-05-21 |
アボット・ラボラトリーズ |
小児対象における脳損傷を査定する方法
|
EP4348263A1
(en)
|
2021-05-28 |
2024-04-10 |
Alexion Pharmaceuticals, Inc. |
Methods for detecting cm-tma biomarkers
|
WO2022256723A2
(en)
|
2021-06-03 |
2022-12-08 |
Scholar Rock, Inc. |
Tgf-beta inhibitors and therapeutic use thereof
|
CA3218590A1
(en)
|
2021-06-07 |
2022-12-15 |
Providence Health & Services - Oregon |
Cxcr5, pd-1, and icos expressing tumor reactive cd4 t cells and their use
|
WO2022261183A2
(en)
|
2021-06-08 |
2022-12-15 |
Dana-Farber Cancer Institute, Inc. |
Compositions and methods for treating and/or identifying an agent for treating intestinal cancers
|
EP4356129A1
(en)
|
2021-06-14 |
2024-04-24 |
Abbott Laboratories |
Methods of diagnosing or aiding in diagnosis of brain injury caused by acoustic energy, electromagnetic energy, an over pressurization wave, and/or blast wind
|
EP4355776A1
(en)
|
2021-06-14 |
2024-04-24 |
Argenx BV |
Anti-il-9 antibodies and methods of use thereof
|
EP4358995A1
(en)
|
2021-06-23 |
2024-05-01 |
Scholar Rock, Inc. |
A myostatin pathway inhibitor in combination with a glp-1 pathway activator for use in treating metabolic disorders
|
US20240165229A1
(en)
|
2021-06-29 |
2024-05-23 |
Seagen Inc. |
Methods of treating cancer with a combination of a nonfucosylated anti-cd70 antibody and a cd47 antagonist
|
IL309997A
(en)
|
2021-07-09 |
2024-03-01 |
Janssen Biotech Inc |
Production methods for the production of anti-TNF antibody compositions
|
KR20240034215A
(ko)
|
2021-07-09 |
2024-03-13 |
얀센 바이오테크 인코포레이티드 |
항-il12/il23 항체 조성물을 생산하기 위한 제조 방법
|
IL309996A
(en)
|
2021-07-09 |
2024-03-01 |
Janssen Biotech Inc |
Production methods for the production of anti-TNF antibody compositions
|
WO2023285878A1
(en)
|
2021-07-13 |
2023-01-19 |
Aviation-Ophthalmology |
Methods for detecting, treating, and preventing gpr68-mediated ocular diseases, disorders, and conditions
|
WO2023288267A1
(en)
|
2021-07-14 |
2023-01-19 |
2Seventy Bio, Inc. |
Engineered t cell receptors fused to binding domains from antibodies
|
AU2022320051A1
(en)
|
2021-07-30 |
2024-01-25 |
ONA Therapeutics S.L. |
Anti-cd36 antibodies and their use to treat cancer
|
AU2022328390A1
(en)
|
2021-08-10 |
2024-03-21 |
Adimab, Llc |
Anti-gdf15 antibodies, compositions and uses thereof
|
WO2023025927A1
(en)
|
2021-08-26 |
2023-03-02 |
Glycanostics S.R.O |
Glycoprotein biomarkers for diagnosing cancer
|
WO2023034777A1
(en)
|
2021-08-31 |
2023-03-09 |
Abbott Laboratories |
Methods and systems of diagnosing brain injury
|
WO2023039243A2
(en)
*
|
2021-09-13 |
2023-03-16 |
Achelois Biopharma, Inc. |
Hepatitis b virus antivirus (hbv-antivirus) compositions and methods of use
|
AU2022346688A1
(en)
|
2021-09-14 |
2024-04-04 |
Glycanostics S.R.O |
Use of lectins to determine mammaglobin-a glycoforms in breast cancer
|
WO2023044483A2
(en)
|
2021-09-20 |
2023-03-23 |
Voyager Therapeutics, Inc. |
Compositions and methods for the treatment of her2 positive cancer
|
AU2022345881A1
(en)
|
2021-09-20 |
2024-03-21 |
Alnylam Pharmaceuticals, Inc. |
Inhibin subunit beta e (inhbe) modulator compositions and methods of use thereof
|
AU2022354059A1
(en)
|
2021-09-30 |
2024-03-28 |
Abbott Laboratories |
Methods and systems of diagnosing brain injury
|
WO2023069421A1
(en)
|
2021-10-18 |
2023-04-27 |
Byomass Inc. |
Anti-activin a antibodies, compositions and uses thereof
|
CA3236779A1
(en)
|
2021-10-29 |
2023-05-04 |
Janssen Biotech, Inc. |
Methods of treating crohn's disease with anti-il23 specific antibody
|
EP4177266A1
(en)
|
2021-11-05 |
2023-05-10 |
Katholieke Universiteit Leuven |
Neutralizing anti-sars-cov-2 human antibodies
|
WO2023084488A1
(en)
|
2021-11-15 |
2023-05-19 |
Janssen Biotech, Inc. |
Methods of treating crohn's disease with anti-il23 specific antibody
|
WO2023092004A1
(en)
|
2021-11-17 |
2023-05-25 |
Voyager Therapeutics, Inc. |
Compositions and methods for the treatment of tau-related disorders
|
US20230159633A1
(en)
|
2021-11-23 |
2023-05-25 |
Janssen Biotech, Inc. |
Method of Treating Ulcerative Colitis with Anti-IL23 Specific Antibody
|
WO2023097254A1
(en)
|
2021-11-24 |
2023-06-01 |
Visterra, Inc. |
Engineered antibody molecules to cd138 and uses thereof
|
WO2023097119A2
(en)
|
2021-11-29 |
2023-06-01 |
Dana-Farber Cancer Institute, Inc. |
Methods and compositions to modulate riok2
|
CA3238574A1
(en)
|
2021-12-01 |
2023-06-08 |
Gregory Babcock |
Methods of using interleukin-2 agents
|
WO2023114978A1
(en)
|
2021-12-17 |
2023-06-22 |
Abbott Laboratories |
Systems and methods for determining uch-l1, gfap, and other biomarkers in blood samples
|
WO2023122213A1
(en)
|
2021-12-22 |
2023-06-29 |
Byomass Inc. |
Targeting gdf15-gfral pathway cross-reference to related applications
|
WO2023118508A1
(en)
|
2021-12-23 |
2023-06-29 |
Bavarian Nordic A/S |
Recombinant mva viruses for intraperitoneal administration for treating cancer
|
US20230213536A1
(en)
|
2021-12-28 |
2023-07-06 |
Abbott Laboratories |
Use of biomarkers to determine sub-acute traumatic brain injury (tbi) in a subject having received a head computerized tomography (ct) scan that is negative for a tbi or no head ct scan
|
WO2023147107A1
(en)
|
2022-01-31 |
2023-08-03 |
Byomass Inc. |
Myeloproliferative conditions
|
WO2023150652A1
(en)
|
2022-02-04 |
2023-08-10 |
Abbott Laboratories |
Lateral flow methods, assays, and devices for detecting the presence or measuring the amount of ubiquitin carboxy-terminal hydrolase l1 and/or glial fibrillary acidic protein in a sample
|
WO2023150778A1
(en)
|
2022-02-07 |
2023-08-10 |
Visterra, Inc. |
Anti-idiotype antibody molecules and uses thereof
|
US20230312703A1
(en)
|
2022-03-30 |
2023-10-05 |
Janssen Biotech, Inc. |
Method of Treating Psoriasis with IL-23 Specific Antibody
|
WO2023192436A1
(en)
|
2022-03-31 |
2023-10-05 |
Alexion Pharmaceuticals, Inc. |
Singleplex or multiplexed assay for complement markers in fresh biological samples
|
GB202205203D0
(en)
|
2022-04-08 |
2022-05-25 |
UCB Biopharma SRL |
Combination with inhibitor
|
GB202205200D0
(en)
|
2022-04-08 |
2022-05-25 |
Ucb Biopharma Sprl |
Combination with chemotherapy
|
US20240092921A1
(en)
|
2022-04-25 |
2024-03-21 |
Visterra, Inc. |
Antibody molecules to april and uses thereof
|
WO2023209177A1
(en)
|
2022-04-29 |
2023-11-02 |
Astrazeneca Uk Limited |
Sars-cov-2 antibodies and methods of using the same
|
WO2023220695A2
(en)
|
2022-05-13 |
2023-11-16 |
Voyager Therapeutics, Inc. |
Compositions and methods for the treatment of her2 positive cancer
|
WO2023223265A1
(en)
|
2022-05-18 |
2023-11-23 |
Janssen Biotech, Inc. |
Method for evaluating and treating psoriatic arthritis with il23 antibody
|
WO2023240124A1
(en)
|
2022-06-07 |
2023-12-14 |
Regeneron Pharmaceuticals, Inc. |
Pseudotyped viral particles for targeting tcr-expressing cells
|
EP4296279A1
(en)
|
2022-06-23 |
2023-12-27 |
Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. |
Anti-transthyretin (ttr) binding proteins and uses thereof
|
WO2024006876A1
(en)
|
2022-06-29 |
2024-01-04 |
Abbott Laboratories |
Magnetic point-of-care systems and assays for determining gfap in biological samples
|
WO2024013727A1
(en)
|
2022-07-15 |
2024-01-18 |
Janssen Biotech, Inc. |
Material and methods for improved bioengineered pairing of antigen-binding variable regions
|
WO2024015953A1
(en)
|
2022-07-15 |
2024-01-18 |
Danisco Us Inc. |
Methods for producing monoclonal antibodies
|
WO2024030976A2
(en)
|
2022-08-03 |
2024-02-08 |
Voyager Therapeutics, Inc. |
Compositions and methods for crossing the blood brain barrier
|
WO2024050354A1
(en)
|
2022-08-31 |
2024-03-07 |
Washington University |
Alphavirus antigen binding antibodies and uses thereof
|
WO2024050524A1
(en)
|
2022-09-01 |
2024-03-07 |
University Of Georgia Research Foundation, Inc. |
Compositions and methods for directing apolipoprotein l1 to induce mammalian cell death
|
WO2024054436A1
(en)
|
2022-09-06 |
2024-03-14 |
Alexion Pharmaceuticals, Inc. |
Diagnostic and prognostic biomarker profiles in patients with hematopoietic stem cell transplant-associated thrombotic microangiopathy (hsct-tma)
|
WO2024059708A1
(en)
|
2022-09-15 |
2024-03-21 |
Abbott Laboratories |
Biomarkers and methods for differentiating between mild and supermild traumatic brain injury
|
WO2024062038A1
(en)
|
2022-09-21 |
2024-03-28 |
Elthera Ag |
Novel binding molecules binding to l1cam
|